

US008747859B2

(12) **United States Patent**
Mengeling et al.

(10) **Patent No.:** **US 8,747,859 B2**
(45) **Date of Patent:** ***Jun. 10, 2014**

(54) **PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE BASED ON ISOLATE JA-142**
(75) Inventors: **William L. Mengeling**, Ames, IA (US); **Ann Vorwald**, Ames, IA (US); **Kelly Lager**, Neveda, IA (US); **Mike Roof**, Ames, IA (US); **Kelly Burkhardt**, Radcliffe, IA (US); **David E. Gorcyca**, St. Joseph, MO (US)

(73) Assignees: **The United States of America, as Represented by the Secretary of Agriculture**, Washington, DC (US); **Boehringer Ingelheim Vetmedica, Inc.**, St. Joseph, MO (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 272 days.
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/389,558**

(22) Filed: **Feb. 20, 2009**

(65) **Prior Publication Data**

US 2011/0104201 A1 May 5, 2011

Related U.S. Application Data

(60) Continuation of application No. 11/459,542, filed on Jul. 24, 2006, which is a division of application No. 10/654,545, filed on Sep. 3, 2003, now Pat. No. 7,081,342, which is a continuation of application No. 09/981,282, filed on Oct. 18, 2001, now Pat. No. 6,641,819, which is a continuation-in-part of application No. 09/461,879, filed on Dec. 15, 1999, now abandoned, which is a continuation-in-part of application No. 09/298,110, filed on Apr. 22, 1999, now abandoned.

(51) **Int. Cl.**
A61K 39/12 (2006.01)
C07H 21/04 (2006.01)
C12N 7/00 (2006.01)
A61P 37/02 (2006.01)
A61P 31/12 (2006.01)

(52) **U.S. Cl.**
USPC **424/204.1**; 536/23.72; 435/235.1

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,080,291 A 3/1963 Sinha et al.
3,137,631 A 6/1964 Soloway
3,959,457 A 5/1976 Speaker et al.
4,015,100 A 3/1977 Gnanamuthu et al.
4,122,167 A 10/1978 Buynak et al.
4,205,060 A 5/1980 Monsimer et al.

4,224,412 A 9/1980 Dorofeev et al.
4,452,747 A 6/1984 Gersonde et al.
4,468,346 A 8/1984 Paul et al.
4,554,159 A 11/1985 Roizman et al.
4,606,940 A 8/1986 Frank et al.
4,636,485 A 1/1987 van der Smissen
4,744,933 A 5/1988 Rha et al.
4,753,884 A 6/1988 Kit et al.
4,810,493 A 3/1989 Patrick et al.
4,921,706 A 5/1990 Roberts et al.
4,927,637 A 5/1990 Morano et al.
4,944,948 A 7/1990 Uster et al.
5,008,050 A 4/1991 Cullis et al.
5,009,956 A 4/1991 Baumann
5,132,117 A 7/1992 Speaker et al.
5,206,163 A 4/1993 Renard et al.
5,213,759 A 5/1993 Castberg et al.
5,419,907 A 5/1995 Paul et al.
5,476,778 A 12/1995 Chladek et al.
5,510,258 A 4/1996 Sanderson et al.
5,587,164 A 12/1996 Sanderson et al.
5,597,721 A 1/1997 Brun et al.
5,620,691 A 4/1997 Wensvoort et al.
5,674,500 A 10/1997 Peeters et al.
5,677,429 A 10/1997 Benfield
5,683,865 A 11/1997 Collins et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2103460 A1 12/1992
DE 145705 A1 1/1981

(Continued)

OTHER PUBLICATIONS

Greiner et al. Quantitative Effect of Porcine Reproductive Respiratory Syndrome Virus on Pig Growth and Immune Response (1999); (Iowa State University Digital Repository @ Iowa State University; Swine Research Report, 1998. Paper 5.*

(Continued)

Primary Examiner — Shanon A Foley

(74) *Attorney, Agent, or Firm* — Michael P. Morris; Joyce L. Morrison

(57) **ABSTRACT**

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

19 Claims, 2 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

5,690,940 A 11/1997 Joo
 5,695,766 A 12/1997 Paul et al.
 5,698,203 A 12/1997 Visser et al.
 5,789,388 A 8/1998 Visser et al.
 5,840,563 A 11/1998 Chladek et al.
 5,846,805 A 12/1998 Collins et al.
 5,858,729 A 1/1999 Van Woensel et al.
 5,866,401 A 2/1999 Hesse
 5,888,513 A 3/1999 Plana Duran et al.
 5,910,310 A 6/1999 Heinen et al.
 5,925,359 A 7/1999 Van Woensel et al.
 5,968,525 A 10/1999 Fitzgerald et al.
 5,976,537 A * 11/1999 Mengeling et al. 424/184.1
 5,989,563 A 11/1999 Chladek et al.
 5,998,601 A 12/1999 Murtaugh et al.
 6,001,370 A 12/1999 Burch et al.
 6,015,663 A 1/2000 Wesley et al.
 6,042,830 A 3/2000 Chladek et al.
 6,080,570 A 6/2000 Chladek et al.
 6,110,467 A 8/2000 Paul et al.
 6,110,468 A 8/2000 Collins et al.
 6,197,310 B1 3/2001 Wensvoort et al.
 6,241,990 B1 6/2001 Collins et al.
 6,251,397 B1 6/2001 Paul et al.
 6,251,404 B1 6/2001 Paul et al.
 6,268,199 B1 7/2001 Meulenberg et al.
 6,380,376 B1 4/2002 Paul et al.
 6,391,314 B1 5/2002 Allan et al.
 6,455,245 B1 9/2002 Wensvoort et al.
 6,495,138 B1 12/2002 van Nieuwstadt et al.
 6,498,008 B2 12/2002 Collins et al.
 6,500,662 B1 * 12/2002 Calvert et al. 435/235.1
 6,592,873 B1 7/2003 Paul et al.
 6,641,819 B2 * 11/2003 Mengeling et al. 424/204.1
 6,660,513 B2 12/2003 Mengeling et al.
 6,773,908 B1 8/2004 Paul et al.
 6,806,086 B2 10/2004 Wensvoort et al.
 6,841,364 B2 1/2005 Yuan et al.
 6,855,315 B2 2/2005 Collins et al.
 6,982,160 B2 * 1/2006 Collins et al. 435/235.1
 7,018,638 B2 3/2006 Chu et al.
 7,081,342 B2 7/2006 Mengeling et al.
 7,109,025 B1 9/2006 Eloit et al.
 7,122,347 B2 10/2006 Verheije et al.
 7,132,106 B2 * 11/2006 Calvert et al. 424/205.1
 7,169,394 B2 1/2007 Chu et al.
 7,211,379 B2 5/2007 Ellis et al.
 7,232,680 B2 * 6/2007 Calvert et al. 435/235.1
 7,264,804 B2 9/2007 Collins et al.
 7,273,617 B2 9/2007 Yuan et al.
 7,312,030 B2 12/2007 van Rijn et al.
 7,335,361 B2 2/2008 Liao et al.
 7,335,473 B2 2/2008 Wensvoort et al.
 7,368,117 B2 5/2008 Fetzer et al.
 7,618,797 B2 11/2009 Calvert et al.
 7,632,636 B2 12/2009 Roof et al.
 7,691,389 B2 4/2010 Calvert et al.
 7,722,878 B2 5/2010 Vaughn et al.
 7,897,343 B2 3/2011 Wensvoort et al.
 2002/0012670 A1 1/2002 Elbers et al.
 2002/0098573 A1 7/2002 Meulenberg et al.
 2002/0172690 A1 11/2002 Calvert et al.
 2003/0049274 A1 3/2003 Meulenberg et al.
 2003/0118608 A1 6/2003 Wensvoort et al.
 2003/0157689 A1 8/2003 Calvert et al.
 2003/0219732 A1 11/2003 van Rijn et al.
 2004/0009190 A1 1/2004 Elbers et al.
 2004/0132014 A1 7/2004 Wensvoort et al.
 2004/0197872 A1 10/2004 Meulenberg et al.
 2004/0213805 A1 10/2004 Verheije
 2004/0224327 A1 11/2004 Meulenberg et al.
 2004/0253270 A1 12/2004 Meng et al.
 2006/0063151 A1 3/2006 Roof et al.
 2006/0205033 A1 9/2006 Meulenberg et al.
 2006/0240041 A1 10/2006 Meulenberg et al.

2006/0286123 A1 12/2006 Fetzer et al.
 2007/0003570 A1 1/2007 Murtaugh et al.
 2007/0042000 A1 2/2007 Mengeling et al.
 2009/0148474 A1 6/2009 Roof et al.
 2010/0003278 A1 1/2010 Roof et al.
 2010/0028860 A1 2/2010 Roof et al.
 2010/0129398 A1 5/2010 Klinge et al.
 2011/0104201 A1 * 5/2011 Mengeling et al. 424/204.1
 2011/0117129 A1 5/2011 Roof et al.
 2011/0195088 A1 8/2011 Roof et al.
 2012/0189655 A1 7/2012 Wu et al.

FOREIGN PATENT DOCUMENTS

EP 208672 A1 1/1987
 EP 0440219 A1 8/1991
 EP 0529584 A2 3/1993
 EP 587780 A1 3/1994
 EP 595436 5/1994
 EP 0610250 A1 8/1994
 EP 0676467 10/1995
 EP 732340 A2 9/1996
 EP 0835929 A1 4/1998
 EP 0835930 A1 4/1998
 EP 0839912 A1 5/1998
 EP 1018557 A2 7/2000
 FR 2602791 A1 2/1988
 GB 2282811 A 4/1995
 GB 2289279 A 11/1995
 JP 62/198626 A 9/1987
 WO 8803410 A1 5/1988
 WO 8908701 A1 9/1989
 WO 9221375 A1 12/1992
 WO 93/03760 3/1993
 WO 9306211 A1 4/1993
 WO 9307898 A1 4/1993
 WO 9314196 A1 7/1993
 WO 94/18311 8/1994
 WO 9528227 A1 10/1995
 WO 9531550 A1 11/1995
 WO 9604010 A1 2/1996
 WO 9606619 A1 3/1996
 WO 9636356 A1 11/1996
 WO 9640932 A1 12/1996
 WO 9700696 A1 1/1997
 WO 9731651 A1 9/1997
 WO 9731652 A1 9/1997
 WO 9818933 A1 5/1998
 WO 9835023 A1 8/1998
 WO 9850426 A1 11/1998
 WO 9855625 A1 12/1998
 WO 9855626 A2 12/1998
 WO 0053787 A1 9/2000
 WO 0065032 A1 11/2000
 WO 0159077 A1 8/2001
 WO 0190363 A1 11/2001
 WO 02095040 A1 11/2002
 WO 03062407 A1 7/2003
 WO 2006002193 A2 1/2006
 WO 2006034319 A2 3/2006
 WO 2006074986 A2 7/2006
 WO 2007064742 A2 6/2007
 WO 2008109237 A2 9/2008
 WO 2008121958 A1 10/2008
 WO 2010025109 A1 3/2010
 WO 2011128415 A1 10/2011

OTHER PUBLICATIONS

Greiner 1999 Swine Research Report Citation.*
 Andreyev et al., Arch. Virol., 142:993-1001 (1997).
 Flint et al., Arch. Virol., 2:40-42 (2000).
 Gong et al., J. Gen. Virol., 77:2729-2736 (1996).
 Horsfall et al., Viral and Rickettsial Infections of Man, 239-241 (1965).
 Mengeling et al., Allen D. Leman Swine Conference, 138-145 (1997).
 Nuttall, Arch. Virol., 66:365-369 (1980).

(56)

References Cited

OTHER PUBLICATIONS

- Wesley et al., Proc. Ann. Meet. Am. Assoc. Swine Pract., 27:141-143 (1996).
- Collins et al., J. Vet. Diagn. Invest., 4:117-126 (1992).
- Devereux et al., Nuc. Acids Res., 12(1):387 (1984).
- Office Action in CA 2,650,236, dated Feb. 9, 2011.
- Wesley et al., "Differentiation of a porcine reproductive and respiratory syndrome virus vaccine strain from North American field strains by restriction fragment length polymorphism analysis of ORF 5". Journal of Veterinary Diagnostic Investigation, vol. 10, 1998, pp. 140-144.
- Easterday, B.C., "Swine Influenza". Diseases of Swine, Sixth Edition, Iowa State University Press, 1986, pp. 244-315. (Part One of Two—pp. 244-285).
- "Dutch Team Isolates Mystery Pig Disease Agent", Animal Pharm, vol. 230, Abstract No. 00278268, Jun. 21, 1991, p. 21.
- "For purification of viral RNA from Plasma, Serum, Cell-free body fluids, Cell-Culture supernatants". QIAamp® Viral RNA Mini Kit Handbook, QIAGEN, Jan. 1999, Cat #52906, pp. 1-35.
- "Frontiers closing to mystery disease pigs". Animal Pharm., No. 228, May 24, 1991, p. 2.
- "Revision of the taxonomy of the Coronavirus, Torovirus, and Arterivirus genera". Archives of Virology, vol. 135, 1994, pp. 227-239.
- Abstracts of Papers Presented at the 71st Annual Meeting of the Conference of Research Workers in Animal Disease, Nos. 1-6, Nov. 5-6, 1990, 2 pages.
- Aksenova et al., "Cultivation of the rabies virus in the continuous kidney cell line 4647 from the green marmoset". Vopr. Virusol., vol. 30, No. 2, 1985, pp. 180-182. (See Axenova for English Abstract).
- Albina et al., "Immune responses in pigs infected with porcine reproductive and respiratory syndrome virus (PRRSV)". Veterinary Immunology and Immunopathology, vol. 61, 1998, pp. 49-66.
- Allan et al., "Experimental infection of colostrum deprived piglets with porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) potentiates PCV2 replication". 2000, Archives of Virology, vol. 145, pp. 2421-2429.
- Allende et al., "Mutations in the genome of porcine reproductive and respiratory syndrome virus responsible for the attenuated phenotype". Archives of Virology, vol. 145, No. 6, Jun. 2000, pp. 1149-1161.
- Allende et al., "North American and European porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions". Journal of General Virology, vol. 80, 1999, pp. 307-315.
- Altschul et al., "Basic Local Alignment Search Tool". Journal of Molecular Biology, vol. 215, 1990, pp. 403-410.
- Ashworth et al., "Antibody-dependent cell-mediated cytotoxicity (ADCC) in Aujeszky's disease". Archives of Virology, vol. 59, No. 4, 1979, pp. 307-318.
- Axenova, T.A. "Propagation of Rabies Vaccine Virus in Continuous Green Monkey Kidney Cells 4647". Vopr. Virusol., vol. 30, No. 2, 1985, p. 182. (English Abstract of Aksenova Reference.).
- Backstrom et al., "Respiratory Diseases of Swine". Veterinary Clinics of North America: Large Animal Practice, vol. 4, No. 2, Nov. 1982, pp. 259-276.
- Barfoed et al., "DNA vaccination of pigs with open reading frame 1-7 of PRRS virus". Vaccine, vol. 22, 2004, pp. 3628-3641.
- Baric et al., "Interactions between Coronavirus Nucleocapsid Protein and Viral RNAs: Implications for Viral Transcription". Journal of Virology, vol. 62, No. 11, Nov. 1988, pp. 4280-4287.
- Baric et al., "Subgenomic Negative-Strand RNA Function during Mouse Hepatitis Virus Infection". Journal of Virology, vol. 74, No. 9, May 2000, pp. 4039-4046.
- Bautista et al., "Comparison of Porcine Alveolar Macrophages and CL 2621 for the Detection of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus and Anti-PRRS Antibody". Journal of Veterinary Diagnostic Investigation, vol. 5, No. 2, Apr. 1993, pp. 163-165.
- Bautista et al., "Serologic Survey for Lelystad and VR-2332 Strains of Porcine Respiratory and Reproductive Syndrome (PRRS) Virus in US Swine Herds". Journal of Veterinary Diagnostic Investigation, vol. 5, No. 4, Oct. 1992, pp. 612-614.
- Beale, A.J., "Vaccines and antiviral drugs". Principles of bacteriology, virology and immunity, vol. 3, Ch. 86, 1984, pp. 147-161.
- Beare et al., "Further Studies in Man of Man of HSw1N1 Influenza Viruses". Journal of Medical Virology, vol. 5, 1980, pp. 33-38.
- Beghi et al., "Guillain-Barré Syndrome: Clinicoepidemiologic Features and Effect of Influenza Vaccine". Archives of Neurology, vol. 42, No. 11, 1985, pp. 1053-1057.
- Benfield et al., "Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332)". Journal of Veterinary Diagnostic Investigation, vol. 4, 1992, pp. 127-133.
- Benfield et al., "Etiologic Agent of Swine Infertility and Respiratory Syndrome in the United States". 72st Annual Meeting of the Conference of Research Workers in Animal Disease, Chicago, IL, Nov. 11-12, 1991, p. 48, Abstract No. 268.
- Benfield et al., "Properties of SIRS Virus Isolate ATCC VR-2332 in the United States and Preliminary Characterization of a Monoclonal Antibody to this Virus". American Association of Swine Practitioners Newsletter, vol. 4, No. 4, Jul./Aug. 1992, pp. 19-21.
- Berendt et al., "Evaluation of Commercially Prepared Vaccines for Experimentally Induced Type/A/New Jersey/8/76 Influenza Virus Infections in Mice and Squirrel Monkeys". The Journal of Infectious Diseases, vol. 136, Dec. 1977, pp. S712-S718.
- Berendt et al., "Reaction of Squirrel Monkeys to Intratracheal Inoculation with Influenza/A/New Jersey/76 (Swine) Virus". Infection and Immunity, vol. 16, No. 2, May 1977, pp. 476-479.
- Bilodeau et al., "'Porcine Reproductive and Respiratory Syndrome' in Quebec". The Veterinary Record, Aug. 3, 1991, p. 102.
- Blackburn et al., "Use of human influenza vaccine to protect against blue-eared pig disease". Veterinary Record, vol. 129, No. 1, Jul. 1991, p. 19.
- Bohl et al., "Isolation and Serotyping of Porcine Rotaviruses and Antigenic Comparison with Other Rotaviruses". Journal of Clinical Microbiology, vol. 19, No. 2, Feb. 1984, pp. 105-111.
- Bouillant et al., "Viral Susceptibility of a Cell Line Derived from the Pig Oviduct". Canadian Journal of Comparative Medicine, vol. 39, 1975, pp. 450-456.
- Bournsnel et al., "Sequence of the membrane protein gene from avian coronavirus IBV". Virus Research, vol. 1, 1984, pp. 303-313.
- Bournsnel et al., "Completion of the Sequence of the Genome of the Coronavirus Avian Infectious Bronchitis Virus". Journal of General Virology, vol. 68, 1987, pp. 57-77.
- Bowie et al., "Deciphering the Message of Protein Sequences: Tolerance to Amino Acid Substitutions". Science, vol. 247, 1990, pp. 1306-1310.
- Boyer et al., "Infectious Transcripts and cDNA Clones of RNA Viruses". Virology, vol. 198, No. 2, Feb. 1994, pp. 415-426.
- Bramel-Verheije et al., "Expression of a Foreign Epitope by Porcine Reproductive and Respiratory Syndrome Virus". Virology, vol. 278, 2000, pp. 380-389.
- Bredenbeek et al., "The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism". Nucleic Acids Research, vol. 18, No. 7, 1990, pp. 1825-1832.
- Brenner et al., "A Negative Staining Method for High Resolution Electron Microscopy of Viruses". Biochimica Et Biophysica Acta, vol. 34, 1959, pp. 103-110.
- Brinton-Darnell et al., "Structure and chemical-physical characteristics of lactate dehydrogenase-elevating virus and its RNA". Journal of Virology, vol. 16, No. 2, Aug. 1975, pp. 420-433.
- Brinton-Darnell, M. "Lactate Dehydrogenase-Elevating, Equine Arteritis and Lelystad Viruses". Encyclopedia of Virology, vol. 2, 1999, pp. 763-771.
- Bruner, D.W., "Table XXXII. Characteristics of Viral Respiratory Infections in Swine" Hagan's Infectious Diseases of Domestic Animals: With Special Reference to Etiology, Diagnosis, and Biologic Therapy, Sixth Edition, Comstock Publishing Associations, a division of Cornell University Press, Ithaca and London, 1973, 5 pages.

(56)

References Cited

OTHER PUBLICATIONS

- Brüggemann et al., "Immunoglobulin V region variants in hybridoma cells. I. Isolation of a variant with altered idiotypic and antigen binding specificity". *The EMBO Journal*, vol. 1, No. 5, 1982, pp. 629-634.
- Buck, K. W., "Comparison of the Replication of Positive-Stranded RNA Viruses of Plants and Animals". *Advances in Virus Research*, vol. 47, 1996, pp. 159-251.
- Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue". *The Journal of Cell Biology*, vol. 111, 1990, pp. 2129-2138.
- Burroughs, et al., "Relationship of San Miguel Sea Lion Virus to Other Members of the Calicivirus Group". *Intervirology*, vol. 10, 1978, pp. 51-59.
- Cabasso et al., "Propagation of Infectious Canine Hepatitis Virus in Tissue Culture". *Proceedings of the Society for Experimental Biology and Medicine*, vol. 85, 1954, pp. 239-245.
- Caeiro et al., "In vitro DNA replication by cytoplasmic extracts from cells infected with African swine fever virus". *Virology*, vol. 179, No. 1, Nov. 1990, pp. 87-94.
- Callebaut et al., "Antigenic Differentiation between Transmissible Gastroenteritis Virus of Swine and a Related Porcine Respiratory Coronavirus". *Journal of General Virology*, vol. 69, 1988, pp. 1725-1730.
- Carrascosa et al., "Relationship of San Miguel Sea Lion Virus to Other Members of the Calicivirus Group". *Journal of Virological Methods*, vol. 3, No. 6, Jan. 1982, pp. 303-310.
- Travassos et al., "Carajas and Maraba Viruses, Two New Vesiculoviruses Isolated from Phlebotomine Sand Flies in Brazil". *American Journal of Tropical Medicine and Hygiene*, vol. 33, No. 5, Sep. 1984, pp. 999-1006.
- Tsunemitsu et al., "Isolation, characterization, and serial propagation of a bovine group C rotavirus in a monkey kidney cell line (MA104)". *Journal of Clinical Microbiology*, vol. 29, No. 11, Nov. 1991, pp. 2609-2613.
- Ulmer et al., "Enhancement of DNA vaccine potency using conventional aluminum adjuvants". *Vaccine*, vol. 18, 2000, pp. 18-28.
- Urasawa et al., "Sequential Passages of Human Rotavirus in MA-104 Cells". *Microbiology and Immunology*, vol. 25, No. 10, 1981, pp. 1025-1035.
- Van Alstine, W.G., "Mystery Swine Disease in the United States". *The New Pig Disease: Porcine Respiration and Reproductive Syndrome. A Report on the Seminar/Workshop Held in Brussels by the European Commission (Directorate-General for Agriculture)*, Apr. 29-30, 1991, pp. 65-70.
- Van Alstine, W.G., "Past Diagnostic Approaches and Findings and Potentially Useful Diagnostic Strategies". *Proceedings Mystery Swine Disease Committee Meeting*, Oct. 6, 1990, pp. 52-58.
- Van Berlo et al., "Equine Arteritis Virus-Infected Cells Contain Six Polyadenylated Virus-Specific RNAs". *Virology*, vol. 118, 1982, pp. 345-352.
- Van Der Linden et al., "Virological kinetics and immunological responses to a porcine reproductive and respiratory syndrome virus infection of pigs at different ages". *Vaccine*, vol. 21, 2003, pp. 1952-1957.
- Van Der Meer et al., "ORF1a-Encoded Replicase Subunits Are Involved in the Membrane Association of the Arterivirus Replication Complex". *Journal of Virology*, vol. 72, No. 8, 1998, pp. 6689-6698.
- Van Der Most et al., "A Domain at the 3' End of the Polymerase Gene Is Essential for Encapsidation of Coronavirus Defective Interfering RNAs". *Journal of Virology*, vol. 65, No. 6, Jun. 1991, pp. 3219-3226.
- Van Dinten et al., "An infectious arterivirus cDNA clone: Identification of a replicase point mutation that abolished discontinuous mRNA transcription". *Proceedings of the National Academy of Sciences*, vol. 94, Feb. 1997, pp. 997-996.
- Van Dinten et al., "Processing of the Equine Arteritis Virus Replicase ORF1b Protein: Identification of Cleavage Products Containing the Putative Viral Polymerase and Helicase Domains". *Journal of Virology*, vol. 70, No. 10, Oct. 1996, pp. 6625-6633.
- Van Dinten et al., "Proteolytic Processing of the Open Reading Frame 1b-Encoded Part of Arterivirus Replicase Is Mediated by nsp4 Serine Protease and Is Essential for Virus Replication". *Journal of Virology*, vol. 73, No. 3, Mar. 1999, pp. 2027-2037.
- Van Marle et al., "Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences". *Proceedings of the National Academy of Sciences*, vol. 96, 1999, pp. 12056-12061.
- Van Marle et al., "Characterization of an Equine Arteritis Virus Replicase Mutant Defective in Subgenomic mRNA Synthesis". *Journal of Virology*, vol. 73, No. 7, Jul. 1999, pp. 5274-5281.
- Van Marle et al., "Regulation of Coronavirus mRNA Transcription". *Journal of Virology*, vol. 69, No. 12, Dec. 1995, pp. 7851-7856.
- Van Nieuwstadt et al., "Infection with porcine respiratory coronavirus does not fully protect pigs against intestinal transmissible gastroenteritis virus". *The Veterinary Record*, vol. 125, No. 3, 1989, pp. 58-60.
- Van Nieuwstadt et al., "Proteins Encoded by Open Reading Frames 3 and 4 of the Genome of Lelystad Virus (Arteriviridae) Are Structural Proteins of the Virion". *Journal of Virology*, vol. 70, No. 7, Jul. 1996, pp. 4767-4772.
- Van Nieuwstadt et al., "Use of two enzyme-linked immunosorbent assays to monitor antibody responses in swine with experimentally induced infection with porcine epidemic diarrhea virus". *American Journal of Veterinary Research*, vol. 42, Jul. 1991, pp. 1044-1050.
- Van Zijl et al., "Live Attenuated Pseudorabies Virus Expressing Envelope Glycoprotein E1 of Hog Cholera Virus Protects Swine Against Both Pseudorabies and Hog Cholera". *Journal of Virology*, vol. 65, No. 5, May 1991, pp. 2761-2765.
- Vennema et al., "Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes". *The EMBO Journal*, vol. 15, No. 8, 1996, pp. 2020-2028.
- Verheije et al., "Kissing Interaction between 3' Noncoding and Coding Sequences Is Essential for Porcine Arterivirus RNA Replication". *Journal of Virology*, vol. 76, No. 3, Feb. 2002, pp. 1521-1526.
- Verheije et al., "Safety and protective efficacy of porcine reproductive and respiratory syndrome recombinant virus vaccines in young pigs". *Vaccine*, vol. 21, 2003, pp. 2556-2563.
- Veterinary Bulletin*, vol. 58, No. 11, 1988, Nos. 6903-6909, p. 932.
- Veterinary Bulletin*, vol. 60, No. 3, 1990, Nos. 1536-1551, pp. 255-256.
- Vieira et al., "New pUC-derived cloning vectors with different selectable markers and DNA replication origins". *Gene*, vol. 100, 1991, pp. 189-194.
- VIIIth International Symposium on Nidoviruses (Corona and Arteriviruses), May 20-25, 2000, 32 pages.
- Visser, Nicolaas, "Declaration of Dr. N. Visser". Nov. 14, 1995, pp. 1-11.
- Von Busse, F.W., *Epidemiologic Studies on Porcine Reproductive and Respiratory Syndrome (PRRS)*. Tierärztliche Umschau, Dec. 1991, pp. 708-717 (Abstract in English p. 711).
- Von Ohlinger et al., "Der Seuchenhafte Spatabort beim Schwein Ein Beitrag zur Ätiologie des Porcine Reproductive and Respiratory Syndrome (PRRS)". *Tierärztl*, vol. 46, 1991, pp. 703-708.
- Waltner-Toews et al., "A Field Trial to Evaluate the Efficacy of a Combined Rotavirus-Coronavirus/ *Escherichia coli* vaccine in Dairy Cattle". *Canadian Journal of Comparative Medicine*, vol. 49, No. 1, 1985, pp. 1-9.
- Wang et al., "Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence". *Virology*, vol. 371, 2008, pp. 418-429.
- Ward et al., "Efficiency of human rotavirus propagation in cell culture". *Journal of Clinical Microbiology*, vol. 19, No. 6, Jun. 1984, pp. 748-753.
- Wardley et al., "The Host Response to African Swine Fever Virus". *Progress of Medical Virology*, vol. 34, 1987, pp. 180-192.
- Wassenaar et al., "Alternative Proteolytic Processing of the Arterivirus Replicase ORF1a Polyprotein: Evidence that NSP2 Acts as a Cofactor for the NSP4 Serine Protease". *Journal of Virology*, vol. 71, No. 12, Dec. 1997, pp. 9313-9322.

(56)

References Cited

OTHER PUBLICATIONS

- Webster et al., "Chemotherapy and Vaccination: a Possible Strategy for the Control of Highly Virulent Influenza Virus". *Journal of Virology*, vol. 55, No. 1, 1985, pp. 173-176.
- Welch et al., "Construction and evaluation of genetically engineered replication-defective porcine reproductive and respiratory syndrome virus vaccine candidates". *Veterinary Immunology and Immunopathology*, vol. 102, 2004, pp. 277-290.
- Wensvoort et al., "'Blue ear' disease in pigs". *Veterinary Record*, vol. 128, No. 24, Jun. 1991, p. 574.
- Wensvoort et al., "'Lelystad agent'—the cause of abortus blauw (mystery swine disease)". *Tijdschr Diergeneeskd*, vol. 116, No. 13, Jul. 1991, pp. 675-676.
- Wensvoort et al., "An Enzyme Immunoassay Employing Monoclonal Antibodies and Detecting Specifically Antibodies to Classical Swine Fever Virus". *Veterinary Microbiology*, vol. 17, 1988, pp. 129-140.
- Wensvoort et al., "Antigenic Comparison of Lelystad Virus and Swine Infertility and Respiratory Syndrome (SIRS) Virus". *Journal of Veterinary Diagnostic Investigation*, vol. 4, 1992, pp. 134-138.
- Wensvoort et al., "Bovine viral diarrhoea virus infections in piglets born to sows vaccinated against swine fever with contaminated vaccine". *Research in Veterinary Science*, vol. 45, 1988, pp. 143-148.
- Wensvoort et al., "Characterization of Porcine and Some Ruminant Pestiviruses by Cross-neutralization" vol. 20, 1989, pp. 291-306.
- Wensvoort et al., "Lelystad virus, the cause of porcine epidemic abortion and respiratory syndrome: a review of mystery swine disease research in Lelystad". *Veterinary Microbiology*, vol. 33, Nos. 1-4, Nov. 1992, pp. 185-193.
- Wensvoort et al., "Mystery Swine Disease in the Netherlands the Isolation of Lelystad Virus". *The Veterinary Quarterly*, vol. 13, No. 3, 1991, pp. 121-130.
- Wensvoort et al., "Production of Monoclonal Antibodies Against Swine Fever Virus and Their Use in Laboratory Diagnosis". *Veterinary Microbiology*, vol. 12, 1986, pp. 101-108.
- Wensvoort et al., "The Porcine Reproductive and Respiratory Syndrome; Characteristics and diagnosis of the causative virus". *Veterinary Biotechnology Newsletter*, vol. 3, 1993, pp. 113-120.
- Westenbrink et al., "An enzyme-linked immunosorbent assay for detection of antibodies to porcine parvovirus". *Journal of Virological Methods*, vol. 23, 1989, pp. 169-178.
- Wieczorek-Krohmer et al., "Porcine reproductive and respiratory syndrome virus (PRRSV): Monoclonal antibodies detect common epitopes on two viral proteins of European and U.S. isolates". *Veterinary Microbiology*, vol. 51, Nos. 3-4, Aug. 1996, pp. 257-266.
- Witte, K.H. "The Situation of 'Epidemic Late Abortion of Swine' in the State of Northrhine-Westphalia". Workshop Seminar, Apr. 1991.
- Nelson et al., "Differentiation of U.S. and European Isolates of Porcine Reproductive and Respiratory Syndrome Virus by Monoclonal Antibodies". *Journal of Clinical Microbiology*, vol. 31, No. 12, Dec. 1993, pp. 3184-3189.
- Nelson et al., "High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA". *Journal of General Virology*, vol. 81, 2000, pp. 181-188.
- Nielsen et al., "Generation of an Infectious Clone of VR-2332, a Highly Virulent North American-Type Isolate of Porcine Reproductive and Respiratory Syndrome Virus". *Journal of Virology*, vol. 77, No. 6, Mar. 2003, pp. 3702-3711.
- Nishimura et al., "Replication and Synthesis of Japanese Encephalitis Virus Ribonucleic Acids in Vero Cells". *Japanese Journal of Microbiology*, vol. 15, No. 4, 1971, pp. 309-316.
- Nodelijk et al., "A quantitative assessment of the effectiveness of PRRSV vaccination in pigs under experimental conditions". *Vaccine*, vol. 19, 2000, pp. 3636-3644.
- Office Action in CA 2,650,236 dated Feb. 9, 2011.
- Oirschot et al., "Development of an ELISA for detection of antibodies to glycoprotein I of Aujeszky's disease virus: a method for the serological differentiation between infected and vaccinated pigs". *Journal of Virological Methods*, vol. 22, 1988, pp. 191-206.
- Ojeh et al., "Isolation, characterisation and serial propagation of a Nigerian strain of porcine group A rotavirus in a monkey kidney cell line (MA104)". *Discovery and Innovation*, vol. 8, No. 2, Jun. 1996, pp. 159-164.
- Oleksiewicz et al., "Epitope Mapping Porcine Reproductive and Respiratory Syndrome Virus by Phage Display: the nsp2 Fragment of the Replicase Polyprotein Contains a Cluster of B-Cell Epitopes". *Journal of Virology*, vol. 75, No. 7, Apr. 2001, pp. 3277-3290.
- Oleksiewicz et al., "Semen from Boars Infected with Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Contains Antibodies Against Structural as Well as Nonstructural Viral Proteins". *Veterinary Microbiology*, vol. 81, 2001, pp. 109-125.
- Olsthoorn et al., "A conformational switch at the 3' end of a plant virus RNA regulates viral replication". *The EMBO Journal*, vol. 18, No. 17, 1999, pp. 4856-4864.
- Opriessnig et al., "Comparison of Molecular and Biological Characteristics of a Modified Live Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine (Ingelvac PRRS MLV), the Parent Strain of the Vaccine (ATCC VR2332), ATCC VR2385, and Two Recent Field Isolates of PRRSV". *Journal of Virology*, vol. 76, No. 23, Dec. 2002, pp. 11837-11844.
- Opriessnig et al., "Use of an Experimental Model to Test the Efficacy of Planned Exposure to Live Porcine Reproductive and Respiratory Syndrome Virus". *Clinical and Vaccine Immunology*, vol. 14, No. 12, Dec. 2007, pp. 1572-1577.
- Ostrowski et al., "Identification of Neutralizing and Nonneutralizing Epitopes in the Porcine Reproductive and Respiratory Syndrome Virus GP5 Ectodomain". *Journal of Virology*, vol. 76, No. 9, May 2002, pp. 4241-4250.
- Pan et al., "Replication of African swine fever virus in cell cultures". *American Journal of Veterinary Research*, vol. 41, No. 9, Sep. 1980, pp. 1357-1367.
- Parratt et al., "Radioimmunoassay of Antibody and its Clinical Applications". John Wiley & Sons, Chichester, 1982, p. 43.
- Parsley et al., "Poly (rC) binding protein 2 forms a ternary complex with the 5'-terminal sequences of poliovirus RNA and the viral 3CD proteinase". *RNA*, vol. 3, 1997, pp. 1124-1134.
- Patriarca, et al., "Lack of Significant Person-to-Person Spread of Swine Influenza-Like Virus Following Fatal Infection in an Immunocompromised Child". *American Journal of Epidemiology*, vol. 119, No. 2, 1984, pp. 152-158.
- Paul et al., "Porcine Reproductive and Respiratory Syndrome: An Overview". *Journal of Clinical Veterinary Medicine*, vol. 11, No. 12, Nov. 1993, pp. 1-16.
- Pearson et al., "Improved tools for biological sequence comparison". *Proceedings of the National Academy of Sciences*, vol. 85, Apr. 1988, pp. 2444-2448.
- Pedersen et al., "Open Reading Frame 1a-Encoded Subunits of the Arterivirus Replicase Induce Endoplasmic Reticulum-Derived Double-Membrane Vesicles Which Carry the Viral Replication Complex". *Journal of Virology*, vol. 73, No. 3, Mar. 1999, pp. 2016-2026.
- Pejsak et al., "Clinical signs and economic losses caused by porcine reproductive and respiratory syndrome virus in a large breeding farm". *Veterinary Microbiology*, vol. 44, 1997, pp. 317-322.
- Peng et al., "Analysis of Second-Site Revertants of a Murine Coronavirus Nucleocapsid Protein Deletion Mutant and Construction of Nucleocapsid Protein Mutants by Targeted RNA Recombination". *Journal of Virology*, vol. 69, No. 6, Jun. 1995, pp. 3449-3457.
- Penzes et al., "Characterization of a Replicating and Packaged Defective RNA of Avian Coronavirus Infectious Bronchitis Virus". vol. 203, No. 2, Sep. 1994, pp. 286-293.
- Percy et al., "Expression of a Foreign Protein by Influenza A Virus". *Journal of Virology*, vol. 68, No. 7, Jul. 1994, pp. 4486-4492.
- Pirtle et al., "Morphologic Heterogeneity of a Strain of Swine Influenza Virus (A/Swine/Wisconsin/1/68, Hsw1N1) Propagated at Different Temperatures". *American Journal of Veterinary Research*, vol. 36, No. 1, 1975, pp. 1783-1787.
- Plagemann et al., "Lactate Dehydrogenase-Elevating Virus, Equine Arteritis Virus, and Simina Hemorrhagic Fever Virus: A New Group of Positive-Strand RNA Viruses". *Advances in Virus Research*, vol. 41, 1991, pp. 99-192.
- Pol et al., "Pathological, ultrastructural, immunohistochemical changes caused by Lelystad virus in experimentally induced infec-

(56)

References Cited

OTHER PUBLICATIONS

tions of mystery swine disease (synonym: porcine epidemic abortion and respiratory syndrome (PEARS)). *Veterinary Quarterly*, vol. 13, No. 3, Jul. 1991, pp. 137-143.

Polson et al., "An evaluation of the financial impact of Porcine Reproductive and Respiratory Syndrome (PRRS) in nursery pigs". Proceedings of the 13th International Pig Veterinary Society Congress, Jun. 1994, p. 31.

Polson et al., "Financial Implications of Mystery Swine Disease (MSD)". 1993, pp. 8-28.

Polson, DD, "Answers to Your Questions on PRRS". NOBL Laboratories, 1993, 18 Pages.

Polson, DD, "RespPRRS a PRRS Vaccine Review", NOBL Laboratories, 1993, 22 pages.

Porcine Reproductive and Respiratory Syndrome: A Report on the Seminar Held in Brussels on Nov. 4-5, 1991 and Organized by the European Commission.

Poser, C.M., "Swine Influenza Vaccination: Truth and Consequences". *Archives of Neurology*, vol. 42, No. 11, 1985, pp. 1090-1092.

Potgieter et al., "Isolation of Swine Influenza Virus in Oklahoma". *Journal of the American Veterinary Medical Association*, vol. 171, No. 8, 1977, pp. 758-760.

Potts et al., "Peroxidase-labeled primary antibody method for detection of pestivirus contamination in cell cultures". *Journal of Virological Methods*, vol. 26, No. 1, Oct. 1989, pp. 119-124.

Quaife, T. "Mystery Agent Isolated! Isolation of the etiological agent behind mystery swine disease is a major breakthrough". *Swine Practitioner, Mystery Disease: Part 8*, Nov. 1991, pp. 4-7.

Reed et al., "A Simple Method of Estimating Fifty Per Cent Endpoints". *The American Journal of Hygiene*, vol. 27, No. 3, May 1938, pp. 493-497.

Reed et al., "Persistent Respiratory Virus Infection in Tracheal Organ Cultures". *British Journal of Experimental Pathology*, vol. 50, 1969, pp. 378-388.

Rice et al., "Production of Infectious RNA Transcripts from Sindbis Virus cDNA Clones: Mapping of Lethal Mutations, Rescue of a Temperature-Sensitive Marker, and In Vitro Mutagenesis to Generate Defined Mutants". *Journal of Virology*, vol. 61, No. 12, Dec. 1987, pp. 3809-3819.

Roberts et al., "Abortion in Swine". *Veterinary Obstetrics and Genital Diseases*, Edwards Brothers, Inc., Ann Arbor, 1986, pp. 180-192.

Roof et al., "Efficacy of Modified Live Virus Porcine Reproductive and Respiratory Virus Vaccines Against Heterologous Respiratory Challenge". 4th International Symposium on Emerging and Re-emerging Pig Diseases, Rome, Jun. 28-Jul. 2, 2003, pp. 117-118.

Ropp et al., "Characterization of Emerging European-Like Porcine Reproductive and Respiratory Syndrome Virus Isolates in the United States". *Journal of Virology*, vol. 78, No. 7, Apr. 2004, pp. 3684-3703.

Rossow et al., "Experimental porcine reproductive and respiratory syndrome virus infection in one-, four-, and 10-week-old pigs". *Journal of Veterinary Diagnostic Investigation*, vol. 6, 1993, pp. 3-12.

Rossow, K.D., "Porcine Reproductive and Respiratory Syndrome". *Veterinary Pathology*, vol. 35, 1998, pp. 1-20.

Roth et al., "Influenza virus hemagglutinin expression is polarized in cells infected with recombinant SV40 viruses carrying cloned hemagglutinin DNA". *Cell*, vol. 33, No. 2, Jun. 1983, pp. 435-443.

Roth et al., "The large external domain is sufficient for the correct sorting of secreted or chimeric influenza virus hemagglutinins in polarized monkey kidney cells". *The Journal of Cell Biology*, vol. 104, Mar. 1987, pp. 769-782.

Rottier et al., "Predicted Membrane Topology of the Coronavirus Protein E1". *Biochemistry*, vol. 25, 1986, pp. 1335-1339.

Rovira et al., "Experimental Inoculation of Conventional Pigs with Porcine Reproductive and Respiratory Syndrome virus and Porcine Circovirus 2". *J. Virol.*, Apr. 2002, vol. 76, No. 7, pp. 3232-3239.

Sagripanti et al., "The Cap Structure of Simian Hemorrhagic Fever Virion RNA". *Virology*, vol. 151, 1986, pp. 143-150.

Saif et al., "Serial propagation of porcine group C rotavirus (pararotavirus) in a continuous cell line and characterization of the passaged virus". *Journal of Clinical Microbiology*, vol. 26, No. 7, Jul. 1988, pp. 1277-1282.

Saif, L.J., "Coronavirus Immunogens". *Veterinary Microbiology*, vol. 37, No. 3-4, Nov. 1993, pp. 285-297.

Sarnow, P. "Role of 3'-End Sequences in Infectivity of Poliovirus Transcripts Made In Vitro". *Journal of Virology*, vol. 63, No. 1, Jan. 1989, pp. 467-470.

Sawicki et al., "Coronavirus Transcription: Subgenomic Mouse Hepatitis Virus Replicative Intermediates Function in RNA Synthesis". *Journal of Virology*, vol. 64, No. 3, Mar. 1990, pp. 1050-1056.

Schmidt et al., "Infection of Influenza A Viruses of Tracheal Organ Cultures Derived from Homologous and Heterologous Hosts". *The Journal of Infectious Diseases*, vol. 129, No. 1, 1974, pp. 28-36.

Scott, F.W., "Immunization against feline coronaviruses. Advances in Experimental Medicine and Biology", vol. 218, 1987, pp. 569-576.

Seal et al., "Analysis of the Serologic Relationship among San Miguel Sea Lion Virus and Vesicular Exanthema of Swine Virus Isolates. Application of the Western Blot Assay for Detection of Antibodies in Swine Sera to these Virus Types". *Journal of Veterinary Diagnostic Investigation*, vol. 7, No. 2, Apr. 1995, pp. 190-195.

Seal et al., "Isolation of caliciviruses from skunks that are antigenically and genotypically related to San Miguel sea lion virus Original Research". *Virus Research*, vol. 37, No. 1, Jun. 1995, pp. 1-12.

Seneca, H., "Influenza: epidemiology, etiology, immunization and management". *Journal of American Geriatrics Society*, vol. 28, No. 6, Jun. 1980, pp. 241-250.

Sethna et al., "Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons". *Proceedings of the National Academy of Sciences*, vol. 86, Jul. 1989, pp. 5626-5630.

Setzer et al., "Size Heterogeneity in the 3' End of Dihydrofolate Reductase Messenger RNAs in Mouse Cells". *Cell*, vol. 22, Nov. 1980, pp. 361-370.

Shaw et al., "Experimental rotavirus infection in three-week-old pigs". *American Journal of Veterinary Research*, vol. 50, No. 11, Nov. 1989, pp. 1961-1965.

Shen et al., "Determination of the complete nucleotide sequence of a vaccine strain of porcine reproductive and respiratory syndrome virus and identification of the Nsp2 gene with a unique insertion". *Archives of Virology*, vol. 145, No. 5, May 2000, pp. 871-883.

Shibata et al., "Detection of Human Papilloma Virus in Paraffin-Embedded Tissue Using the Polymerase Chain Reaction". *The Journal of Experimental Medicine*, vol. 167, No. 1, Jan. 1988, pp. 225-230.

Shieh et al., "The 5'-End Sequence of the Murine Coronavirus Genome: Implications of Multiple Fusion Sites in Leader-Primed Transcription". *Virology*, vol. 156, 1987, pp. 321-330.

Shin et al., "Assessment of Porcine Reproductive and Respiratory Syndrome Virus RNA Load in Sera and Tissues during Acute Infection". *Journal of Veterinary Science*, vol. 3, No. 2, 2002, pp. 75-85.

Shope et al., "The Susceptibility of Swine to the Virus of Human Influenza". *Annual Meeting of the Society of American Bacteriologists in New York*, 1936, pp. 791-801.

Shortridge et al., "Geographical Distribution of Swine (H5N1) and Hong Kong (H3N2) Influenza Virus Variants in Pigs in South-east Asia". *Intervirology*, vol. 11, No. 1, 1979, pp. 9-15.

Skiadopoulos et al., "Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine". *Journal of Virology*, vol. 73, No. 2, Feb. 1999, pp. 1374-1381.

Smith et al., "Isolation of Swine Influenza Virus from Autopsy Lung Tissue of Man". *New England Journal of Medicine*, vol. 294, Mar. 1976, pp. 708-710.

Smith et al., "San Miguel Sea Lion Virus Isolation, Preliminary Characterization and Relationship to Vesicular Exanthema of Swine Virus". *Nature*, vol. 244, Jul. 1973, pp. 108-110.

Snijder et al., "A 3'-Coterminal Nested Set of Independently Transcribed mRNAs Is Generated during Berne Virus Replication". *Journal of Virology*, vol. 64, No. 1, Jan. 1990, pp. 331-338.

(56)

References Cited

OTHER PUBLICATIONS

- Snijder et al., "Identification of a Novel Structural Protein of Arteriviruses". *Journal of Virology*, vol. 73, No. 8, Aug. 1999, pp. 6335-6345.
- Snijder et al., "Non-structural proteins 2 and 3 interact to modify host cell membranes during the formation of the arterivirus replication complex". *Journal of General Virology*, vol. 83, 2001, pp. 985-994.
- Snijder et al., "Proteolytic Processing of the Replicase ORF1a Protein of Equine Arteritis Virus". *Journal of Virology*, vol. 68, No. 9, Sep. 1994, pp. 5755-5764.
- Snijder et al., "The carboxyl-terminal part of the putative Berne virus polymerase is expressed by ribosomal frameshifting and contains sequence motifs which indicate that toro- and coronaviruses are evolutionarily related". *Nucleic Acids Research*, vol. 18, No. 15, Aug. 1990, pp. 4535-4542.
- Snijder et al., "The molecular biology of arteriviruses". *Journal of General Virology*, vol. 79, 1998, pp. 961-979.
- Snijder et al., "Toviruses: replication, evolution and comparison with other members of the coronavirus-like superfamily". *Journal of General Virology*, vol. 74, 1993, pp. 2305-2316.
- Spaan et al., "Coronaviruses: Structure and Genome Expression". *Journal of General Virology*, vol. 69, 1988, pp. 2939-2952.
- Stephen et al., "Swine Influenza Virus Vaccine: Potentiation in Rhesus Monkeys in Antibody Responses by a Nuclease Resistant Derivative of Ply I-Poly C". U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21701, 1976, 10 pages.
- Stephen et al., "Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys". *Science*, vol. 197, No. 4310, 1977, pp. 1289-1290.
- Stevenson et al., "Endemic Porcine Reproductive and Respiratory Syndrome Virus Infection of Nursery Pigs in Two Swine Herds without Current Reproductive Failure". *Journal of Veterinary Diagnostic Investigation*, vol. 5, 1993, pp. 432-434.
- Stim, T.B., "Arbovirus Plaquing in Two Simian Kidney Cell Lines". *Journal of General Virology*, vol. 5, No. 3, Oct. 1969, pp. 329-338.
- Suarez et al., "Direct detection of the porcine reproductive and respiratory syndrome (PRRS) virus by reverse polymerase chain reaction (RT-PCR)". *Archives of Virology*, vol. 135, No. 1-2, 1994, pp. 89-99.
- Suarez et al., "Phylogenetic relationships of European strains of porcine reproductive and respiratory syndrome virus (PRRSV) inferred from DNA sequences of putative ORF-5 and ORF-7 genes". *Virus Research*, vol. 42, Nos. 1-2, Jun. 1996, pp. 159-165.
- Sumiyoshi et al., "Infectious Japanese Encephalitis Virus RNA Can Be Synthesized from In Vitro-Ligated cDNA Templates". *Journal of Virology*, vol. 66, No. 9, Sep. 1992, pp. 5425-5431.
- Tahara et al., "Coronavirus Translational Regulation: Leader Affects mRNA Efficiency". *Virology*, vol. 202, No. 1, Aug. 1994, pp. 621-630.
- Tao et al., "Host Range Restriction of Parainfluenza Virus Growth Occurs at the Level of Virus Genome Replication". *Virology*, vol. 220, 1996, pp. 69-77.
- Tauraso et al., "Simian Hemorrhagic Fever: III. Characterization of a Viral Agent". *The American Journal of Tropical Medicine and Hygiene*, vol. 17, No. 3, May 1968, pp. 422-431.
- Terpstra et al., "Experimental reproduction of porcine epidemic abortion and respiratory syndrome (mystery swine disease) by infection with Lelystad virus: Koch's postulates fulfilled". *The Veterinary Quarterly*, vol. 13, No. 3, Jul. 1991, pp. 131-136.
- Thacker, B., "Clinical Manifestations of PRRS Virus". 2003 PRRS Compendium: Second Edition, National Pork Board, Des Moines, IA, 2003, pp. 7-15.
- Thanawongnuwech et al., "Effects of Low (Modified-live Virus Vaccine) and High (VR-2385)-Virulence Strains of Porcine Reproductive and Respiratory Syndrome Virus on Pulmonary Clearance of Copper Particles in Pigs". *Veterinary Pathology*, vol. 35, 1998, pp. 398-406.
- Theil et al., "Isolation and Serial Propagation of Turkey Rotaviruses in a Fetal Rhesus Monkey Kidney (MA104) Cell Line". *Avian Diseases*, vol. 30, No. 1, 1985, pp. 93-104.
- Theil et al., "Partial characterization of a bovine group A rotavirus with a short genome electropherotype". *Journal of Clinical Microbiology*, vol. 26, No. 6, Jun. 1988, p. 1094-1099.
- Thomson et al., "Ontario. Proliferative and necrotizing pneumonia (PNP) of swine: the Ontario situation". *Canadian Veterinary Journal*, vol. 32, May 1991, p. 313.
- Thouless et al., "Isolation of two lapine rotaviruses: Characterization of their subgroup, serotype and RNA electropherotypes". *Archives of Virology*, vol. 89, Nos. 1-4, 1986, pp. 161-170.
- Tian et al., "Emergence of Fatal PRRSV Variants: Unparalleled Outbreaks of Atypical PRRS in China and Molecular Dissection of the Unique Hallmark". *PLoS One*, vol. 2, No. 6, e526, 2007, pp. 1-10.
- Timony, P.J. "Equine Viral Arteritis", *Manual of Standards for Diagnostic Tests and Vaccines*, 1992, pp. 493-500.
- Tobita et al., "Plaque Assay and Primary Isolation of influenza A Viruses in an Established Line of Canine Kidney Cells (MDCK) in the Presence of Trypsin". *Medical Microbiology and Immunology*, vol. 162, No. 1, Dec. 1975, pp. 9-14.
- Todd et al., "Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations". *Vaccine*, vol. 15, No. 5, 1997, pp. 564-570.
- Wootton et al., "Structure-function of the ORF7 protein of porcine reproductive and respiratory syndrome virus in the viral capsid assembly". *Proceedings of the International Symposium on PRRS and Aujeszky's Disease*, Ploufragan, France, pp. 37-38.
- Yuan et al., "Complete genome comparison of porcine reproductive and respiratory syndrome virus parental and attenuated strains". *Virus Research*, vol. 74, 2001, pp. 99-110.
- Yuan et al., "Erratum to 'Complete genome comparison of porcine reproductive and respiratory syndrome virus parental and attenuated strains' [*Virus Research* 74 (2001) 99-110]". *Virus Research*, vol. 79, 2001, p. 187.
- Yuan et al., "Molecular characterization of a highly pathogenic strain of PRRSV associated with porcine High Fever syndrome in China". 2007 International Porcine Reproductive and Respiratory Syndrome (PRRS) Symposium, Chicago, Illinois, Nov.-Dec. 2007, Poster 70.
- Yuan et al., American Society for Virology, 16th Annual Meeting, Bozeman, Montana, Jul. 19-23, 1997, Abstract p. 29-5, p. 229.
- Zeijst, et al., "The Genome of Equine Arteritis Virus". *Virology*, vol. 68, 1975, pp. 418-425.
- Zhou et al., "Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus". *Proceedings of the National Academy of Sciences*, vol. 92, Mar. 1995, pp. 3009-3013.
- Zimmerman et al., "General overview of PRRSV: A perspective from the United States". *Veterinary Microbiology*, vol. 55, Nos. 1-4, Apr. 1997, pp. 187-196.
- Easterday, B.C., "Swine Influenza". *Diseases of Swine*, Sixth Edition, Iowa State University Press, 1986, pp. 244-315. (Part Two of Two—pp. 286-315).
- Carvajal et al., "Evaluation of a Blocking ELISA Using Monoclonal Antibodies for the Detection of Porcine Epidemic Diarrhea Virus and Its Antibodies". *Journal of Veterinary Diagnostic Investigation*, vol. 7, No. 1, Jan. 1995, pp. 60-64.
- Cavanagh, D., "Nidovirales: a new order comprising Coronaviridae and Arteriviridae". *Archives of Virology*, vol. 142, No. 3, 1997, pp. 629-633.
- Chang et al., "A cis-Acting Function for the Coronavirus Leader in Defective Interfering RNA Replication". *Journal of Virology*, vol. 68, No. 12, Dec. 1994, pp. 8223-8231.
- Chang et al., "Evolution of Porcine Reproductive and Respiratory Syndrome Virus during Sequential Passages in Pigs". *Journal of Virology*, vol. 76, No. 10, May 2002, pp. 4750-4763.
- Chao et al., "Monoclonal Antibodies to Metacyclic Stage Antigens of *Trypanosoma cruzi*". *The American Journal of Tropical Medicine and Hygiene*, vol. 34, No. 4, Jul. 1985, pp. 694-701.
- Charley, B., "Interaction of influenza virus with swine alveolar macrophages: Influence of anti-virus antibodies and cytochalasin B". *Annales de l'Institut Pasteur. Virologie*, vol. 134, No. 1, Jan. 1983, pp. 51-59.

(56)

References Cited

OTHER PUBLICATIONS

- Chasey et al., "Replication of Atypical Ovine Rotavirus in Small Intestine and Cell Culture". *Journal of General Virology*, vol. 67, No. 3, Mar. 1986, pp. 567-576.
- Chen et al., "Determination of the 5' end of the lactate dehydrogenase-elevating virus genome by two independent approaches". *Journal of General Virology*, vol. 75, 1994, pp. 925-930.
- Christianson et al., "Experimental Reproduction of a Newly Described Viral Disease, Swine Infertility and Respiratory Syndrome (SIRS), in Pregnant Sows". 72nd Annual Meeting of the Conference of Research Workers in Animal Disease, Chicago, IL, Nov. 11 & 12, 1991, p. 48, Abstract No. 269.
- Christianson et al., "Experimental reproduction of swine infertility and respiratory syndrome in pregnant sows". *American Journal of Veterinary Research*, vol. 53, No. 4, Apr. 1992, pp. 485-488.
- Christianson et al., "Porcine reproductive and respiratory syndrome: A review". *Journal of Swine Health and Production*, vol. 2, No. 2, Mar. and Apr. 1994, pp. 10-28.
- Christianson et al., "Swine Infertility and Respiratory Syndrome". *Pig Veterinary Journal*, vol. 27, No. 9, Apr. 1991, pp. 9-12.
- Chutivongse et al., "One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine". *Vaccine*, vol. 9, No. 8, Aug. 1991, pp. 573-576.
- Clark et al., "Trypsin enhancement of rotavirus infectivity: mechanism of enhancement". *Journal of Virology*, vol. 39, No. 3, Sep. 1981, pp. 816-822.
- Collins et al., "Experimental Transmission of Swine Reproductive Failure Syndrome (Mystery Swine Disease) in Gnotobiotic Piglets". 71st Annual Meeting of the Conference of Research Workers in Animal Disease, Chicago, IL, Nov. 5-6, 1990, Abstract No. 2.
- Collins et al., "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development". *Proceedings of the National Academy of Sciences*, vol. 92, Dec. 1995, pp. 11563-11567.
- Collins et al., "Respiratory Disease in a Swine Herd Experiencing a Reproductive Failure Syndrome". *Minnesota Swine Conference for Veterinarians*, Sep. 16-18, 1990, pp. 206-207.
- Collins et al., "Swine Diagnostic Pathology". *Allen D. Leman Swine Conference*, College of Veterinary Medicine, University of Minnesota, Sep. 18-22, 1998, pp. 1-4.
- Collins et al., "Swine Infertility and Respiratory Syndrome (Mystery Swine Disease)". *Minnesota Swine Conference for Veterinarians*, St. Paul, MN, Sep. 15-17, 1991, pp. 200-205.
- Collins, J.E., "Newly Recognized Respiratory Syndromes in North American Swine Herds". *American Association of Swine Practitioners Newsletter*, vol. 3, No. 7, Sep.-Oct. 1991, pp. 7, 10-11.
- Conner et al., "Isolation and characteristics of an equine reovirus type 3 and an antibody prevalence survey to reoviruses in horses located in New York State". *Veterinary Microbiology*, vol. 9, No. 1, Feb. 1984, pp. 15-25.
- Conzelmann et al., "Molecular Characterization of Porcine Reproductive and Respiratory Syndrome Virus, a Member of the Arterivirus Group". *Virology*, vol. 193, 1993, pp. 329-339.
- Cooper et al., "Porcine Reproductive and Respiratory Syndrome: NEB-1 PRRSV Infection did not Potentiate Bacterial Pathogens". *Journal of Veterinary Diagnostic Investigation*, vol. 7, No. 3, Jul. 1995, pp. 313-320.
- Corn et al., "Isolation of Vesicular Stomatitis Virus New Jersey Serotype from Phlebotomine Sand Flies in Georgia". *The American Journal of Tropical Medicine and Hygiene*, vol. 42, No. 5, May 1990, pp. 476-482.
- Dacso, et al., "Sporadic occurrence of zoonotic swine influenza virus infections". *Journal of Clinical Microbiology*, vol. 20, No. 4, Oct. 1984, pp. 833-835.
- Database WPIL Week 8702, Derwent Publications Ltd., London, GB; AN 87-009295 [2] & EP, A,208672 (Regional Wallonne-Chiron Corp, Wallonne Regional) Jan. 14, 1987.
- Database WPIL Week 8741, Derwent Publications Ltd., London, GB; AN 87-286929 [41] & EP, A,62, 198626 (Za Bieseibutsu Kagaku Ken) Sep. 2, 1987.
- Database WPIL Week 8821, Derwent Publications Ltd., London, GB; AN 88-147502 [21] & WO,A,8 803 410 (Inst Pasteur) May 19, 1988.
- De Mazancourt et al., "Antibody response to the rubella virus structural proteins in infants with the congenital rubella syndrome". *Journal of Medical Virology*, vol. 19, No. 2, Jun. 1986, pp. 111-122.
- De Vries et al., "Genetic Manipulation of Equine Arteritis Virus Using Full-Length cDNA Clones: Separation of Overlapping Genes and Expression of a Foreign Epitope". *Virology*, vol. 270, No. 1, 2000, pp. 84-97.
- De Vries et al., "The Genome Organization of the Nidovirales: Similarities and Differences between Arteri-, Toro-, and Coronaviruses". *Seminars in Virology*, vol. 8, 1997, pp. 33-47.
- De Vries, et al., "All subgenomic mRNAs of equine arteritis virus contain a common leader sequence". *Nucleic Acids Research*, vol. 18, No. 11, 1990, pp. 3241-3247.
- Dea et al., "Antigenic Variability among North American and European Strains of Porcine Reproductive and Respiratory Syndrome Virus as Defined by Monoclonal Antibodies to the Matrix Protein". *Journal of Clinical Microbiology*, vol. 34, No. 5, Jun. 1996, pp. 1488-1493.
- Dea et al., "Antigenic variant of swine influenza virus causing proliferative and necrotizing pneumonia in pigs". *Journal of Veterinary Diagnostic Investigation*, vol. 4, No. 4, 1992, pp. 380-392.
- Dea et al., "Caracteristiques d'Isolats des virus influenza et de l'encephalomyocardite associes au Syndrome Reproducteur et Respiratoire Porcine (S.R.R.P.) au Quebec.sup.a." *Le Medecin Veterinaire Du Quebec*, vol. 21, No. 4, Nov. 1991, pp. 170-175.
- Dea et al., "Current knowledge on the structural proteins of porcine reproductive and respiratory syndrome (PRRS) virus: comparison of the North American and European isolate". *Archives of Virology*, vol. 145, No. 4, Apr. 2000, pp. 659-688.
- Dea et al., "Isolation of encephalomyocarditis virus among stillborn and post-weaning pigs in Quebec". *Archives of Virology*, vol. 117, Nos. 1-2, 1991, pp. 121-128.
- Dea et al., "Swine reproductive and respiratory syndrome in Quebec: Isolation of an enveloped virus serologically-related to Lelystad virus". *Canadian Veterinary Journal*, vol. 33, No. 12, Dec. 1992, pp. 801-808.
- Dea et al., "Virus Isolations from Farms in Quebec Experiencing Severe Outbreaks of Respiratory and Reproductive Problems". *Proceedings of the Mystery Swine Disease Committee Meeting*, Denver, CO, Oct. 6, 1990, pp. 67-72.
- Del Val et al., "Glycosylated components of African swine fever virus particles". *Virology*, vol. 152, No. 1, Jul. 1986, pp. 39-49.
- Den Boon et al., "Equine Arteritis Virus Is Not a Togavirus but Belongs to the Coronaviruslike Superfamily". *Journal of Virology*, vol. 65, No. 6, 1991, pp. 2910-2920.
- Den Boon et al., "Processing and Evolution of the N-Terminal Region of the Arterivirus Replicase ORF1a Protein: Identification of Two Papainlike Cysteine Proteases". *Journal of Virology*, vol. 69, No. 7, Jul. 1995, pp. 4500-4505.
- Deng et al., "An improved procedure for utilizing terminal transferase to add homopolymers to the 3' termini of DNA". *Nucleic Acids Research*, vol. 9, No. 16, 1981, pp. 4173-4188.
- Derbyshire, J.B. "Porcine Enterovirus Infections". *Diseases of Swine*, Fifth Edition, Chapter 20, 1981, pp. 265-270.
- Dianzani et al., "Is Human Immunodeficiency Virus RNA Load Composed of Neutralized Immune Complexes". *The Journal of Infectious Diseases*, vol. 185, 2002, pp. 1051-1054.
- Dildrop et al., "Immunoglobulin V region variants in hybridoma cells. II. Recombination between V genes". *The EMBO Journal*, vol. 1, No. 5, 1982, pp. 635-640.
- Dreher, T.W., "Functions of the 3'-Untranslated Regions of Positive Strand RNA Viral Genomes". *Annual Review of Phytopathology*, vol. 37, 1999, pp. 151-174.

(56)

References Cited

OTHER PUBLICATIONS

- Drew et al., "Production, characterization and reactivity of monoclonal antibodies to porcine reproductive and respiratory syndrome virus". *Journal of General Virology*, vol. 76, 1995, pp. 1361-1369.
- Drew, T., "Porcine Reproductive and Respiratory Syndrome Virus: A Review". Apr. 1996, 3 pages.
- Duan et al., "Identification of a putative Receptor for Porcine Reproductive and Respiratory Syndrome Virus on Porcine Alveolar Macrophages". *Journal of Virology*, vol. 72, No. 5, May 1998, pp. 4520-4523.
- Fenner et al., "Viral Genetics and Evolution", *Veterinary Virology*, Ch. 5, 1992, pp. 89-95.
- Ferrari et al., "Isolation of Cytopathic Strains of Rotavirus from Pigs". *Microbiologica*, vol. 9, No. 3, Jul. 1986, pp. 287-294.
- Foss et al., "Adjuvant Danger Signals Increase the Immune Response to Porcine Reproductive and Respiratory Syndrome Virus". *Viral Immunology*, vol. 15, No. 4, 2002, pp. 557-566.
- Frolov et al., "Alphavirus-based expression vectors: Strategies and applications". *Proceedings of the National Academy of Sciences*, vol. 93, Oct. 1996, pp. 11371-11377.
- Fu et al., "Detection and survival of group A rotavirus in a piggery". *Veterinary Record*, vol. 125, 1989, pp. 576-578.
- Fukuhara et al., "Evidence for endocytosis-independent infection by human rotavirus". *Archives of Virology*, vol. 97, Nos. 1-2, 1987, pp. 93-99.
- Funkhouser et al., "Mutations in the 5'-noncoding, 2C and P3 Regions of the Genome Increase the Efficiency of Hepatitis A Virus Growth in MRC-5 Cells". *Vaccines*, vol. 94, Cold Springs Harbor Laboratory Press, 1994, pp. 345-349.
- Garwes, D.J., "Transmissible gastroenteritis". *Veterinary Record*, vol. 122, 1988, pp. 462-463.
- Geisbert et al., "Use of Immunoelectron Microscopy to Show Ebola Virus During the 1989 United States Epizootic". *Journal of Clinical Pathology*, vol. 43, No. 10, Oct. 1990, pp. 813-816.
- Girard et al., "Experimentally induced porcine proliferative and necrotising pneumonia with an influenza A virus". *The Veterinary Record*, vol. 130, Mar. 1992, pp. 206-207.
- Godeny et al., "Map location of lactate dehydrogenase-elevating virus (LDV) capsid protein (Vpl) gene". *Virology*, vol. 177, No. 2, Aug. 1990, pp. 768-771.
- Godeny et al., "The 3' Terminus of Lactate Dehydrogenase-Elevating Virus Genome RNA Does Not Contain Togavirus or Flavivirus Conserved Sequences". *Virology*, vol. 72, 1989, pp. 647-650.
- Goldfield et al., "Influenza in New Jersey in 1976: Isolations of Influenza A/New Jersey/76 Virus at Fort Dix". *The Journal of Infectious Diseases*, vol. 136, Supp. 3, 1977, pp. S347-S355.
- Goldstein, et al., "Evaluation of Three Cell Culture Systems as Substrates for Influenza Virus Assay". *Applied Microbiology*, vol. 19, No. 4, Apr. 1970, pp. 580-582.
- Gorcyca et al., ResPPRRS: A new tool for the prevention and control of PRRS in pigs. *Proceedings of the American Association of Swine Practitioners*, Omaha, Nebraska, Mar. 1995, pp. 1-22.
- Gourreau et al., "Diffusion du virus de la grippe du porc (H1N1=Hsw1N1) en France". *Annales de l'Institut Pasteur/Virologie*, vol. 132, No. 2, Apr.-Jun. 1981, pp. 287-294.
- Goyal, S., "Porcine Reproductive and Respiratory Syndrome". *Journal of Veterinary Diagnostic Investigation*, vol. 5, No. 4, 1993, pp. 656-664.
- Gravell et al., "Differences among isolates of simian hemorrhagic fever (SHF) virus". *Proceedings of the Society for Experimental Biology and Medicine*, vol. 181, No. 1, 1986, pp. 112-119.
- Graves, J.H., "Swine Vesicular Disease". *Diseases of Swine*, Fifth Edition, Chapter 23, The Iowa State University Press, Ames, Iowa, 1958, pp. 288-293.
- Grebennikova et al., "Genomic characterization of virulent, attenuated, and revertant passages of a North American porcine reproductive and respiratory syndrome virus strain". *Virology*, vol. 321, 2004, pp. 383-390.
- Greiner et al., "Quantitative relationship of systemic virus concentration on growth and immune response in pigs". *Journal of Animal Science*, vol. 78, 2000, pp. 2690-2695.
- Grizzard et al., "Experimental production of respiratory tract disease in cebus monkeys after intratracheal or intranasal infection with influenza A/Victoria/3/75 or influenza A/New Jersey/76 virus". *Infection and Immunity*, vol. 21, No. 1, Jul. 1978, pp. 201-205.
- Halbur et al., "Effects of different US isolates of porcine reproductive and respiratory syndrome virus (PRRSV) on blood and bone marrow parameters of experimentally infected pigs". *Veterinary Record*, vol. 151, 2002, pp. 344-348.
- Hao et al., "Polymorphic genetic characterization of the ORF7 gene of porcine reproductive and respiratory syndrome virus (PRRSV) in China". *Virology Journal*, vol. 8:73, pp. 1-9.
- Haynes et al., "Temporal and Morphologic Characterization of the Distribution of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) by In Situ Hybridization in Pigs Infected with Isolates of PRRSV that Differ in Virulence". *Veterinary Pathology*, vol. 34, 1997, pp. 39-43.
- Heath, et al., "The Behaviour of Some Influenza Viruses in Tissue Cultures of Kidney Cells of Various Species". *Archiv. f. Virusforschung Bd. VIII, HS, 1958*, pp. 577-591.
- Hedger et al., "Swine Vesicular Disease Virus". *Virus Infections of Porcines*, Elsevier Science Publishers, B.V., 1989, pp. 241-250.
- Hennen, J., "Statistical methods for longitudinal research on bipolar disorders". *Bipolar Disorders*, vol. 5, 2003, pp. 156-168.
- Hill, Howard, "Overview and History of Mystery Swine". *Proceedings of the Mystery Swine Disease Committee Meeting*, Denver, CO, Oct. 6, 1990, pp. 29-40.
- Hirsch et al., "Ultrastructure of Human Leukocytes After Simultaneous Fixation with Glutaraldehyde and Osmium Tetroxide and "Postfixation" in Uranyl Acetate". *The Journal of Cell Biology*, vol. 38, 1968, pp. 615-627.
- Meulenberg et al., "Characterization of Proteins Encoded by ORFs 2 to 7 of Lelystad Virus". *Virology*, vol. 206, No. 1, Jan. 1995, pp. 155-163.
- Meulenberg et al., "Identification and Characterization of a Sixth Structural Protein of Lelystad Virus: The Glycoprotein GP2 Encoded by ORF2 Is Incorporated in Virus Particles". *Virology*, vol. 225, No. 1, Nov. 1996, pp. 44-51.
- Meulenberg et al., "Infectious Transcripts from Cloned Genome-Length cDNA of Porcine Reproductive and Respiratory Syndrome Virus". *Journal of Virology*, vol. 72, No. 1, Jan. 1998, pp. 380-387.
- Meulenberg et al., "Lelystad Virus, the Causative Agent of Porcine Epidemic Abortion and Respiratory Syndrome (PEARS), is Related to LDV and EAV". *Virology*, vol. 192, 1993, pp. 62-72.
- Meulenberg et al., "Localization and Fine Mapping of Antigenic Sites on the Nucleocapsid Protein N of Porcine Reproductive and Respiratory Syndrome Virus with Monoclonal Antibodies". *Virology*, vol. 252, 1998, pp. 106-114.
- Meulenberg et al., "Molecular characterization of Lelystad virus". *Veterinary Microbiology*, vol. 55, 1997, pp. 197-202.
- Meulenberg et al., "Nucleocapsid Protein N of Lelystad Virus: Expression by Recombinant Baculovirus, Immunological Properties, and Suitability for Detection of Serum Antibodies". *Clinical and Diagnostic Laboratory Immunology*, vol. 2, No. 6, Nov. 1995, pp. 652-656.
- Meulenberg et al., "Posttranslational Processing and Identification of a Neutralization Domain of the GP4 Protein Encoded by ORF4 of Lelystad Virus". *Journal of Virology*, vol. 71, No. 8, Aug. 1997, pp. 6061-6067.
- Meulenberg et al., "Subgenomic RNAs of Lelystad virus contain a conserved leader-body junction sequence". *Journal of General Virology*, vol. 74, 1993, pp. 1697-1701.
- Molenkamp et al., "Isolation and Characterization of an Arterivirus Defective Interfering RNA Genome". *Journal of Virology*, vol. 74, No. 7, 2000, pp. 3156-3165.
- Molenkamp et al., "The arterivirus replicase is the only viral protein required for genome replication and subgenomic mRNA transcription". *Journal of General Virology*, vol. 81, No. 10, 2000, pp. 2491-2496.

(56)

References Cited

OTHER PUBLICATIONS

- Montagnon, B.J., "Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line". *Dev Biol Stand.*, vol. 70, 1989, pp. 27-47.
- Moore, C., "Porcine Proliferative and Necrotizing Pneumonia Clinical Findings". Presented at American Association of Swine Practitioners, 22nd Annual Meeting, Mar. 3-5, 1991, pp. 443-453.
- Moormann et al., "Hog cholera virus: identification and characterization of the viral RNA and the virus specific RNA synthesized in infected swine kidney cells". *Virus Research*, vol. 11, 1988, pp. 281-291.
- Moormann et al., "Infectious RNA Transcribed from an Engineered Full-Length cDNA Template of the Genome of a Pestivirus". *Journal of Virology*, vol. 70, No. 2, Feb. 1996, pp. 763-770.
- Moormann et al., "Molecular cloning and nucleotide sequence of hog cholera virus strain brescia and mapping of the genomic region encoding envelope protein E1". *Virology*, vol. 177, No. 1, Jul. 1990, pp. 184-198.
- Morin et al., "Severe proliferative and necrotizing pneumonia in pigs: A newly recognized disease". *Canadian Veterinary Journal*, vol. 31, Dec. 1990, pp. 837-839.
- Morozov et al., "Sequence analysis of open reading frames (ORFs) 2 to 4 of a U.S. isolate of porcine reproductive and respiratory syndrome virus". *Archives of Virology*, vol. 140, No. 7, 1995, pp. 1313-1319.
- Morrison et al., "Brief Communications Serologic evidence incriminating a recently isolated virus (ATCC VR-2332) as the cause of swine infertility and respiratory syndrome (SIRS)". *Journal of Veterinary Diagnostic Investigation*, vol. 4, No. 2, Apr. 1992, pp. 186-188.
- Morrison et al., "Sero-epidemiologic Investigation of Swine Infertility and Respiratory Syndrome (SIRS)". 72st Annual Meeting of the Conference of Research Workers in Animal Disease, Chicago, IL, Nov. 11-12, 1991, p. 55, Abstract No. 309.
- Mountz et al., "The in vivo generation of murine IgD-secreting cells is accompanied by deletion of the C_μ gene and occasional deletion of the gene for the CD1 domain". *The Journal of Immunology*, vol. 145, No. 5, Sep. 1990, pp. 1583-1591.
- Mukamoto et al., "Immunogenicity in Aujeszky's disease virus structural glycoprotein gVI (gp50) in swine". *Veterinary Microbiology*, vol. 29, No. 2, Oct. 1991, pp. 109-121.
- Murakami, et al., "Difference in growth behavior of human, swine, equine, and avian influenza viruses at a high temperature". *Archives of Virology*, vol. 1000, Nos. 3-4, 1988, pp. 231-244.
- Murphy et al., "Immunization Against Virus" in *Virology*, 2nd Edition, vol. 1, Fields, et al., eds. Raven Press, NY, 1990, pp. 469-502.
- Murphy et al., "Virus Taxonomy". Chapter 2 in *Fields Virology*, 2nd Edition, Fields, et al., eds, Raven Press, New York, 1990, pp. 9-35.
- Murtaugh et al., "Comparison of the structural protein coding sequences of the VR-2332 and Lelystad virus strains of the PRRS virus". *Archives of Virology*, vol. 140, No. 8, 1995, pp. 1451-1460.
- Murtaugh et al., "Genetic Variation in the PRRS Virus". *Coronaviruses and Arteriviruses*, Plenum Press, New York, 1998, pp. 787-794.
- Murtaugh et al., "Immunological Responses of Swine to Porcine Reproductive and Respiratory Syndrome Virus Infection". *Viral Immunology*, vol. 15, No. 4, 2002, pp. 533-547.
- Murtaugh et al., "Role of Viral Proteases in PRRS Immunity, Project Period Sep. 1, 1997-Dec. 31, 2002, no cost extension Jan. 1, 2003-Jun. 30, 2003". Final Report: Aug. 30, 2003, Department of Veterinary Pathology, University of Minnesota, St. Paul, MN and Boehringer Ingelheim Vetmedica, Inc., Ames, IA, 2003, pp. 1-38.
- Murtaugh, "Allen D Lehman Swine Conference: the Evolution of the Swine veterinary profession: The PRRS Virus". University of Minnesota, Veterinary Continuing Education and Extension, vol. 20, 1993, pp. 43-47.
- Myers et al., "Propagation of avian rotavirus in primary chick kidney cell and MA104 cell cultures". *Avian Diseases*, vol. 33, No. 3, Jul.-Sep. 1989, pp. 578-581.
- Nakamura et al., "Studies on Swine Influenza III. Propagation of Swine Influenza Virus in Explants of Respiratory Tract Tissues from Fetal Pigs". *The Cornell Veterinarian*, vol. LX, No. 1, Jan. 1970, pp. 27-35.
- Narayanan et al., "Characterization of the Coronavirus M Protein and Nucleocapsid Interaction in Infected Cells". *Journal of Virology*, vol. 74, No. 17, Sep. 2000, pp. 8127-8134.
- NCBI: Accession No. AE005172. "*Arabidopsis thaliana* chromosome 1, top arm complete sequence." Dec. 14, 2000.
- NCBI: Accession No. AF046869. "Porcine reproductive and respiratory syndrome virus isolate 16244B, Feb. 18, 1997 (Nebraska) pass.3, complete genome." Mar. 17, 1999.
- NCBI: Accession No. AF066183. "Porcine reproductive and respiratory syndrome virus RespPRRS MLV, complete genome." Feb. 22, 2001.
- NCBI: Accession No. AF159149. "Porcine reproductive and respiratory syndrome virus isolate MLV RespPRRS/Repro, complete genome." Aug. 28, 2000.
- NCBI: Accession No. AF176348. "Porcine reproductive and respiratory syndrome virus isolate PA8 complete genome." Sep. 3, 2002.
- NCBI: Accession No. AF184212. "Porcine reproductive and respiratory syndrome virus strain SP, complete genome." Sep. 28, 2000.
- NCBI: Accession No. AF325691. "Porcine reproductive and respiratory syndrome virus isolate NVSL 977985 IA 1-4-2, complete genome." Feb. 11, 2001.
- NCBI: Accession No. AF331831. "Porcine reproductive and respiratory syndrome virus BJ-4, complete genome." Jan. 15, 2001.
- NCBI: Accession No. M96262. "Lelystad virus, complete genome." Nov. 8, 2000.
- NCBI: Accession No. M96262.2. "Lelystad virus, complete genome." Nov. 8, 2000.
- NCBI: Accession No. NC_001639. Lactate dehydrogenase-elevating virus, complete genome. Dec. 8, 2008.
- NCBI: Accession No. NC_001961. "Porcine reproductive and respiratory syndrome virus, complete genome." Jan. 12, 2004.
- NCBI: Accession No. NC_002533. "Lelystad virus, complete genome." Nov. 11, 2000.
- NCBI: Accession No. NC_002534. "Lactate dehydrogenase-elevating virus, complete genome." Dec. 29, 2003.
- NCBI: Accession No. U15146. "Lactate dehydrogenase-elevating virus Plegemann strain, complete genome." Jan. 26, 1996.
- NCBI: Accession No. U87392 AF030244 U00153. "Porcine reproductive and respiratory syndrome virus strain VR-2332, complete genome." Nov. 17, 2000.
- Nelsen et al., "Porcine Reproductive and Respiratory Syndrome Virus Comparison: Divergent Evolution on Two Continents". *Journal of Virology*, vol. 73, No. 1, Jan. 1999, pp. 270-280.
- Labarque et al., "Effect of cellular changes and onset of humoral immunity on the replication of porcine reproductive and respiratory syndrome virus in the lungs of pigs". *Journal of General Virology*, vol. 81, 2000, pp. 1327-1334.
- Labarque et al., "Respiratory tract protection upon challenge of pigs vaccinated with attenuated porcine reproductive and respiratory syndrome virus vaccines". *Veterinary Microbiology*, vol. 95, 2003, pp. 187-197.
- Lai et al., "Coronavirus: how a large RNA viral genome is replicated and transcribed". *Infectious Agents and Disease*, vol. 3, Nos. 2-3, 1994, pp. 98-105.
- Lai et al., "Coronavirus: organization, replication and expression of genome". *Annual Review of Microbiology*, vol. 33, 1990, pp. 303-333.
- Lai et al., "Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus". *Proceedings of the National Academy of Sciences*, vol. 88, Jun. 1991, pp. 5139-5143.
- Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities". *Molecular and Cellular Biology*, vol. 8, No. 3, Mar. 1988, pp. 1247-1252.
- Leitner et al., "DNA and RNA-based vaccines: principles, progress and prospects". *Vaccine*, vol. 18, 2000, pp. 765-777.
- Levy et al., "Freeze-drying is an effective method for preserving infectious type C retroviruses". *Journal of Virological Methods*, vol. 5, Nos. 3-4, Nov. 1982, pp. 165-171.

(56)

References Cited

OTHER PUBLICATIONS

- Liljestrom et al., "A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon". *Nature Biotechnology*, vol. 9, 1991, pp. 1356-1361.
- Lin et al., "Deletion Mapping of a Mouse Hepatitis Virus Defective Interfering RNA Reveals the Requirement of an Internal and Discontiguous Sequence for Replication". *Journal of Virology*, vol. 67, No. 10, Oct. 1993, pp. 6110-6118.
- Lin et al., "Identification of the cis-Acting Signal for Minus-Strand RNA Synthesis of a Murine Coronavirus: Implications for the Role of Minus-Strand RNA in RNA Replication and Transcription". *Journal of Virology*, vol. 68, No. 12, Dec. 1994, pp. 8131-8140.
- Lin et al., "The 3' Untranslated Region of Coronavirus RNA Is Required for Subgenomic mRNA Transcription from a Defective Interfering RNA". *Journal of Virology*, vol. 70, No. 10, Oct. 1995, pp. 7236-7240.
- Liu et al., "A Specific Host Cellular Protein Binding Element Near the 3' End of Mouse Hepatitis Virus Genomic RNA". *Virology*, vol. 232, No. 1, May 1997, pp. 74-85.
- Loula, T., "Clinical Presentation of Mystery Pig Disease in the Breeding Herd and Suckling Piglets". *Proceedings of the Mystery Swine Disease Committee Meeting, Denver, CO, Oct. 6, 1990*, pp. 37-40.
- Loula, T., "Mystery Pig Disease", *Agri-Practice*, vol. 12, No. 1, Jan.-Feb. 1991, pp. 29-34.
- Luytjes et al., "Replication of Synthetic Defective Interfering RNAs Derived from Coronavirus Mouse Hepatitis Virus-A59". *Virology*, vol. 216, No. 1, Feb. 1996, pp. 174-183.
- Lv et al., "An infectious cDNA clone of a highly pathogenic porcine reproductive and respiratory syndrome virus variant associated with porcine high fever syndrome". *Journal of General Virology*, vol. 89, 2008, pp. 2075-2079.
- Madec et al., "Consequences pathologiques d'un episode grippal severe (virus swine A/H1N1 dans les conditions naturelles chez la truie non immune en debut de gestation)". *Comparative Immunology, Microbiology and Infectious Diseases*, vol. 12, Nos. 1-2, 1989, pp. 17-27.
- Madin, S.H. "Vesicular Exanthema Virus". *Virus Infections of Porcines*, Elsevier Science Publishers B.V., 1989, pp. 267-271.
- Makabe et al., "Hemagglutination with Ovine Rotavirus". *Archives of Virology*, vol. 90, 1986, pp. 153-158.
- Makino et al., "Leader sequences of murine coronavirus mRNAs can be freely reassorted: Evidence for the role of free leader RNA in transcription". *Proceedings of the National Academy of Sciences*, vol. 83, Jun. 1986, pp. 4204-4208.
- Makino et al., "Primary Structure and Translation of a Defective Interfering RNA of Murine Coronavirus". *Virology*, vol. 166, 1988, pp. 550-560.
- Masters et al., "Functions of the coronavirus nucleocapsid protein". *Coronaviruses and Their Diseases*, Plenum Press, New York, pp. 235-238.
- McQueen et al., "Influenza in animals". *Advances in Veterinary Science*, vol. 12, 1968, pp. 285-336.
- Meikeljohn et al., "Respiratory Virus Vaccine Evaluation and Surveillance". *Semi-Annual Contract Progress Report to the National Institute of Allergy and Infectious Diseases*, Sep. 15, 1965 to Mar. 15, 1966, 21 pgs.
- Melchers et al., "Cross-talk between orientation-dependent recognition determinants of a complex control RNA element, the enterovirus oriR". *RNA*, vol. 6, 2000, pp. 976-987.
- Mendez et al., "Molecular Characterization of Transmissible Gastroenteritis Coronavirus Defective Interfering Genomes: Packaging and Heterogeneity". *Virology*, vol. 217, 1996, pp. 495-507.
- Meng et al., "Characterization of a High-Virulence US Isolate of Porcine Reproductive and Respiratory Syndrome Virus in a Continuous Cell Line, ATCC CRL11171". *Journal of Veterinary Diagnostic Investigation*, vol. 8, No. 3, Jul. 1996, pp. 374-381.
- Meng et al., "Molecular cloning and nucleotide sequencing of the 3'-terminal genomic RNA of the porcine reproductive and respiratory syndrome virus". *Journal of General Virology*, vol. 75, 1994, pp. 1795-1801.
- Meng et al., "Phylogenetic analyses of the putative M (ORF 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome virus (PRRSV): implication for the existence of two genotypes of PRRSV in the U.S.A. and Europe". *Archives of Virology*, vol. 140, No. 4, 1995, pp. 745-755.
- Meng, X.J., "Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development". *Veterinary Microbiology*, vol. 74, 2000, pp. 309-329.
- Mengeling et al., "Clinical consequences of exposing pregnant gilts to strains of porcine reproductive and respiratory syndrome (PRRS) virus isolated from field cases of "atypical" PRRS". *American Journal of Veterinary Research*, vol. 59, No. 12, Dec. 1998, pp. 1540-1544.
- Mengeling et al., "Clinical Effects of porcine reproductive and respiratory syndrome virus on pigs during the early postnatal interval". *American Journal of Veterinary Research*, vol. 59, No. 1, Jan. 1998, pp. 52-55.
- Mengeling et al., "Comparative safety and efficacy of attenuated single-strain and multi-strain vaccines for porcine reproductive and respiratory syndrome". *Veterinary Microbiology*, vol. 93, 2003, pp. 25-38.
- Mengeling et al., "Comparison among strains of porcine reproductive and respiratory syndrome virus for their ability to cause reproductive failure". *American Journal of Veterinary Research*, vol. 57, No. 6, Jun. 1996, pp. 834-839.
- Mengeling et al., "Mystery Pig Disease: Evidence and Considerations for its Etiology". *Proceedings of the Mystery Swine Disease Committee Meeting, Oct. 6, 1990, Denver, Colorado*, Livestock Conservation Institute, Madison, WI, USA, pp. 88-90.
- Mengeling et al., "Strain specificity of the immune response of pigs following vaccination with various strains of porcine reproductive and respiratory syndrome virus". *Veterinary Microbiology*, vol. 93, 2003, pp. 13-24.
- Meredith, M.J., "Porcine Reproductive and Respiratory Syndrome (PRRS)", *Pig Disease Information Center, 1st North American Edition*, University of Cambridge, Aug. 1994, pp. 1-57.
- Mettenleiter et al., "Isolation of a viable herpesvirus (pseudorabies virus) mutant specifically lacking all four known nonessential glycoproteins". *Virology*, vol. 179, No. 1, Nov. 1990, pp. 498-503.
- Meulenbergh et al., "An infectious cDNA clone of Porcine Reproductive and Respiratory Syndrome Virus". *Coronaviruses and Arteriviruses (Advances in Experimental Medicine and Biology*, vol. 440), Ch. 24, 1998, pp. 199-206.
- Hofmann et al., "Propagation of the virus of porcine epidemic diarrhea in cell culture". *Journal of Clinical Microbiology*, vol. 26, No. 11, Nov. 1988, pp. 2235-2239.
- Hofmann et al., "Quantitation, biological and physicochemical properties of cell culture-adapted porcine epidemic diarrhea coronavirus (PEDV)". *Veterinary Microbiology*, vol. 20, No. 2, Jun. 1989, pp. 131-142.
- Honda et al., "A Serological Comparison of 4 Japanese Isolates of Porcine Enteroviruses with the International Reference Strains". *The Japanese Journal of Veterinary Science*, vol. 52, No. 1, 1990, pp. 49-54.
- Horowitz et al., "Anti-schistosome monoclonal antibodies of different isotypes—correlation with cytotoxicity". *The EMBO Journal*, vol. 2, No. 2, 1983, pp. 193-198.
- Horzinek et al., "Studies on the Substructure of Togaviruses: II. Analysis of Equine Arteritis Rubella, Bovine Viral Diarrhea, and Hog Cholera Viruses". *Archiv Für die gesamte Virusforschung*, vol. 33, 1971, pp. 306-318.
- Hoshino et al., "Isolation and characterization of an equine rotavirus". *Journal of Clinical Microbiology*, vol. 18, No. 3, Sep. 1983, pp. 585-591.
- Hoshino et al., "Serotypic Similarity and Diversity of Rotaviruses of Mammalian and Avian Origin as Studied by Plaque-Reduction Neutralization". *The Journal of Infectious Diseases*, vol. 149, No. 5, May 1984, pp. 694-702.
- Hsue et al., "Characterization of an Essential RNA Secondary Structure in the 3' Untranslated Region of the Murine Coronavirus Genome". *Journal of Virology*, vol. 74, No. 15, Aug. 2000, pp. 6911-6921.

(56)

References Cited

OTHER PUBLICATIONS

- Huang et al., "Polypyrimidine Tract-Binding Protein Binds to the Complementary Strand of the Mouse Hepatitis Virus 3' Untranslated Region, Thereby Altering RNA Conformation". *Journal of Virology*, vol. 73, No. 11, Nov. 1999, pp. 9110-9116.
- Hurrelbrink et al., "Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein". *Journal of Virology*, vol. 75, No. 16, Aug. 2001, pp. 7692-7702.
- Hwang et al., "A 68-Nucleotide Sequence within the 3' Noncoding Region of Simian Hemorrhagic Fever Virus Negative-Strand RNA Binds to Four MA104 Cell Proteins". *Journal of Virology*, vol. 72, No. 5, May 1998, pp. 4341-4351.
- Hyllseth, B., "Structural Proteins of Equine Arteritis Virus". *Archiv Für die gesamte Virusforschung*, vol. 30, 1973, pp. 177-188.
- Iltis et al., "Persistent Varicella-Zoster virus infection in a human rhabdomyosarcoma cell line and recovery of a plaque variant". *Infection and Immunity*, vol. 37, No. 1, Jul. 1982, pp. 350-358.
- Imagawa et al., "Isolation of Foal Rotavirus in MA-104 Cells". *Bulleting of Equine Research Institute*, vol. 18, 1981, pp. 119-128.
- International Search Report for PCT/US2000/10852 mailed on Aug. 3, 2000.
- Izeta et al., "Replication and Packaging of Transmissible Gastroenteritis Coronavirus-Derived Synthetic Minigenomes". *Journal of Virology*, vol. 73, No. 2, Feb. 1999, pp. 1535-1545.
- Jackwood et al., "Replication of Infectious Bursal Disease Virus in Continuous Cell Lines". *Avian Diseases*, vol. 31, No. 2, Apr.-Jun. 1987, pp. 370-375.
- Johnson et al., "Feline panleucopaenia virus. IV. Methods for obtaining reproducible in vitro results". *Research in Veterinary Science*, vol. 8, No. 2, Apr. 1967, pp. 256-264.
- Johnson et al., "Pathogenic and humoral immune responses to porcine reproductive and respiratory syndrome virus (PRRSV) are related to viral load in acute infection". *Veterinary Immunology and Immunopathology*, vol. 102, No. 3, PRRS Immunology and Immunopathology Special Issue, Dec. 2004, pp. 233-247.
- Johnston et al., "Genetic to genomic vaccination". *Vaccine*, vol. 15, No. 8, 1997, pp. 808-809.
- Joo et al., "Encephalomyocarditis Virus As a Potential Cause for Mystery Swine Disease", *Livestock Conservation Institute, Proceedings of the Mystery Swine Disease Committee Meeting, Denver, CO, Oct. 6, 1990, pp. 62-66.*
- Jun et al., "Comparison of Dynamics in Viremia Levels in Chickens Inoculated with Marek's Disease Virus Strains of Different Pathotypes". *Virologica Sinica*, vol. 16, No. 1, Mar. 2001, pp. 59-63.
- Jusa et al., "Effect of heparin on infection of cells by porcine reproductive and respiratory syndrome virus". *American Journal of Veterinary Research*, vol. 58, No. 5, May 1997, pp. 488-491.
- Just et al., "A New Jersey/76 influenza vaccine trial in seronegative schoolchildren: Comparison of a subunit vaccine with a whole-virus vaccine". *Medical Microbiology and Immunology*, vol. 164, No. 4, 1978, pp. 277-284.
- Kang et al., "Primary Isolation and Identification of Avian Rotaviruses from Turkeys Exhibiting Signs of Clinical Enteritis in a Continuous MA-104 Cell Line". *Avian Diseases*, vol. 30, 1986, pp. 494-499.
- Kapur et al., "Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the midwestern United States". *Journal of General Virology*, vol. 77, 1996, pp. 1271-1276.
- Kasza et al., "Establishment, viral susceptibility and biological characteristics of a swine kidney cell line SK-6". *Research in Veterinary Science*, vol. 13, No. 1, Jan. 1972, pp. 46-51.
- Kasza et al., "Isolation and Characterization of a Rotavirus from Pigs". *Veterinary Record*, vol. 87, 1970, pp. 681-686.
- Katz et al., "Antigenic differences between European and American isolates of porcine reproductive and respiratory syndrome virus (PRRSV) are encoded by the carboxyterminal portion of viral open reading frame 3". *Veterinary Microbiology*, vol. 44, No. 1, Apr. 1995, pp. 65-76.
- Keffaber, K., "Reproductive Failure of Unknown Etiology". *AASP Newsletter*, vol. 1, No. 2, Sep.-Oct. 1989, pp. 1, 4-5, 8-10.
- Keffaber, K.K., "Swine Reproductive Failure of Unknown Etiology". *The George A. Young Swine Conference & Annual Nebraska SPF Swine Conference*, Aug. 13-14, 1990, pp. 55-67.
- Key et al., "Genetic variation and phylogenetic analyses of the ORF5 gene of acute porcine reproductive and respiratory syndrome virus isolates". *Veterinary Microbiology*, vol. 83, 2001, pp. 249-263.
- Kim et al., "Analysis of cis-Acting Sequences Essential for Coronavirus Defective Interfering RNA Replication". *Virology*, vol. 197, No. 1, Nov. 1993, pp. 53-63.
- Kim et al., "Different Biological Characteristics of Wild-Type Porcine Reproductive and Respiratory Syndrome Viruses and Vaccine Viruses and Identification of the Corresponding Genetic Determinants". *Journal of Clinical Microbiology*, vol. 46, No. 5, May 2008, pp. 1758-1768.
- Kim et al., "Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line". *Archives of Virology*, vol. 133, 1993, pp. 477-483.
- Klein et al., "Deletion of the IgH enhancer does not reduce immunoglobulin heavy chain production of a hybridoma IgD class switch variant". *The EMBO Journal*, vol. 3, No. 11, Nov. 1984, pp. 2473-2476.
- Klinge et al., "Age-dependent resistance to Porcine reproductive and respiratory syndrome virus replication in swine". *Virology Journal*, vol. 6, No. 177, Oct. 2009.
- Klinge et al., "PRRS replication and subsequent immune responses in swine of various ages". *Abstract of Poster No. 56, International Porcine Reproductive and Respiratory Syndrome (PRRS) Symposium, PRRS and PRRSV-Related Diseases: Prevention and Control Strategies, Chicago, IL, Nov. 30-Dec. 1, 2007.*
- Klovins et al., "A Long-range Pseudoknot in Q β RNA is Essential for Replication". *Journal of Molecular Biology*, vol. 294, 1999, pp. 875-884.
- Klump et al., "Complete Nucleotide Sequence of Infectious Coxsackievirus B3 cDNA: Two Initial 5' Uridine Residues Are Regained during Plus-Strand RNA Synthesis". *Journal of Virology*, vol. 64, No. 4, Apr. 1990, pp. 1573-1583.
- Klupp et al., "Sequence and expression of the glycoprotein gH gene of pseudorabies virus". *Virology*, vol. 182, No. 2, Jun. 1991, pp. 732-741.
- Knowles et al., "Classification of porcine enteroviruses by antigenic analysis and cytopathic effects in tissue culture: Description of 3 new serotypes". *Archives of Virology*, vol. 62, No. 3, 1979, pp. 201-208.
- Kolodziej et al., "Epitope tagging and protein surveillance". *Methods in Enzymology*, vol. 194, 1991, pp. 508-519.
- Kouvelos et al., "Comparison of Bovine, Simian and Human Rotavirus Structural Glycoproteins". *Journal of General Virology*, vol. 65, Jul. 1984, pp. 1211-1214.
- Kreutz, L.C., "Cellular membrane factors are the major determinants of porcine reproductive and respiratory syndrome virus tropism". *Virus Research*, vol. 53, 1998, pp. 121-128.
- Kundin, W.D., "Hong Kong A-2 Influenza Virus Infection among Swine during a Human Epidemic in Taiwan". *Nature*, vol. 228, Nov. 1970, p. 857.
- Kuo et al., "A Nested Set of Eight RNAs Is Formed in Macrophages Infected with Lactate Dehydrogenase-Elevating Virus". *Journal of Virology*, vol. 65, No. 9, Sep. 1991, pp. 5118-5123.
- Kusanagi et al., "Isolation and Serial Propagation of Porcine Epidemic Diarrhea Virus in Cell Cultures and Partial Characterization of the Isolate". *Journal of Veterinary Medical Science*, vol. 54, No. 2, 1992, pp. 313-318.
- Kutsuzawa et al., "Isolation of Human Rotavirus Subgroups 1 and 2 in Cell Culture". *Journal of Clinical Microbiology*, vol. 16, No. 4, Oct. 1982, pp. 727-730.
- Kwang et al., "Cloning, expression, and sequence analysis of the ORF4 gene of the porcine reproductive and respiratory syndrome virus MN-1b". *Journal of Veterinary Diagnostic Investigation*, vol. 6, No. 3, Jul. 1994, pp. 293-296.
- Matanin et al., "Purification of the major envelop protein GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) from native virions". *Journal of Virological Methods*, vol. 147, 2008, pp. 127-135.

(56)

References Cited

OTHER PUBLICATIONS

- Pesch et al., "New insights into the genetic diversity of European porcine reproductive and respiratory syndrome virus (PRRSV)". *Veterinary Microbiology*, vol. 107, 2005, pp. 31-48.
- Darwich et al., "Genetic and immunobiological diversities of porcine reproductive and respiratory syndrome genotype I strains". *Veterinary Microbiology*, vol. 150, 2011, pp. 49-62.
- Gao et al., "Genomic characterization of two Chinese isolates of Porcine respiratory and reproductive syndrome virus". *Archives of Virology*, vol. 149, 2004, pp. 1341-1351.
- UniProt: Accession No. C9E449. "SubName: Full=M protein; SubName: Full=Membrane protein". Nov. 3, 2009.
- UniProt: Accession No. D0VEE4. "SubName: Full=Unglycosylated membrane protein". Dec. 15, 2009.
- UniProt: Accession No. Q6TLB4. "SubName: Full= Membrane protein M". Jul. 5, 2004.
- Cano et al., "Impact of a modified-live porcine reproductive and respiratory syndrome virus vaccine intervention on a population of pigs infected with a heterologous isolate". *Vaccine*, vol. 25, 2007, pp. 4382-4391.
- Duran et al. "Recombinant Baculovirus Vaccines Against Porcine Reproductive and Respiratory Syndrome (PRRS)". Abstracts PRRS, Aug. 9 to 10, 1995, Copenhagen, Denmark, 2 pages.
- Dykhuizen et al., "Determining the Economic Impact of the 'New' Pig Disease", *Porcine Reproductive and Respiratory Syndrome, A Report on the Seminar Held in Brussels on Nov. 4-5, 1991 and Organized by the European Commission*, pp. 53-60.
- Easterday, et al., "Swine Influenza". In *Diseases of Swine (8th Edition)*, BE Straw, S D'Allaire, WI. Mengeling, DJ Taylor, eds., Ames: Iowa State University Press, 1999, pp. 277-290.
- Edwards et al., "Oligodeoxyribonucleotide ligation to single-stranded cDNAs: a new tool for cloning 5' ends of mRNAs and for constructing cDNA libraries by in vitro amplification". *Nucleic Acids Research*, vol. 19, No. 19, pp. 5227-5232, 1991.
- Ehresmann et al., "RNA synthesized in calicivirus-infected cells is atypical of picornaviruses". *Journal of Virology*, vol. 22, No. 2, May 1977, pp. 572-576.
- Ellis, R.W., "New Technologies for Making Vaccines". *Vaccines*, Chapter 29, Plotkin et al Eds., WB Saunders Company, Philadelphia, PA, 1988, pp. 568-575.
- Enjuanes et al., "Isolation and Properties of the DNA of African Swine Fever (ASF) Virus". *Journal of General Virology*, vol. 32, No. 3, Sep. 1976, pp. 479-492.
- Enzo Biochem Inc. v. Gen-Probe Incorporated et al.*, No. 01-01230; Decided Jul. 15, 2002.
- Estes et al., "Simian rotavirus SA11 replication in cell cultures". *Journal of Virology*, vol. 31, No. 3, Sep. 1979, pp. 810-815.
- Fang et al., "Heterogeneity in nsp2 of European-like porcine reproductive and respiratory syndrome viruses isolated in the United States". *Virus Research*, vol. 100, 2004, pp. 229-235.
- Fenner et al., "Immunization against Viral Diseases", *Veterinary Virology*, Ch. 14, 1992, pp. 265-271.
- Grouse, L.D., "Swine Flue Sequelae". *Journal of the American Medical Association*, vol. 243, No. 24, 1980, p. 2489.
- Grunert et al., "Sensitivity of Influenza A/New Jersey/8/76 (HswINI) Virus to Amantadine-HCl". *Journal of Infectious Diseases*, vol. 136, No. 2, 1977, pp. 297-300.
- Guan et al., "Requirement of a 5'-Proximal Linear Sequence on Minus Strands for Plus-Strand Synthesis of a Satellite RNA Associated with Turnip Crinkle Virus". *Virology*, vol. 268, No. 2, Mar. 2000, pp. 355-363.
- Gubler et al., "A simple and very efficient method for generating cDNA libraries". *Gene*, vol. 25, 1983, pp. 263-269.
- Gustafson, D.P., "Pseudorabies". *Diseases of Swine, Fifth Edition*, Ch. 14, The Iowa State University Press, Ames, Iowa, 1981, pp. 209-223.
- Halbur et al., "Comparative pathogenicity of nine US porcine reproductive and respiratory syndrome virus (PRRSV) isolates in a five-week-old cesarean-derived, colostrum-deprived pig model". *Journal of Veterinary Diagnostic Investigation*, vol. 8, 1996, pp. 11-20.
- Halbur et al., "Effects of different US isolates of porcine reproductive and respiratory syndrome virus (PRRSV) on blood and bone marrow parameters of experimentally infected pigs". *Veterinary Record*, vol. 151, 2002, pp. 344-348.
- Halbur et al., "Variable Pathogenicity of Nine Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Isolates". *Conference of Research Workers in Animal Diseases, Abstracts of Papers, Chicago, Illinois, paper #222, Nov. 1993.*
- Halbur et al., "Viral Pneumonia in Neonatal and Nursery pigs. Experimental Work with SIRS Agent and Evidence of Another New Viral Agent". *Agri-Practice*, vol. 12, No. 1, Jan.-Feb. 1991, pp. 23-34.
- Hao et al., "Polymorphic genetic characterization of the ORF7 gene of porcine reproductive and respiratory syndrome virus (PRRSV) in China". *Virology Journal*, vol. 8:73, pp. 1-9, 2011.
- Harlow & Lane, Editors, "Antibodies, A Laboratory Manual". Cold Spring Harbor: Cold Spring Harbor Laboratory, New York, 1988, pp. 423, 464-468.
- Woode, et al., "Porcine Rotavirus Infection". *Diseases of Swine, Fifth Edition*, Chapter 26, The Iowa State University Press, Ames, Iowa, 1981, pp. 310-322.
- Woods et al., "Antigenicity of Inactivated Swine Influenza Virus Concentrated by Centrifugation". *Research Communications in Chemical Pathology and Pharmacology*, vol. 13, No. 1, 1976, pp. 129-132.
- Woods et al., "Experimental challenge of pregnant gilts with swine influenza virus after vaccination". *Research Communications in Chemical Pathology and Pharmacology*, vol. 15, No. 4, Dec. 1976, pp. 787-795.
- Woods et al., "Investigation of Four Outbreaks of Acute Respiratory Disease in Swine and Isolation of Swine Influenza Virus". *Health Laboratory Science*, vol. 5, No. 4, Oct. 1968, pp. 218-224.
- Wootton et al., "Structure-function of the ORF7 protein of porcine reproductive and respiratory syndrome virus in the viral capsid assembly". *Proceedings of the International Symposium on PRRS and Aujeszky's Disease*, Ploufragan, France, pp. 37-38, 1999.
- Yamane et al., "Annual Examination of Influenza Virus Infection Among Pigs in Miyagi Prefecture, Japan: The Appearance of Hsw1N1 Virus". *Acta Virologica*, vol. 23, 1979, pp. 240-248.
- Yang et al., "Comparative sequence analysis of open reading frames 2 to 7 of the modified live vaccine virus and other North American isolates of the porcine reproductive and respiratory syndrome virus". *Archives of Virology*, vol. 143, 1998, pp. 601-612.
- Yoon et al., "A modified serum neutralization test for the detection of antibody to porcine reproductive and respiratory syndrome virus in swine sera". *Journal of Veterinary Diagnostic Investigation*, vol. 6, No. 3, Jul. 1994, pp. 289-292.
- Yoon et al., "Failure to Consider the Antigenic Diversity of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus Isolates May Lead to Misdiagnosis". *Journal of Veterinary Diagnostic Investigation*, vol. 7, Jul. 1995, pp. 386-387.
- Yoon et al., "Isolation of a Cytopathic Virus from Weak Pigs on Farms with a History of Swine Infertility and Respiratory Syndrome". *Journal of Veterinary Diagnostic Investigation*, vol. 4, Apr. 1992, pp. 139-143.
- Yu et al., "Specific Binding of Host Cellular Proteins to Multiple Sites within the 3' End of Mouse Hepatitis Virus Genomic RNA". *Journal of Virology*, vol. 69, No. 4, Apr. 1995, pp. 2016-2023.
- Mardassi et al., "Identification of major differences in the nucleocapsid protein genes of a Québec strain and European strains of porcine reproductive and respiratory syndrome virus". vol. 75, No. 3, Mar. 1994, pp. 681-685.
- Mardassi et al., "Molecular analysis of the ORFs 3 to 7 of porcine reproductive and respiratory syndrome virus, Québec reference strain". *Archives of Virology*, vol. 140, No. 8, 1995, pp. 1405-1418.
- Mason, P.W., "Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells". *Virology*, vol. 169, No. 2, Apr. 1989, pp. 354-364.
- Masters et al., "Functions of the coronavirus nucleocapsid protein". *Coronaviruses and Their Diseases*, Plenum Press, New York, pp. 235-238, 1991.
- Masurel, N., "Swine Influenza Virus and the Recycling of Influenza-A Viruses in Man". *The Lancet*, Jul. 31, 1976, pp. 244-247.

(56)

References Cited

OTHER PUBLICATIONS

McAuliffe et al., "Codon Substitution Mutations at Two Positions in the L Polymerase Protein of Human Parainfluenza Virus Type 1 Yield Viruses with a Spectrum of Attenuation In Vivo and Increased Phenotypic Stability In Vitro". *Journal of Virology*, vol. 78, No. 4, Feb. 2004, pp. 2029-2036.

McCullough et al., "9. Experimental Transmission of Mystery Swine Disease", *The New Pig Disease Porcine Respiration and Reproductive Syndrome, A report on the seminar/workshop held in Brussels on Apr. 29-30, 1991*, pp. 46-52.

McDaniel, H.A., "African Swine Fever". *Diseases of Swine*, 5th Edition, Chapter 18, The Iowa State University Press, Ames, Iowa, 1981, pp. 237-245.

McFerran, J.B., "Reovirus Infection". *Diseases of Swine*, Fifth Edition, Chapter 28, The Iowa State University Press, Ames, Iowa, 1981, pp. 330-334.

McIntosh, "Diagnostic Virology". *Fields Virology*, Ch. 17, Second Edition, vol. 1, 1990, pp. 411-437.

McKinney, W.P., "Fatal Swine Influenza Pneumonia During Late Pregnancy". *Archives of Internal Medicine*, vol. 150, No. 1, Jan. 1990, pp. 213-215.

Mardassi et al., "Structural Gene Analysis of a Quebec Reference Strain of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)". *Corona- and Related Viruses*, Edited by P.J. Talbot and G.A. Levy, Plenum Press, New York, 1995, pp. 277-281.

* cited by examiner




FIG. 1




FIG. 2

1

**PORCINE REPRODUCTIVE AND
RESPIRATORY SYNDROME VACCINE
BASED ON ISOLATE JA-142**

RELATED APPLICATION

This is a continuation application of application Ser. No. 11/459,542 filed Jul. 24, 2006, which is a divisional application of application Ser. No. 10/654,545 filed Sep. 3, 2003 which is a continuation of application Ser. No. 09/981,282 filed Oct. 18, 2001, which issued as U.S. Pat. No. 6,641,819, which is a continuation-in-part of application Ser. No. 09/461,879 filed Dec. 15, 1999, which is now abandoned, which is a continuation-in-part of application Ser. No. 09/298,110 filed Apr. 2, 1999, which is now abandoned.

SEQUENCE DISCLOSURE

A Sequence Listing in the form of a computer readable ASCII file in connection with the present invention was filed in application Ser. No. 09/981,282. This earlier filed CRF is incorporated herein by reference and applicant requests that this previously filed CRF be used as the CRF for this application. A paper copy of this sequence is included herein and is identical to this previously-filed CRF.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is broadly concerned with attenuated avirulent atypical porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV), and corresponding live virus vaccines for administration to swine in order to confer effective immunity in the swine against PRRSV. The invention also includes methods of immunizing swine against PRRSV, and a new, highly efficient method of passaging viruses to attenuation. Furthermore, the invention provides methods of detecting and differentiating between field strains and an attenuated strain of PRRSV.

2. Description of the Prior Art

PRRS emerged in the late 1980's as an important viral disease of swine. PRRSV causes severe reproductive failure in pregnant sows, manifested in the form of premature farrowings, increased numbers of stillborn, mummified and weak-born pigs, decreased farrowing rate, and delayed return to estrus. Additionally, the respiratory system of swine infected with PRRSV is adversely affected, which is evidenced by lesions that appear in the lungs of infected swine. To combat the problems associated with PRRSV infection, vaccines have been developed which conferred immunity to then extant PRRSV strains.

Epidemics of an unusually severe form of PRRS, referred to hereafter as "atypical PRRS", were first recognized in North America in the latter part of 1996. They differed from epidemics of "typical PRRS" in that: 1) clinical signs were more prolonged as well as more severe; 2) the incidence of abortion was greater, especially during early and middle gestation; 3) there was a higher incidence of gilt and sow mortality; 4) PRRSV was less often isolated from aborted fetuses, stillborn pigs, and liveborn pigs—perhaps because abortions were more often the result of acute maternal illness rather than transplacental infection; 5) lung lesions of young affected pigs were more extensive; and 6) commercially available vaccines provided little or no protection. Collectively these observations indicated the emergence of more virulent and antigenically distinct strains of PRRSV and the need for a new generation of PRRS vaccines.

2

The most frequently used method for producing attenuated, live-virus vaccine is to serially passage the virus in a substrate (usually cell culture) other than the natural host (S) until it becomes sufficiently attenuated (i.e., reduced in virulence or diseases-producing ability) to be used as a vaccine. For the first passage, a cell culture is infected with the selected inoculum. After obtaining clear evidence of virus replication (e.g., virus-induced cytopathic effects [CPE] in the infected cells), an aliquot of the cell culture medium, or infected cells, or both, of the first passage are used to infect a second cell culture. The process is repeated until one or more critical mutations in the viral genome cause sufficient attenuation so that the virus can be safely used as a vaccine. The degree of attenuation is usually determined empirically by exposing the natural host (S) to progressively greater passage levels of the virus.

The above procedure is fundamentally sound and has been successfully used for the development of numerous vaccines for human and veterinary use. However, it is relatively inefficient because the logarithmic phase of virus replication, during which mutations are most likely to occur, is often completed long before evidence of virus replication becomes visibly obvious.

Therefore, there is a decided need in the art for a vaccine that confers effective immunity against PRRSV strains, including recently discovered atypical PRRSV strains. There is also a need in the art for a method of making such a vaccine. Finally, what is needed is a method of passaging a virus that attenuates the virus more efficiently than was heretofore thought possible with the resulting attenuated virus eliciting PRRSV specific antibodies in swine thereby conferring effective immunity against subsequent infection by PRRSV.

SUMMARY OF THE INVENTION

The present invention overcomes the problems outlined above, and provides attenuated, atypical PRRSV strains, and corresponding improved modified-live vaccines which confer effective immunity to newly discovered atypical PRRSV strains. "Effective immunity" refers to the ability of a vaccine to prevent swine PRRSV infections, including atypical PRRSV infections, which result in substantial clinical signs of the disease. That is to say, the immunized swine may or may not be serologically positive for PRRSV, but do not exhibit any substantial clinical symptoms. "Atypical PRRSV" refers to these new strains of PRRSV that are substantially more virulent than typical PRRSV strains.

In preferred forms, the vaccine of the invention includes live virus which has been attenuated in virulence. The resulting attenuated virus has been shown to be avirulent and to confer effective immunity. A particularly virulent strain of atypical PRRS (denominated JA-142) which caused especially severe symptoms of PRRS and represents the dominant strain of atypical PRRSV, was chosen for subsequent attenuation through passaging. The resultant attenuated virus has been deposited in the American Type Culture Collection (ATCC), Manassas, Va. 20110-2209 U.S.A. on Feb. 2, 1999, and was accorded ATCC Accession No. VR-2638.

This attenuated virus is a preferred Master Seed Virus (MSV) which has been subsequently passaged and developed as an effective PRRSV vaccine.

The name given the unattenuated virus, JA-142, arises from the restriction enzyme pattern. The 1 represents the inability of the enzyme MLU 1 to cleave the virus in open reading frame 5 (ORF 5). The 4 represents cleavage by Hinc II at base pair positions 118 and 249 of ORF 5 and short

contiguous sequences. The 2 represents cleavage by Sac II at base pair position 54 of ORF 5 and short, contiguous sequences.

Additionally, the present invention provides another way to differentiate between field strains of PRRSV and strain JA-142. The method is based upon differences in RNA cleavage by a restriction enzyme, Nspl. Briefly, isolated PRRSV RNA is subjected to digestion by Nspl. Digestion of the attenuated strain, JA-142, results in at least one additional fragment in comparison to field strains of PRRSV. In preferred methods, the RNA is isolated and RT-PCR is performed on the isolated RNA. This RNA is then subject to electrophoresis and a 1 Kd product is identified and purified for digestion by Nspl. This digestion results in three fragments for JA-142 and either one or two fragments for PRRSV field strains.

Passaging of the virus to attenuation was accomplished using a novel method which resulted in increased efficiency. Specifically, the virus was kept in the logarithmic phase of replication throughout multiple cell culture passages in order to materially shorten the time to attenuation. This is achieved by ensuring that in each cell culture there is a substantial excess of initially uninfected cells relative to the number of virus present. Thus, by transferring only small numbers of virus from passage-to-passage, logarithmic replication is assured.

In practice, the process is normally initiated by inoculation of several separate cell cultures with progressively smaller viral aliquots (i.e., lesser numbers of virus in each culture.) For example, starting cultures could contain 200 μ l, 20 μ l and 2 μ l viral aliquots. After an initial short incubation period (e.g., ~24 hours), the same viral aliquots (in the example, 200 μ l, 20 μ l and 2 μ l) from each cell culture are transferred to individual fresh (previously uninfected) cultures, while the starting cultures are monitored until cytopathic effect (CPE) is or is not observed. This process is continued in serial order for multiple passages, using the same viral aliquots in each case and preserving the cultures for CPE observation. If all of the serial culture passages exhibit CPE after a selected number of passages are complete, the larger viral aliquot series may be terminated (in the example 200 μ l and 20 μ l), whereupon another series of progressively smaller viral aliquots are employed (e.g., 2 μ l, 0.2 μ l and 0.02 μ l) and the process is again repeated, again keeping the cell cultures after transfer for CPE observation.

At some point in this successively smaller viral aliquot inoculation process. CPE will not be observed in a given cell culture. When this occurs, the next higher viral aliquot level showing CPE is substituted for the passage in which CPE was not observed, whereupon subsequent passages will be inoculated using previously employed viral aliquots.

Inasmuch as a virus will tend to become more efficient at infecting cells and also replicate to a higher infectivity titer for cell cultures over time, (which is especially true with RNA viruses such as PRRSV), it will be seen that smaller and smaller viral aliquots are required to maintain infection during serial transfer. The use of the smallest aliquot that maintains infection helps to assure that viral replication remains in a logarithmic phase throughout the process.

The DNA sequence of the attenuated passaged virus from the 201st passage was then determined using conventional methods. The sequence of this attenuated virus was designated as MSV JA-142 Passage No. 201, the sequence of which is given as SEQ ID No. 1. The sequence of the virulent virus, JA-142, is given as SEQ ID No. 2.

As used herein, the following definitions will apply: "Sequence Identity" as it is known in the art refers to a

relationship between two or more polypeptide sequences or two or more polynucleotide sequences, namely a reference sequence and a given sequence to be compared with the reference sequence. Sequence identity is determined by comparing the given sequence to the reference sequence after the sequences have been optimally aligned to produce the highest degree of sequence similarity, as determined by the match between strings of such sequences. Upon such alignment, sequence identity is ascertained on a position-by-position basis, e.g., the sequences are "identical" at a particular position if at that position, the nucleotides or amino acid residues are identical. The total number of such position identities is then divided by the total number of nucleotides or residues in the reference sequence to give % sequence identity. Sequence identity can be readily calculated by known methods, including but not limited to, those described in Computational Molecular Biology, Lesk, A. N., ed., Oxford University Press, New York (1988). Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data. Part I, Griffin. A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinze, G. Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), the teachings of which are incorporated herein by reference. Preferred methods to determine the sequence identity are designed to give the largest match between the sequences tested. Methods to determine sequence identity are codified in publicly available computer programs which determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et. al., Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and FASTA (Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et. al., NCVI NLM NIH Bethesda, Md. 20894, Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990), the teachings of which are incorporated herein by reference). These programs optimally align sequences using default gap weights in order to produce the highest level of sequence identity between the given and reference sequences. As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "sequence identity" to a reference nucleotide sequence, it is intended that the nucleotide sequence of the given polynucleotide is identical to the reference sequence except that the given polynucleotide sequence may include up to 5 point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, in a polynucleotide having a nucleotide sequence having at least 95% identity relative to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having a given amino acid sequence having at least, for example, 95% sequence identity to a reference amino acid sequence, it is intended that the given amino acid sequence of the polypeptide is identical to the reference sequence except that the given polypeptide sequence may

5

include up to 5 amino acid alterations per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a given polypeptide sequence having at least 95% sequence identity with a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number or amino acids up to 5% of the total number of amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or the carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in the one or more contiguous groups within the reference sequence. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included as a match when determining sequence identity.

Similarly, "sequence homology", as used herein, also refers to a method of determining the relatedness of two sequences. To determine sequence homology, two or more sequences are optimally aligned as described above, and gaps are introduced if necessary. However, in contrast to "sequence identity", conservative amino acid substitutions are counted as a match when determining sequence homology. In other words, to obtain a polypeptide or polynucleotide having 95% sequence homology with a reference sequence, 95% of the amino acid residues or nucleotides in the reference sequence must match or comprise a conservative substitution with another amino acid or nucleotide, or a number of amino acids or nucleotides up to 5% of the total amino acid residues or nucleotides, not including conservative substitutions, in the reference sequence may be inserted into the reference sequence.

A "conservative substitution" refers to the substitution of an amino acid residue or nucleotide with another amino acid residue or nucleotide having similar characteristics or properties including size, hydrophobicity, etc. such that the overall functionality does not change significantly.

Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

Preferably, sequences sharing at least about 75%, more preferably at least about 85%, still more preferably at least about 90% and most preferably at least about 95% sequence homology with SEQ ID No. 1 are effective as conferring immunity upon animals vaccinated with attenuated viruses containing such homologous sequences. Alternatively, sequences sharing at least about 65%, more preferably at least about 75%, still more preferably at least about 85%, and most preferably at least about 95% sequence identity with SEQ ID No. 1 are also effective at conferring immunity upon animals vaccinated with attenuated viruses containing such identical sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph illustrating the ratio of samples which tested positive for antibodies against PRRSV to the total number of samples over a 196 day testing period; and

6

FIG. 2 is a graph illustrating the ratio of samples which tested positive for antibodies against PRRSV to the total number of samples over a 38 day testing period after challenge.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following examples set forth preferred embodiments of the present invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.

EXAMPLE 1

Materials and Methods

This example describes a passage method of attenuating viruses which maximizes attenuation efficiency by ensuring that the virus is preferably in a logarithmic phase of replication. Virus was passed (i.e. an aliquot of nutrient medium including the virus, unattached cells, and cell debris from a virus-infected cell culture was added to the nutrient medium of a noninfected culture) at daily intervals. Different amounts of virus were added at each interval by using multiple cultures. For example, at the beginning, 200 μ l was transferred to one noninfected culture, 20 μ l was added to a second noninfected culture, and 2 μ l to a third noninfected culture. The goal was to have a sufficient amount of susceptible cells so that the replication cycles could continue until the next transfer. The procedure was deemed successful if the cells eventually showed CPE. However, because PRRSV-induced CPE do not appear until sometime after the logarithmic growth phase, passages were made before it was known whether or not they would be ultimately successful ("blind passages"). Passages that resulted in virus induced CPE were said to have resulted in a "take". If a passage did not result in a take, the passage was restarted using the highest dilution from the last passage which did result in a take. As more and more passages were made, the virus became more adapted to replicate in the cell line and less able to produce disease symptoms in its original host. These changes occur through random mutations that occur during replication.

Using this method, the following procedures were used to passage an exemplary virus in accordance with the present invention, MSV, JA-142. This strain was passaged in MARC-145 cell cultures at daily intervals. Twenty-four-well plates were used for the process to minimize the amount of cells and nutrient medium required, and to simplify the multiple-aliquot passage technique. Cells and nutrient medium were added to each well and the cells were allowed to form, or nearly form (greater than about 70%), a confluent monolayer. The nutrient medium comprised approximately 90% Earle's balanced salt solution minimal essential medium (MEM), 10% fetal calf serum and 0.05 mgm/ml of gentamicin sulfate. The volume of nutrient medium used was approximately 1 ml. Usually, three wells of a column were used for each amount of virus that was transferred. An aliquot of nutrient medium from the previous passage was transferred to the first well in the column at 48 or 72 hours, after the cell cultures had been prepared, nutrient medium from the first well was transferred to the second well of the same column at 72 or 96 hours and the third well of the same column at 96 or 120 hours. Plates were usually set up twice a week so sometimes the fourth well of the column was used and sometimes it was not used. Passaging conditions were maintained at 37° C. in a moist atmosphere containing 5% CO₂.

Different sized aliquots (having different amounts of virus) for each passage were tested to determine if the amount of virus was sufficient to induce CPE. For example, a separate series of aliquot transfers (passages) of 200 μ l, 20 μ l, and 2 μ l, respectively, was used until the smaller aliquots consistently exhibited CPE with the goal being to transfer the smallest aliquot that produced CPE. When the smallest aliquot (e.g. 2 μ l) of the group of aliquots being tested consistently resulted in CPE, smaller amounts were tested (e.g. 0.2 μ l and 0.02 μ l). When a certain dilution did not exhibit CPE, that series of cultures was restarted with the next lower amount which did result in CPE at that passage (i.e. if the 2 μ l transfer was unsuccessful at producing CPE in the 25th passage but the 20 μ l transfer in the 25th passage was successful, the 2 μ l transfer was repeated using 20 μ l with 2 μ l transfers resuming for the 26th passage.)

Using this method, the smallest amount of virus necessary to transfer to obtain CPE was determined. Virus was passed successfully at daily intervals using the following amounts of virus-infected nutrient medium (which reflect the highest dilution [i.e., smallest aliquot] which resulted in CPE keeping in mind that other dilutions would also work):

Passage Number	Amount Transferred
3-21	200 μ l
22, 23	20 μ l
24-41	200 μ l
42-83	20/200 μ l (alternating)
84-90	20 μ l
91-112	2 μ l
113	0.2 μ l
114-116	2 μ l
117	0.2 μ l
118-120	2 μ l
121	0.2 μ l
122-124	2 μ l
125-167	0.2 μ l
168	0.02 μ l
169-171	0.2 μ l
172	0.02 μ l
173-175	0.2 μ l
176	0.02 μ l
177-179	0.2 μ l
180	0.02 μ l
181-183	0.2 μ l
184	0.02 μ l
185-187	0.2 μ l
188	0.02 μ l
189-191	0.2 μ l
192	0.02 μ l
193-195	0.2 μ l
196	0.02 μ l
197	0.2 μ l

Results and Discussion

The passaging of the virus using the above method resulted in an attenuated PRRSV, JA-142. As is apparent, the virus became more adapted to replicate in the cell culture and therefore required a smaller amount of virus-infected nutrient medium to be transferred as passaging continued. For transfers using a very small amount of virus-infected nutrient medium (e.g. 0.2 μ l or 0.02 μ l), a separate dilution was required. This dilution was accomplished by adding a small amount of virus-infected nutrient medium to a larger amount of nutrient medium. For example, to obtain a transfer of 0.2 μ l, 2 μ l of virus infected nutrient medium was added to 20 μ l of nutrient medium and 2 μ l of this dilution was added to the next culture in the series. Using this approach, the highest dilution which resulted in CPE was used and the time necessary for passaging the virus was minimized. Passaging at daily inter-

vals ensured that the virus was always in a logarithmic phase of replication. Daily transferring also ensured that there was an adequate number of cells for virus replication.

Because the mutations (which are probably cumulative) that are likely to result in attenuation only occur during replication, there is no advantage to having substantially all cells infected and replication either proceeding at a slower rate or stopping before the next transfer. Based on previous studies of PRRSV, it was known that the replication cycle is about 8 hours, therefore, transferring a minimal amount of virus from virus-infected nutrient medium to uninfected nutrient medium at daily intervals results in the virus always having plenty of cells within which to replicate.

As can be readily appreciated, passaging using this method results in a savings of time that was heretofore thought impossible (i.e. each passage required less time). This is especially important when a high number of passages are required for adequate virus attenuation. If each passage, using old methods, was performed at a 3 day interval, a procedure requiring 200 passages would take 400 fewer days using the method of the present invention.

EXAMPLE 2

Materials and Methods

This example determined if passage 200 of PRRS Virus, JA-142, would revert in virulence when passed in the host animal six times. This study consisted of six groups. Five pigs from group 1 (principle group) were inoculated intra-nasally with PRRS MSV, JA-142 passage 200, while three pigs from group 1A, (control group) were inoculated intra-nasally with sterile diluent. The animals were provided commercial feed and water ad libitum throughout the study. Pigs of both treatment groups were monitored daily for clinical signs (appearance, respiratory, feces, etc.). After six days, the animals were weighed, bled and sacrificed. After scoring the lungs for lesions, lung lavages were collected from each animal. The lung lavages were frozen and thawed one time, and a pool was prepared using 2.0 ml of serum and 2.0 ml of lung lavage from each animal within a group to prepare Backpassage 1 and 1A, respectively. This pool was used to challenge (intra-nasally) the animals in group 2 and group 2A, respectively. This process was repeated for groups 3 and 3A through 6 and 6A. Animals in each group were housed in separate but identical conditions.

Following inoculation, blood samples were collected and body temperatures were monitored. Rectal temperatures were measured for each animal periodically from -1 DPE (days post exposure) to 6 DPE and averaged together with other animal temperatures from the same group. The health status of each animal was monitored daily for the duration of the study. Results were compiled and scored on a daily observation form. The scoring parameters are as follows:

1. Appearance
normal=0; depressed=1; excited=2; comatose/death=30.
2. Respiration
normal=0; sneeze=1; cough=1; rapid/short=2; labored=3.
3. Feces
normal=0; dry=; loose=fluid=3.
4. Eyes
normal=0; watery=1; matted=2; sunken=3.
5. Nostrils
normal=0; watery discharge=1; red/inflamed=2; crusted ulcers=3.
6. Mouth
normal=0; slobbers=2; ulcer=3.

TABLE 1-continued

		Daily Clinical Scores								
Treatment		Day -1	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Average
Backpassage 3A	560	0	0	0	0	0	0	0	0	0
	571	0	0	0	0	0	0	0	0	0
	575	0	0	0	0	0	0	0	0	0
	Average	0	0	0	0	0	0	0	0	0
Group 5 Pig #										
Backpassage 4	1	0	2	0	0	2	0	2	2	1
	2	0	0	0	0	0	0	0	0	0
	3	2	0	2	2	2	2	2	2	1.75
	4	0	0	0	0	0	0	0	0	0
	5	0	0	0	0	0	0	0	0	0
	Average	0.4	0.4	0.4	0.4	0.8	0.4	0.8	0.8	0.55
Backpassage 4A	6	0	0	0	0	0	0	0	0	0
	7	0	0	2	2	2	2	2	2	1.5
	8	0	0	0	0	0	0	0	0	0
	Average	0	0.08	0.48	0.48	0.56	0.48	0.56	0.56	0.4
Group 6 Pig #										
Backpassage 5	10	0	0	0	0	2	0	0	2	0.5
	12	0	0	0	2	2	0	0	2	0.75
	14	0	0	0	0	0	0	0	0	0
	15	2	2	2	0	0	0	0	2	1
	16	2	2	2	0	0	1	1	2	1.25
	Average	0.8	0.8	0.8	0.4	0.8	0.2	0.2	1.6	0.7
Backpassage 5A	9	0	0	0	0	0	0	0	0	0
	11	2	2	0	0	0	0	0	0	0.5
	13	0	0	0	0	0	0	0	0	0
	Average	0.666667	0.56	0.16	0.08	0.16	0.04	0.04	0.32	0.253333

There were no significant differences between groups for rectal temperatures or daily weight gains. All lung scores were negative.

Serologically, ELISA S/P ratios and SN titers were negative throughout each group's trial period. Virus isolation was attempted on all serum samples and lung lavages. By day 6, 60-100% of the serum samples from the groups given JA-142, passage 200, and subsequent back passes were positive. The groups given saline were negative. In the first three passes, virus was recovered in the lung lavages from only 20-40% of the pigs, but by the last three passes, the virus was recovered from 50-80% of the pigs.

Based on this data, JA-142 passage 200 did not revert to virulence when passed through pigs six times.

EXAMPLE 3

Materials and Methods

This example demonstrated that the level of attenuation of safety of MSV, JA-142, passage 200 did not change significantly during six backpassages in the host animal. Evaluation of level of attenuation or safety was performed using the pregnant sow model and monitoring the effect on reproductive performance. This model is the most sensitive test system and does not rely upon subjective factors for virulence testing. This example consisted of four groups (A, B, C & D) having seven sows per group. Group A was inoculated intra-nasally with PRRS MSV, JA-142 passage 200. Group B was inoculated intra-nasally with JA-142, 200, Backpassage 6. Group C was inoculated intra-nasally with sterile diluent, to act as normal controls. Group D was inoculated intra-nasally with PRRSV JA-142, passage 4. The test articles (challenge with JA-142, passage 4) were given at about 93 days gestation. Body temperatures of the sows were monitored for the first seven days following vaccination. Blood samples were col-

lected from the sows once a week and at time of farrowing. Blood samples were collected and weights were recorded from piglets at birth, 7, and 14 days of age. The health status of each animal was monitored daily for the duration of the study up to and following farrowing for 14 days. The farrowing performance was evaluated by observing the health status of the piglets born.

PRRS ELISA assays were performed following the exposures of the sows with the test article. PRRS ELISA assays were also performed on the piglet sera weekly following farrowing. Following exposure to the test article, attempts to isolate PRRSV from serum samples were performed on MA-104 cells. Rectal temperatures were measured periodically from 0 days post vaccination (DPV) to 7 DPV and the average temperature of each group was determined. Prior to and after inoculation, total white blood cell counts were determined as in Example 1. Clinical observations of the sows, as in Example 2, were made from -1 DPV through farrowing. Clinical observations of the piglets were made from farrowing until 14 days of age. Finally, at necropsy, the lungs of each piglet were scored for percent lung involvement.

Results

The ELISA results indicate that the animals used in this study were naive to PRRSV. Those animals that received virus inocula, groups A, B, and D, sero-converted at 14 days post treatment. Three sows of group B remained negative at 14 days post treatment. At the time of farrowing, the negative sows of group B tested positive for antibody to PRRSV.

The pigs' ELISA results indicated that the majority of the piglets born to sows of group A and group B were sampled after they had nursed. Those pigs that were negative at zero days post farrowing (0 DPF) tested positive at 7 DPF. All pigs born to sows of group C tested sero-negative throughout the study. Only a few pigs were tested from group D, since the majority were either stillborn or mummies. Half of those pigs

13

that were tested were sero-positive. This indicated that the sero-negative pigs were sampled prior to nursing or they were not capable of nursing. All piglets born to sows of group D died before 7 DPF. Isolations of PRRSV from the sows of groups A and B were sporadic. Although the results of the ELISA test indicated that these sows were successfully inoculated with the viral test articles, many remained negative for virus isolation from serum.

The majority of pigs born to sows from groups A and B tested positive for virus isolation during the performance of the study. The litter born to one sow of group A never tested positive and the litter born to one sow of group B had only two of eight piglets test positive for virus isolation. No virus was recovered from the piglets born to sows from group C. Virus was recovered from the majority (71%) of piglets born from sows of group D.

Post treatment rectal temperatures were unremarkable. The groups that were treated with either MSV, backpassage 6 or sterile diluent experienced no measurements exceeding 101.7° F. Group D, treated with JA-142, passage 4, had four (out of seven) sows that experienced temperatures that exceeded 102° F. with one sow reaching 103.4° F. for one of the days. The weight gain performance of the piglets born to sows of groups A (treated with MSV) and B (treated with

14

MSV, backpassage 6) was greater than that of the pigs born to the control sows of group C. The average weight gain for the 14 day observation period was 7.9 lbs. For group A, it was 7.7 lbs; for group B and group C it was 6.9 lbs. The difference in the weight gain was not related to the size of the litter remaining at 14 days. The average litter sizes at 14 days post farrowing (DPF) were 9 for group A, 7 for group B, and 10 for group C. No pig born to the sows of group D survived beyond 3 DPF.

The white blood cell (WBC) counts for the sows of groups A, B, and C remained relatively constant. The average percentages of the pre-challenge values were equal to or greater than 92% for the duration of the observation period. Three sows of group D experienced WBC counts that were lower than the expected normal range ($7-20 \times 10^6/\text{ml}$).

The post inoculation clinical scores were unremarkable for the sows of groups A and B. Several sows of group C were observed to experience clinical signs over a period of several days. The majority of the clinical symptoms observed were in the category of decreased appetite, respiratory symptoms, and depression. One sow of group C died on trial day 31 of chronic bacterial pneumonia. Six of the seven sows of group D were observed to have clinical signs, primarily of varying degrees in severity, of lost appetite, ranging from decreased to anorexic. Results of the clinical scoring for the sows are given in Table 2.

TABLE 2

		Sow Clinical Scores															
Treatment	Sow#	-3	-2	-1	0	1	2	3	4	5	6	7	8	9	10	11	12
Group A	98	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JA-142 MSV	133	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Passage 200	147	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	178	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	233	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	243	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Avg.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
Group A	98	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JA-142 MSV	133	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Passage 200	147	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	178	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	233	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	243	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Avg.	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44
Group A	98	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JA-142 MSV	133	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Passage 200	147	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	178	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	233	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	243	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Avg.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Treatment	Sow#	-3	-2	-1	0	1	2	3	4	5	6	7	8	9	10	11	12
Group B	49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Backpassage6	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	135	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	149	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	209	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	212	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	226	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Avg.	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1

TABLE 2-continued

		Sow Clinical Scores									
		29	30	31	32	33	34	35	36	37	38
Group D	2	0	0	0	1	1	1	3	3	1	1
JA-142	106	0	0	0	0	0	0	0	0	0	0
Pass 4	159	0	0	0	0	0	0	0	0	0	0
	190	0	0	0	0	0	0	0	0	0	0
	206	0	0	0	0	0	0	0	0	0	0
	232	0	0	0	0	0	0	0	0	0	0
	234	0	0	0	0	0	0	0	0	0	0
	Avg.	0	0	0	0.1	0.1	0.1	0.4	0.4	0.1	0.1

Clinical observations of the piglets fell into two major categories, death and reduced appetite. There were no significant differences between groups A, B and C in the area of average deaths per litter (DPL). Group A had an average of 1.3 DPL, group B had an average of 2.4 DPL, group C had an average of 2.0 DPL, and no pigs from group D survived beyond three days post farrowing. Clinical scores for the piglets are given in Table 3.

TABLE 3

Treatment	Sow#	Pig#	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Group A	98	813	0	0	1	30										
JA-142		814	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pass 200		815	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		816	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		817	1	0	1	0	0	0	0	0	0	0	0	0	0	0
		818	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		819	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		820	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		821	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		822	1	30												
		Avg.	0.3	3	0.2	3.3	0	0	0	0	0	0	0	0	0	0
	133	720	30													
		721	0	1	0	0	0	0	0	0	0	0	0	0	0	0
		722	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		723	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		724	0	1	0	0	0	1	0	0	0	0	0	0	0	0
		725	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		798	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		799	30													
		800	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		807	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		809	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		810	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		812	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Avg.	4.6	0.2	0	0.1	0	0.1	0	0	0	0	0	0.1	0	0
	147	823	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		824	0	0	0	0	0	0	0	3	1	1	1	1	1	1
		825	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		845	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		846	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		847	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		848	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		849	0	0	0	0	0	0	0	0	0	0	0	0	0	2
		850	30													
		976	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		977	0	0	0	0	1	1	3	30						
		978	30													
		Avg.	5	0	0	0	0.1	0.1	0.4	3.3	0.1	0.1	0.1	0.1	0.1	0.3
	178	486	30													
		487	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		488	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		489	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		490	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		491	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		492	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		493	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		494	0	1	0	0	0	0	0	0	0	0	0	0	0	0
		Avg.	3.3	0.1	0	0	0	0	0	0	0	0	0	0.1	0	0

TABLE 3-continued

Treatment	Sow#	Pig#	1	2	3	4	5	6	7	8	9	10	11	12	13	14		
Group A JA-142 Pass 200	215	495	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		496	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		497	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		498	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		499	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		808	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Avg.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	233	476	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		477	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		478	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		478	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		480	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		481	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		482	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		483	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		484	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		485	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Avg.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		243	707	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			708	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			709	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			710	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	711		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	712		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	713		0	0	0	0	0	0	0	0	0	1	30					
	714		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	715		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	716		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	717		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
	718		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
	719		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Avg.	0		0	0	0	0	0	0	0	0	0	0.1	2.3	0.2	0	0		
Group B																		
Backpassage 6	49		430	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			431	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		432	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		433	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		434	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		435	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		436	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		437	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		438	30	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Avg.	3.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	100	459	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		460	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		461	0	0	0	0	0	0	1	1	1	1	0	0	0	0		
		462	0	0	0	0	1	1	1	1	1	1	1	1	1	1		
		463	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		464	0	0	1	1	1	1	30									
		465	0	30														
	Avg.	0	4.3	0.2	0.2	0.3	0.3	5.3	0.4	0.4	0.2	0.2	0.2	0.2	0.2	0.2		
	135	439	0	0	0	0	0	0	0	30								
		440	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		441	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		442	0	0	0	1	1	1	1	1	1	1	3	3	3	30		
		443	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		444	0	0	0	0	0	0	1	1	0	0	0	0	0	0		
		445	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		446	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		447	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Avg.	0	0	0	0.1	0.1	0.1	0.2	3.6	0.1	0.1	0.4	0.4	0.4	3.8		
		149	231	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			232	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	233		0	0	0	0	0	0	30									
	234		0	0	0	0	0	0	3	1	1	3	1	1	1	1		
235	0		0	0	0	0	0	3	2	3	3	0	0	0	0			
236	0		0	0	0	0	0	0	0	0	0	0	0	0	0			
237	0		0	0	0	0	0	1	1	1	1	1	1	1	1			
238	0		0	0	0	0	2	0	0	0	0	0	0	0	0			
239	0		0	30														
240	30																	
241	3		30															
242	0		0	0	0	0	2	3	3	30								
Avg.	2.8		2.7	3	0	0	0.4	4.4	0.9	4.4	1	0.3	0.3	0.3	0.3			

TABLE 3-continued

Treatment	Sow#	Pig#	1	2	3	4	5	6	7	8	9	10	11	12	13	14		
Group B Backpassage 6	209	448	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		449	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		450	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		451	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	
		452	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		453	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		454	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	
		455	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	
		456	30															
		457	0	0	0	0	0	0	0	0	0	2	1	1	1	1	1	
	458	30																
	Avg.	5.5	0	0	0	0	0	0	0	0	0.4	0.4	0.4	0.4	0.4	0.4		
	212	243	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		244	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		245	0	0	0	0	3	1	30									
		246	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		247	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	
		248	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	
		249	0	0	0	0	0	0	2	2	0	0	2	0	0	0	0	
		250	0	0	0	3	30											
426		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
427		0	0	0	1	3	1	1	30									
428	0	0	0	1	3	3	30											
429	0	0	0	0	2	3	3	3	3	3	3	1	30					
Avg.	0	0	0	0.4	3.6	0.9	6.2	3.9	0.4	0.4	0.6	0.1	3.8	0				
226	Not Preg.																	
Group C																		
Sterile Diluent	58	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		25	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		46	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		47	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		48	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		49	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		50	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		51	0	0	0	2	2	1	1	1	30							
		Avg.	0	0	0	0.3	0.3	0.1	0.1	0.1	3.8	0	0	0	0	0		
		113	17	30														
18	30																	
19	30																	
20	30																	
21	0		30															
22	30																	
23	30																	
Avg.	25.7		30															
117	52		1	0	0	0	0	0	0	0	0	0	0	0	0	0		
	53		0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	55	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	56	1	0	0	0	30												
	57	1	0	0	0	0	0	0	0	0	0	0	0	0	0			
	58	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	60	0	0	0	0	0	0	0	0	0	0	0	1	0	0			
	61	1	0	0	0	0	0	0	0	1	1	1	0	0	0			
62	1	0	0	0	0	0	0	0	0	0	0	0	0	0				
Avg.	0.5	0	0	0	2.7	0	0	0	0.1	0.1	0.1	0.1	0	0				
144	146	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	147	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	148	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	149	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	150	0	0	0	0	0	0	0	0	1	0	1	1	1	0			
	221	0	0	0	0	0	2	2	0	0	0	0	0	0	0			
	222	0	0	0	0	0	2	2	1	1	1	1	1	0	1			
	223	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	224	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
	225	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
970	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
971	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Avg.	0	0	0	0	0	0.3	0.3	0.1	0.2	0.1	0.2	0.2	0.1	0.1				

TABLE 3-continued

Treatment	Sow#	Pig#	1	2	3	4	5	6	7	8	9	10	11	12	13	14		
Group C Sterile Diluent	156	63	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		64	0	0	1	0	30											
		65	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	
		66	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
		67	0	0	0	0	1	0	1	1	30							
		68	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		69	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
		70	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		71	0	0	0	0	0	2	2	0	0	0	0	0	0	1	0	
		72	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		74	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
		75	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Avg.	0	0	0.1	0	2.5	0.2	0.3	0.3	2.6	0.1	0.1	0.1	0.1	0.1	0	
		Group D	166	76	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				77	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				78	0	0	0	0	0	0	0	0	0	0	0	0	0	0
79	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
80	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
81	1			0	0	0	0	0	0	0	0	0	0	0	0	0		
141	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
142	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
143	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
144	0			0	0	0	0	0	0	0	0	0	0	0	0	0		
Avg.	0.2	2.7	0	0	0	0	0	0	0	0	0	0	0	0	0			
Group D	JA-142 Passage 4	891	1	3	30													
		892	1	30														
		Avg.	1	16.5	30													
		106	Aborted	NA														
		159	883	30														
		884	30															
		Avg.	30															
		190	Aborted	NA														
		206	890	30														
		Avg.	30															
Group D	232	888	30															
		889	30															
		Avg.	30															
234	Aborted	NA																

The farrowing performance results provided the most dramatic differences and similarities between the various treatment groups. Since the treatments would not have an effect on the size of the litters, the most appropriate way to compare the farrowing results would be by using percentage values. Group A had an average percentage of live/born of 85% (SD+/-9.6). Group B had an average percentage of 89% (SD+/-11.6). The control group (group C) had an average percentage of live/born of 83.4% (SD+/-7.9). The average percentages for stillborns for groups A, Band C were 8.8 (SD+/-9.66), 6.6 (SD+/-9.7), and 14 (SD+/-11.39), respectively. The average percentages of mummies born to sows of groups A, B, and C were 6.1 (SD+/-6.01), 3.9 (SD+/-4.45), and 2.6 (SD+/-4.01), respectively. The average percentages of live/born, stillborn and mummies born to the sows of group D were 8.7 (SD+/-8.92), 10.7 (SD+/-11.39), and 81.9 (SD+/-17.18), respectively.

The results of this example demonstrated the stability of the MSV, JA-142, passage 200 after being passed in the host animal six times. There were no significant differences between the group of sows treated with the MSV (group A) and those sows that were exposed to the Backpassage 6 virus (group B) in the categories of farrowing performance, leukopenia, rectal temperatures, and the clinical observations of either the sows or the piglets. In addition, the results in these same categories for the groups A and B were comparable to those achieved by group C that had been treated with sterile

diluent. Finally, the performance of the sows that had been exposed to the virulent parent virus of MSV, JA-142, passage 4, clearly illustrated the level of attenuation of the MSV and the lack of reversion to virulence by the Backpassage 6, JA-142 virus.

EXAMPLE 4

Materials and Methods

This example evaluated the safety and level of attenuation of administering a 10x concentration of MSV, JA-142, passage 201. The study was performed on the pregnant sow model and monitored the effect of this dosage on reproductive performance. The study consisted of three groups, A, C, and D. Group A was inoculated intra-nasally with PRRS MSV, JA-142, passage 200. Group C was inoculated intra-nasally with sterile diluent, to act as a normal control group. Group D was inoculated intra-nasally with 10x JA-142, passage 201. All inoculations were given at about 93 days gestation. Body temperatures of the sows were monitored for the first seven days following inoculation (vaccination). Blood samples were collected from the sows once a week and at time of farrowing. Prior to and following inoculation, total white blood cell counts were determined as in Example 2. The health status of each animal was monitored daily for the duration of the study up to and following farrowing for 14 days. Clinical observations of the sows were made from -1

DPV through farrowing. The farrowing performance was evaluated by observing the health status of the piglets born. PRRSV ELISA assays were performed following the exposures of the sows with the test article. Attempts to isolate PRRSV from serum samples were performed on MA-104 cells following exposure to the test article. Clinical observations of the piglets were made from farrowing until 14 days of age. Blood samples were collected from the piglets at birth, 7 and 14 days of age. PRRSV ELISA assays were performed on the piglet sera weekly following farrowing. Piglets were also weighed at birth, day 7 post farrowing, and at necropsy. At necropsy, the lungs of each piglet were scored for percent lung involvement.

Results and Discussion

There were no significant differences between groups given a 10× close of MSV, JA-142, passage 201, groups given a regular dose of MSV, JA-142, passage 200, and groups given sterile diluent. Therefore, based on the safety and attenuation of MSV, JA-142, passage 200 and the lack of any significant difference in the results comparing these groups, a 10× dose of MSV, JA-142, passage 201 was shown to be safe, attenuated and effective in inducing antibodies against PRRSV.

EXAMPLE 5

Materials and Methods

This example demonstrated that a minimal vaccine close of PRRSV, JA-142, passage 205, representing MSV+5, is efficacious in an experimental respiratory challenge model in feeder pigs. Pigs were divided into three groups. Group 1 was inoculated intramuscularly with PRRS MSV, JA-142, passage 205 at a titer of 2.0 logs/dose. Group 2 was inoculated intramuscularly with sterile diluent. Group 3 acted as normal controls. Pigs from groups 1 and 2 were challenged with a PRRSV isolate with an RFLP pattern of 144 on day 28 post vaccination. Body temperatures of the pigs were monitored for the first seven days following vaccination and daily following challenge. Each animal was weighed at vaccination, challenge, weekly throughout the study, and necropsy. Blood samples were collected weekly following vaccination and every two days following challenge. The health status of each animal was monitored daily for the duration of the study. At necropsy, each animal was sacrificed and the lungs were scored for percent lung involvement as in Example 2. PRRSV ELISA assays were performed following the exposures of the pigs with the test articles and challenge. Following exposure to the test articles, attempts to isolate PRRSV from serum samples were performed on MA-104 cells. Virus isolation and ELISA results were analyzed using a Chi-square analysis which tests whether the percentage of positive animals is the same in each group. White blood cell counts were performed as in Example 2.

Results and Discussion

Pigs from group 1 (vaccinated pigs) fared better in all aspects of this example than did the pigs from group 2 (pigs given sterile diluent). Clinical scores, rectal temperatures, and percent lung involvement were all higher for the pigs given sterile diluent. Weight gain and white blood cell counts were lower for the pigs receiving the sterile diluent. There was also a significant reduction in viremia beginning on day 4 post-challenge in the group given vaccine. On days 10 and 11 post-challenge, the number of animals positive for viremia decreased further in the vaccinated group, but remained the same in the group receiving sterile diluent.

An ELISA was used to monitor anti-PRRSV serological status prior to and following vaccination and challenge. All

pigs were negative (S/P ratio <0.4) at the time of vaccination. All pigs including the vaccinates were negative at 7 DPV (Days Post Vaccination). Seven days later, 21 of 22 vaccinated pigs were tested as positive for antibody to PRRSV. Two pigs of group 1 remained negative during the pre-challenge period and serologically converted at 8 days post challenge (8 DPC). All of the pigs in group 2 were negative at trial day 0 and remained negative throughout the pre-challenge period. On trial day 39 (8 DPC) 17 of the 22 non-vaccinated challenged pigs (Group 2) tested as sero positive. All of the pigs in group 3 (normal controls) remained sero-negative throughout the study.

Virus isolations from sera were performed before and after vaccination. Of the 22 vaccinated pigs, 17 were positive by 2 DPV, 18 were positive by 4 DPV and 19 were positive by 7 DPV. Following vaccination, vaccine virus was not recovered at all from one pig and not until 0 DPC, for another. These results correspond to the sero-negative status of these pigs during the post vaccination observation period. At the time of challenge, 55% of the vaccinated pigs were viremic positive. Following challenge, this percentage rose to 82% (at 2 DPC) and gradually decreased to 9% on 11 DPC. All pigs in group 2 were negative at 0 DPC and increased to 82% positive at 2 DPC and 91% at 4 DPC. On 6 and 10 DPC, group 2 was approximately 82% virus positive and 73% of this group was positive on 11 DPC. The normal controls, group 3, remained negative for the duration of the study.

Rectal temperature monitoring showed an overall group increase experienced by group 2. One-half or the pigs in this group experienced a rise of 1° F. over the pre-challenge average for 2 or more days during the 11 day observation period. In comparison, only four of the 22 pigs in the vaccinated group experienced temperatures of 1° F. over their pre-challenge average. The average duration of those animals experiencing elevated temperatures for two or more days was 2.2 days for group 1 and 4 days for group 2. None of the pigs in group 3 experienced increases of 1° F. over their pre-challenge average for two days or longer.

Weight gain was monitored over the 11 day observation period. Pigs in group 3 gained an average of 1.06 pounds/day, pigs in group 2 gained an average of 0.94 pounds/day and pigs in 1 gained an average of 0.53 pounds/day. Therefore, non-vaccinated challenged pigs gained only about 57% as much weight as did vaccinated challenged pigs and only 50% as much weight as the control group.

Leukopenia (white blood cell counts) were monitored during the post challenge observation period. Group 3 experienced a 5% reduction in the group average on trial day 33 (2 DPC) when compared to the pre-challenge average. For group 2, white blood cell counts dropped an average of 41% and did not return to pre-challenge levels until 11 DPC. The vaccinated group experienced a group average drop of 12% on trial day 34 (3 DPC). The counts returned to pre-challenge level on the next day and remained equal to the pre-challenge level for the duration of the observation period.

Daily clinical observations were made from trial day 28 (-4 DPC) through trial day 42 (11 DPC). All pigs were free of any observable clinical signs during the pre-challenge period. Group 3 remained free of any clinical signs for the duration of the post challenge period. Five of the pigs in group 2 were observed to have post challenge clinical signs. These signs became evident at 6 DPC and were not considered to be severe. The vaccinated pigs had only 1 clinical sign observed during the 11 day post challenge observation period.

At the termination of the study, lungs were evaluated for observable lung lesions. Group 3 had normal lungs and a group average score of 0.02. The individual pig scores for

group 2 ranged from a low of 33 to a high of 98 for a group average of 78.33. The scores of the vaccinated group ranged from 30 to a high of 90 with a group average of 53.20.

The data in this example demonstrated the efficacy of a modified live Atypical PRRS viral vaccine. The vaccine was administered at a minimal dose of 2.0 logs per close containing the fifth passage beyond the MSV (JA-142, passage 205). Efficacy of the vaccine was demonstrated by significantly reducing the extent of lung lesions, the severity of post challenge leukopenia, and post challenge fever. Additionally, a normal growth rate was maintained in vaccinated/challenged pigs compared to that achieved by the normal control pigs and significantly better than that achieved by non-vaccinated/challenged pigs.

EXAMPLE 6

Materials and Methods

This example compared four groups, groups 1, 2, and 3 having twenty pigs each, and group 4 having 10 pigs. Group 1 was inoculated intramuscularly (IM) with PRRS MSV, JA-142, passage 205, at a titer of about 2.5 logs/dose. Group 2 was inoculated intra-nasally with PRRS MSV, JA-142, passage 205, at a titer of about 5.0 logs/dose. Group 3 was inoculated IM with sterile diluent. Group 4 acted as strict controls. Pigs were challenged with a PRRSV isolate from South Dakota State University (SDSU) with an RFLP pattern of 144 on day 28 post-vaccination. Body temperatures of the pigs were monitored daily following challenge. Each animal was weighed at vaccination, challenge, weekly for the duration of the study, and necropsy. Blood samples were collected weekly following vaccination and every two days following challenge. The health status of each animal was monitored daily for the duration of the study. At the termination of the study, animals were sacrificed and their lungs scored for percent lung involvement.

PPRSV ELISA assays were performed following the exposures of the pigs with the test articles and challenge. Attempts to isolate PRRSV from serum samples were also performed on MA-104 cells following exposure to the test articles. WBC counts and clinical observations were determined post inoculation as in Example 2.

Results and Discussion

At zero days post vaccination (DPV), all pigs in this example were serologically negative to PRRSV as indicated by having a S/P ratio <0.4. At 14 DPV, 70% of the pigs in group 1 and 95% of the pigs in group 2 tested positive for the presence of anti-PPRSV antibody. Only one vaccinated pig of group 1, remained sero-negative throughout the pre-challenge period. This pig became sero-positive at seven days post challenge (DPC). All of the pigs in groups 3 and 4 remained negative throughout the pre-challenge period. At nine DPC, all of the pigs in group 3, the sterile diluent treated group, tested positive by ELISA for PRRSV antibody. The normal controls, group 4, remained negative for the duration of the study.

The virus isolation results correlated well with serological results. Only one pig remained negative for virus isolation from serum and this corresponded to the sero-negative status during the post vaccination period. These results indicate a relationship between post vaccination viremia and serological conversion with vaccine dosage. Group 2 was 100% sero-positive at 14 DPV as compared to 70% for group 1. The high dose group (group 2) was 85% and 90% viremia positive at 14 and 21 DPV, respectively. In comparison, the low dose group (group 1) was 55% and 85% positive for the same test days.

Following challenge, 89% of the animals in group 3 experienced temperatures that were one degree F. or greater than the pre-challenge values for two or more days. In group 1, 75% of the animals experienced temperatures or one degree or greater for two or more days. While only 45% of the animals of group 2 experienced elevated temperatures. In comparison, 30% of the animals in the normal control group (group 4) experienced elevated temperatures for two or more days during the 11 day observation period.

Treatment with either the high vaccine dose or the low vaccine dose appeared to have no detrimental effect on the growth performance during the post-vaccination period (-3 DPV to 28 DPV). The average daily weight gain for groups 1 and 2 was 0.77 lbs./day and 0.76 lbs./day, respectively. For comparison, groups 3 and 4 had average daily weight gains of 0.77 lbs. and 0.78 lbs., respectively. Following challenge, the vaccinated groups outperformed the sterile diluent group by 0.05 lbs./day (group 1) and 0.15 lbs./day (group 2). The normal controls outgained the vaccinates during the same time period by an average of 0.4 to 0.5 lbs./day.

Eighty-four percent (16 of 19) of group 3, the sterile diluent treatment group, experienced a 25% or greater drop in their WBC count for one or more days after challenge. The normal controls had 3 of 10 (30%) that had experienced similar decreases. Following challenge, the vaccinated groups, the low dose (group 1) and the high dose (group 2) had 11 of 20 (55%) and 3 of 20 (15%) experiencing leukopenia of 25% for one or more days.

The clinical observations made prior to the challenge indicated that the pigs were of good health status. Following challenge, the level of health status did not significantly change for those pigs that were challenged (groups 1, 2, & 3). Lethargy, respiratory signs, and lost appetite were the clinical signs observed and these were described as mild in severity. The clinical signs reported for one pig in group 2 could be attributed to the bacterial pneumonia (see discussion below on lung lesions) that it was experiencing. The normal control group (group 4) was free of any observable clinical signs during the 11 day observation period.

At the termination of the study, pigs were sacrificed and the lungs were observed for PRRS-like lesions to score the extent of lung involvement. The percent of involvement was scored for each lobe then multiplied by the percent the lung represented for the total lung capacity. For example, 50% lung involvement for a diaphragmatic lobe was then multiplied by 25% to equal 12.5% of the total lung capacity. The maximum score that could be obtained was 100. The group average lung score for the normal controls (group 4) was zero. The group average score for the sterile diluent treatment group (group 3) was 70.08. The vaccinated treatment groups average scores were 48.83 for the low dose (group 1) and 17.76 for the high dose (group 2). One pig was observed to have a lung score of 62.5, the highest score within group 2. The lesions noted on this pig's lungs were described to be associated with bacterial pneumonia.

From the results of this study, both dosage levels of the atypical PRRS MSV vaccine reduced the severity of the clinical signs associated with the respiratory disease caused by the PRRSV. A full field dose outperformed the minimal dose as indicated by the significant reduction in lung lesion scores.

EXAMPLE 7

Materials and Methods

This example determined the sequence of the attenuated MSV, JA-142 from the 201st passage as well as the sequence of passage 3 of the field isolate virus, JA-142. The attenuated

virus isolate was obtained from the master seed stock representing the 201st passage in MA-104 simian cells of a PRRSV isolated from swine affected with PRRS.

The virus was grown on 2621 cells, a monkey kidney cell line, also referred to as MA-104 and as USU-104 (Gravel) et al., 181 Proc. Soc. Exp. Biol. Med. 112-119 (1986), Collins et al., Isolation of Swine Infertility and Respiratory Syndrome Virus (Isolate ATCC VR-2332) in North America and Experimental Reproduction of the Disease in Gnotobiotic Pigs, 4 J. Vet. Diagn. Invest. 117-126 (1992)) (the teachings of which are hereby incorporated by reference). Cells were cultured in 50 ml Dulbecco modified Eagle's MEM medium (Life Technologies, Inc., Gaithersburg, Md.), supplemented with 10% fetal calf serum and 50 gentamicin (Sigma Chemical Co., St. Louis, Mo.) in a 5% humidified CO₂ atmosphere at 37° C. in 75 cm² plastic tissue culture flasks. Cells were maintained by passage at 5-7 day intervals. Cells were dislodged from the surface with trypsin-versene and split 1:4. To infect cells, media was decanted and 1 ml of cell supernatant containing virus at a titer of approximately 10⁵-10⁶ tissue culture infective doses (TCID₅₀) was added for 30 min. Thirty ml fresh media containing 4% fetal calf serum was added. Cells were incubated as described above for 5 days, at which time cytopathic effect was evident in the culture. Culture medium containing virus was centrifuged at 2000 rpm in a Beckman TJ6 centrifuge to pellet cellular debris.

Viral genomic RNA was purified by adding 1120 µl of prepared Buffer AVL (QIAamp Viral RNA Isolation Kit, Qiagen) (QIAGEN, inc. Valencia, Calif.)/carrier RNA to a 280 µl sample of virus-containing culture medium. The mixture was vortexed and incubated at room temperature for 10 min. 1120 µl ethanol was added and the mixture was inverted several times. RNA was absorbed to the matrix of a QIAamp spin column by repeated centrifugation of 630 µl aliquots at 6,000×g for 1 min. The column was washed with 500 µl buffer AW and centrifuged to remove all traces of wash solution. RNA was eluted from the column with 60 µl of diethylpyrocarbonate-treated water at room temperature. Purified RNA was stored at -70° C. or used immediately for synthesis of cDNA.

For cDNA synthesis, viral RNA was heated at 67° C. for 7 min, primed with random hexamers or PRRSV-specific primers, and reverse transcribed with Superscript II RNase H⁻ reverse transcriptase (RT) (Life Technologies, Inc.). Reactions contained 5 mM MgCl₂, 1× standard buffer II (Perkin Elmer Corp. Wellesley, Mass.), 1 mM each of dATP, dCTP, dGTP and dTTP, 1 unit/µl of RNase inhibitor, 2 units of RT, and 1 µl of RNA in a 40 µl reaction. Reaction mixtures were incubated for 15 min at 42° C., for 5 min at 99° C. and for 5 min at 5° C.

Polymerase chain reaction (PCR) was performed to obtain DNA fragments for sequencing as follows: 10 µl portions of cDNA reaction mixture were combined with the following reagents, resulting in a 25 µl reaction containing 2 mM MgCl₂, 1× standard buffer II (Perkin Elmer), 0.2 mM each of dATP, dCTP, dGTP and dTTP, 0.3 µM of 5'- and 3'-PRRSV-specific primer, and 0.375 units AmpliTaq Taq polymerase (Perkin Elmer). Reactions were prepared by heating for 4 min at 93° C. in a thermal cycler, then 35 cycles consisting of 50-59° C. for 30 sec, 72° C. for 30-60 sec, and 94° C. for 30 sec. Specific times and temperatures varied depending on the annealing temperatures of the primers in each reaction and the predicted length of the amplification product. A final incubation was performed for 10 min at 72° C. and reactions were placed at 4° C. PCR products were purified with a Microcon 100 kit (Amicon, Bedford, Mass.).

Rapid amplification of cDNA ends (RACE) PCR was performed to obtain the extreme 5'-end sequence of the genomic RNA, based on the method of Frohman, Mass., On Beyond Classic RACE (Rapid Amplification of cDNA Ends), 4 PCR Methods and Applications S40-S58 (1994) (the teachings of which are hereby incorporated by reference). Viral RNA was isolated and converted to cDNA as described above, with random hexamers as primers. Reaction products were purified on a Microcon 100 column (Amicon). A poly(dA) tail was added to the 3'-end by incubating 10 µl of cDNA in a 20 µl volume containing 1× buffer 4 (New England Biolabs, Beverly, Mass.), 2.5 mM CoCl₂, 0.5 mM dATP and 2 units terminal transferase (New England Biolabs), for 15 min at 37° C. The reaction was stopped by heating for 5 min at 65° C. and then was diluted to 200 µl with water.

PCR was performed using the Expand^a Long Template PCR System (Boehringer Mannheim, Mannheim, Germany) in a 50 µl reaction volume containing 10 µl of diluted, poly(dA)-tailed cDNA, 1× buffer 3, 0.35 mM each dATP, dCTP, dGTP and dTTP, 0.625 mM MgCl₂, 0.04 µM Q₁ primer (Frohman, 1994), 0.3 µM Q₂ primer (Frohman, 1994), 0.3 µM 5'-CGCCCTAATTGAATAGGTGAC-3' (SEQ ID NO:5) and 0.75 µl of enzyme mix. Reactions were heated at 93° C. for 2 min in a thermal cycler and cycled 25 times with each cycle consisting of 93° C. for 10 sec, 63° C. for 30 sec, and 68° C. for 12 min. After 25 cycles, the reaction was incubated at 68° C. for 7 min and held at 4° C. An aliquot of the reaction was diluted 100-fold and 5 µl of diluted product was added to a second PCR reaction containing, in 50 µl, 1× buffer 1, 0.35 mM each of dATP, dCTP, dGTP and dTTP, 0.3 µM primer Qi (Frohman, 1994), 0.3 µM 5'-CCTTCGGCAGGCGGGGAGTAGTGTGGAGGTGCTCAGC-3' (SEQ ID NO:6), and 0.75 µl enzyme mix. Reactions were heated at 93° C. for 2 min in a thermal cycler and cycled 25 times with each cycle consisting of 93° C. for 10 sec, 63° C. for 30 sec, and 68° C. for 4 min. After 25 cycles, the reaction was incubated at 68° C. for 7 min and held at 4° C. Reaction products were electrophoresed on a 1% agarose gel and the band of approximately 1500 by was purified using the QIAGEN QXII gel purification kit. Eluted DNA was cloned into the pGEM-T vector (Promega, Madison, Wis.) using standard procedures. Individual clones were isolated and grown for isolation of plasmid DNA using QIAGEN plasmid isolation kits.

PCR products and plasmid DNA were combined with appropriate primers based on related PRRSV sequences in Genbank or derived from known sequences, and subjected to automated sequencing reactions with Taq DyeDeoxy terminator cycle sequencing kits (Applied Biosystems, Foster City, Calif.) and a PR 2400 Thermocycler (Perkin Elmer) at the University of Minnesota Advanced Genetic Analysis Center. Reactions were electrophoresed on an Applied Biosystems 3700 DNA sequencer. Sequence base calling and proofreading were performed primarily with the Phred program (University of Washington Genome Center) and fragment assembly was performed primarily with the Phrap program (University of Washington Genome Center). Additional computer software including the Lasergene Package (DNASTAR Inc., Madison, Wis.), Wisconsin package version 9.1 (Genetics Computer Group, Madison, Wis.), and EuGene (Molecular Biology Information Resource, Houston, Tex.) was used to analyze the sequence. The final viral genomic sequence was assembled from approximately 100 PCR reactions and 428 DNA sequencing reactions.

Results

The results of Example 7 are given as SEQ ID Nos. 1 and 2 wherein SEQ ID No. 1 represents the DNA sequence of the 201st passage of the Master Seed Virus, JA 142 and SEQ ID

No. 2 represents the DNA sequence of the field-isolated virulent virus. JA 142 after three passages. Additionally, RNA sequences of the 201st passage JA-142 and the field isolated virulent virus, JA-142 are provided as SEQ ID Nos. 3 and 4, respectively. These RNA sequences vary slightly from the DNA sequences at the 5' end of the genome.

EXAMPLE 8

Materials and Methods

This example demonstrated the presence or absence of a NspI restriction endonuclease site for differentiation between field strains of PRRSV and an attenuated strain of PRRSV. Thus, this example provides a diagnostic testing method using restriction fragment length polymorphism (RFLP) analysis. RFLP is useful as a diagnostic tool because the NspI site is present in most field strains of PRRSV. Samples, preferably of serum, should be gathered from a suspected infected individual for RT-PCR/RFLP based diagnostic testing. In this case, known virulent field strains were used for testing to provide known result standards for later diagnostic testing. While Qiagen products and specific method steps are disclosed, it is understood that other methods and products known in the art can be utilized.

For performance of the diagnostic test (and to obtain the standards disclosed below) viral genomic RNA was isolated using a QIAamp Viral RNA Isolation Kit (Qiagen, Inc. Valencia, Calif.) and following the mini spin protocol. The following steps were used:

1. Carrier RNA was added to Buffer AVL and placed at 80° C. for five minutes or until dissolution of the precipitate to form solution 1. Do not heat Buffer AVL over 5 minutes or more than 6 times. Frequent warming/extended incubation will cause degradation of carrier-RNA, leading to reduced recovery of Viral RNA and eventually false negative RT-PCR results.
2. 1120 µl of solution 1 was pipetted into a microfuge tube.
3. 280 µl of serum sample was added to the microfuge tube holding solution 1 and the resulting mixture was vortexed thoroughly to ensure that solution 1 and the sample were well mixed together. This is done to lyse the sample under highly denaturing conditions, inactivate RNases, and ensure isolation of intact viral RNA. Carrier-RNA improves binding of viral RNA to the QIAamp membrane, and limits possible degradation of the viral RNA due to any residual RNase activity.
4. This mixture was incubated at room temperature for 10 minutes. Viral particle lysis is substantially complete after lysis for 10 minutes at room temperature, although longer times may be used with little or no effect on the yield or quality of the purified RNA.
5. 1120 µl of ethanol (EtOH) (96-100%) was added to the incubated mixture and mixed thoroughly by inverting the tube several times.
6. A QIAamp spin column was placed in a 2 ml collection tube and 630 µl of the mixture obtained in step five was added. This mixture was then centrifuged at 6000×g for one minute.
7. The filtrate in the collection tube was discarded.
8. The QIAamp spin column was placed into a clean 2 ml collection tube and another 630 µl of the mixture obtained in step five was added to the spin column and centrifuged at 6000×g.
9. The filtrate in the collection tube was discarded.

10. The QIAamp spin column was placed into a clean 2 ml collection tube and another 630 µl of the mixture obtained in step five was added to the spin column and centrifuged at 6000×g.

11. 500 µl of Buffer AW1 was added to the spin column and centrifuged at 6000×g for one minute.

12. The tube containing the filtrate was discarded.

13. The spin column was placed into a clean 2 ml collection tube and 500 µl of Buffer AW2 was added and centrifuged at 18,500×g for three minutes. The filtrate was discarded.

14. The spin column was placed into a new 2 ml collection tube and centrifuged at 6000×g for one minute to remove the last traces of AW2. The filtrate was discarded.

15. The spin column was placed into a clean 1.5 ml microfuge tube and 60 µl Buffer AVE at room temperature. This mixture was incubated for one minute at room temperature before being centrifuged at 6000×g for one minute to elute the RNA.

16. The eluted RNA was pipetted into a 1.5 ml microfuge tube and stored at -70° C. if the RT-PCR is not able to be done immediately.

RT-PCR was performed on the eluted RNA obtained in the above method. A 20 µl "master mix" containing the following: 5 µl of 1× RT-PCR buffer, 1 µl of 0.4 mM DNTP mixture (containing equal amounts each of dATP, dCTP, dGTP and dUTP), 0.1 µl of 0.08 units/Rx RNase inhibitor, 0.5 µl 500 nM BVDV forward primer, 0.5 µl 500 nM BVDV reverse primer, 11.9 µl RNase/DNase free water, and 1 µl Qiagen "secret" enzyme mix was added to a tube. 5 µl of the eluted RNA was then added to the tube.

Reactions were initially heated at 50° C. for 30 minutes followed by heating at 95° C. for 15 minutes in a thermal cycler and then cycled 35 times with each cycle consisting of 57° C. for 30 seconds, 72° C. for 45 seconds, and 94° C. for 45 seconds. After 35 cycles, the reaction was incubated at 57° C. for 30 seconds followed by 72° C. for 7 minutes and finally held at 4° C. To check the PCR on an agarose gel, 1 g of agarose was added to 100 ml of 1× TAE buffer before microwaving on high for two minutes. Next, 4 µl of 10 mg/ml EtBr was added to the heated gel before casting the gel and allowing it to solidify for 15-30 minutes. 4 µl of the PCR product was mixed with 1 µl loading dye. 3.5 µl of a 1 Kb ladder was added to 13.2 µl of water and 3.3 µl of loading dye for use as a marker. 4 µl of the marker mixture was electrophoresed on the gel, indicating a 1 Kb product. A band from the PCR product should be approximately 1 Kb in size. The gel was then run at 140 volts for 1 hour or 75 volts for two hours.

The band of approximately 1 Kb was purified using the QIAgen Qiaquick PCR Purification Kit (Qiagen, Inc. Valencia, Calif.). A column was placed in a collection tube and 20 µl PCR reaction sample and 100 µl PB buffer were added. This mixture was mixed thoroughly before spinning for 1 minute at full speed in an Eppendorf microfuge. The flow-through products were discarded and the column was replaced in the tube. The tube was spun for another full minute and allowed to stand for at least one minute at room temperature. The column was then spun a third time at lull speed. The eluent remaining contains purified PCR product and water.

The PCR/water product from above was then digested with Nsp I, a restriction enzyme and then electrophoresed on a 1.5% agarose gel to determine fragment numbers and lengths.

Results
The results of Example 8 are used for diagnostic results. It was found that most of the field strains for the PRRS virus contain one Nsp I restriction site, therefore yielding digestion

products of 549 and 476 by from the 1 Kb RT-PCR product. The parent strain of the JA-142 passage 200 possesses this phenotype. Only one PRRS strain, BI-Vetmedica 142 passage 200 (± 5), contains two Nsp I sites, yielding digestion products of 476, 380, and 173 by from the 1 Kb RT-PCR product. Some field strains possess no Nsp I site within this RT-PCR product, and therefore exhibit no digestion and electrophoresis of one fragment of 1021 bp. Thus, the presence of the attenuated virus can be determined.

EXAMPLE 9

Materials and Methods

This Example tested the degree of protective immunity against maternal reproductive failure of swine vaccinated by one or two attenuated strains of PRRSV.

Fifty gilts were separated into live experimental groups designated A-E and having ten gilts in each group. Gilts of group A were neither vaccinated nor challenged and were therefore used as strict controls. Gilts of group B were used as the challenge controls and therefore received no vaccinations but were challenged at or about day 90 of gestation. Gilts of groups C, D, and E were each vaccinated twice before conception with one month between vaccinations. These gilts were then challenged at or about day 90 of gestation. Two strains of vaccine virus (strains RespPRRS/Repro and JA-142) were used to challenge the gilts. The challenge consisted of oronasal exposure to virulent PRRSV. Gilts of group C were vaccinated twice with strain RespPRRS/Repro. Gilts of group D were vaccinated first with RespPRRS/Repro and then with JA-142. Gilts of group E were vaccinated twice with strain JA-142. Gilts and their progeny were observed at least twice daily for clinical signs and tested for both PRRSV and homologous antibody at selected intervals. The gilts of groups C, D, and E were bled just before their first vaccination and at selected times thereafter until they were necropsied, usually at or about 14 days after farrowing or sooner if they aborted. Gilts of group A and B were bled just before challenge and at identical selected times thereafter. Beginning one month after the second vaccination of groups C, D, and E, all gilts were bred as they came into estrus. All of the boars used for breeding purposes were free of antibody against PRRSV. Near the time of challenge, each gilt was moved to an isolation room and was kept in isolation until the experiment was ended for that gilt and her litter at two weeks after farrowing or sooner in the case of abortion or premature death of all progeny. All surviving pigs were weighed when they were two weeks old. Gilts that failed to conceive at their first, second, or third estrus cycle were excluded from the experiment. This reduced the numbers of pregnant gilts for groups

B, C, D, and E to 9, 8, 9, and 9, respectively. The same limitation did not apply to group A because for this group, there were more than ten nonvaccinated gilts available from which to make a random selection for inclusion in group A. Results and Discussion:

All vaccinated gilts (groups C, D, and E) responded to vaccination with the production of antibodies against PRRSV. These results are provided in FIG. 1 which is a graph representing the ratio of the total number of samples to samples positive for PRRSV antibodies. Blood samples were collected from the gilts just before their first vaccination and at selected times thereafter during an interval of 196 days. Depending on when gilts conceived (breeding was started on day 60), they were progressively removed from this group. Beginning at or about 90 days of gestation, blood samples were collected just before they were challenged, seven days after challenge, fourteen days after challenge, at the time of delivery (which was at or about 24 days after challenge if the gilt farrowed normally, or sooner if the gilt aborted), and at the time of necropsy (which was at or about 38 days, i.e. 2 weeks after farrowing, or sooner if the gilt lost all of her live born pigs before 2 weeks after farrowing). These results are provided in FIG. 2.

As shown in FIGS. 1 and 2, antibody levels increased after challenge for groups B, C, D, and E. For group B, the nonvaccinated group, these antibodies appeared only after challenge while they were present prior to challenge for groups C, D, and E. Gilts of group A and all boars used for breeding both vaccinated and nonvaccinated gilts remained free of antibody against PRRSV throughout the experiment. None of the vaccinated gilts had any obvious vaccine-related clinical signs after vaccination. Conversely, all of the gilts (both vaccinated and nonvaccinated) had moderate to severe clinical signs following challenge. A summary of the number of live born and still born pigs, the number of aborted, late term dead, and mummified fetuses, and the number and weight of pigs still alive 14 days after farrowing is presented in Table 4. All of the pigs of groups C, D, and E that survived through day 14 were robust and were judged to be in excellent health. None of these pigs yielded infectious virus from either serum or lung lavage samples. In contrast, all pigs of group B that survived through day 14 were unthrifty and were shown by virus isolation to be infected. A measure of the difference in general health is provided by the relative body weights of pigs of group B versus those of pigs of groups A, C, D, and E. The appearance of pigs of group B suggested that few, if any, would have recovered or would have recovered sufficiently to warrant any expectation of their continued survival under conditions of commercial swine production.

TABLE 4

Effect of Vaccination Against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) on the Health and Survival of Fetuses and Pigs of Gilts Subsequently Exposed to Highly Virulent PRRSV									
Group	Gilts ³	Day 0 ¹					Day 14 ²		
		Liveborn pigs	Stillborn pigs	Late-term dead fetuses	Mummified fetuses	Aborted fetuses	Live pigs	Mean pig weight (lbs)	Mean litter weight (lbs)
A	10	102	17	1	2	0	95	9.8	93.1
B	9	24	3	62	5	0	16	5.6	10.0
C	8	37	8	31	4	13	27	11.1	37.5
D	9	47	10	14	0	39	38	8.7	36.7
E	9	50	13	38	3	0	33	10.4	38.1

¹At the time of farrowing.²On the day the experiment was ended.³Pregnant gilts that aborted or farrowed.

Vaccination with either strain (RespPRRS/Repro and JA-142) of attenuated PRRSV provided a level of protective immunity that was demonstrated by challenge exposure. Although protection was incomplete regardless of the vaccine strain or method of vaccination, it was sufficient to recommend vaccination as an economically beneficial procedure. Whereas the loss of pigs of group B was essentially complete either due to death or ill health, about 40% of the pigs of litters of groups C, D, and E (on a per litter basis and using 100% as the value for litters of group A) would have survived to market. The excellent health status of the surviving pigs of groups C, D, and E is emphasized by the fact that the mean body weight of pigs of these groups (when calculated collectively) is the same as that of pigs of group A. The economic impact of saving about 3.6 pigs/litter through vaccination is difficult

to project with certainty, however, if a reasonable assumption is made that each pig is worth about \$20.00 in profit and reduced overhead through sharing of fixed costs, then two vaccinations at an estimated cost of about \$1.00 each would return \$72.00 for each \$2.00 invested. On the basis of these assumptions, anything more than a prevalence of PRRSV-induced reproductive failure of one case for every 36 pregnancies (or a severe clinical epidemic once every 18 months assuming 2 pregnancies/year) would make vaccination cost effective. Moreover, it seems likely that the results of this study present the worst case scenario. Namely, the strain used for challenge was selected to represent the most virulent field strains of PRRSV currently present in North America and may not accurately reflect the majority of field strains against which vaccines are likely to be more protective.

 SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 6

<210> SEQ ID NO 1

<211> LENGTH: 15424

<212> TYPE: DNA

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus

<400> SEQUENCE: 1

```

tcgcccgggc aggtgttggc tctatgcctt ggcatattgta ttgtcaggag ctgcgacccat      60
tggcacagcc caaaactagc tgcacagaaa acgcccttct gtgacagccc tcttcagggg      120
agcttagggg tctgtcceta gcaccttgc tccggagttg cactgcttta cggctctctc      180
aacctttaa ccatgtctgg gatattgat cgggtcacgt gcaccccaa tgccagggtg      240
tttatggcgg agggccaagt ctactgcaca cgatgtctca gtgcacggtc tctccttctc      300
ctgaatctcc aagttcctga gcttggagtg ctgggcctat tttacaggcc cgaagagcca      360
ctccgggtga cgttgccacg tgcattcccc actgttgagt gctccccgc cggggcctgc      420
tggctttctg cgatctttcc aattgcacga atgaccagtg gaaacctgaa ctttcaacaa      480
agaatggtgc gggtcgcagc tgagatttac agagccggcc agctcaccoc tgcagtcttg      540
aaggtcttac aagtttatga acgggggtgc cgctggtagc ctatagtcgg acctgtccct      600
ggagtggccg attttgccaa ctccctacat gtgagtgata aacctttccc gggagcaact      660
catgtgctaa ccaacctgcc actcccagag aggcctaagc ctgaagactt ttgcccttct      720
gagtgtgcta tggctgacgt ctatgatatt ggccatggcg ccgtcatgta tgtggccaaa      780
gggaaagtct cctgggcccc tcgtggcggg gatgaggcga aatttgaacc tgtccctagg      840
gagttgaagt tgatcgcaa ccaactccac atctccttcc cgcaccacca cgcagtggac      900
atgtetaagt ttgtgttcat agcccctggg agtgggtgtct ctatgcccgt cgagtgccca      960
cacggctgtc tccccgctaa tactgtccct gaagtaact gctgggtggcg cttgtttgac     1020
tcgctcccac tggacgttca gaacaaagaa attcgcctg ccaaccaatt cggtatcaa     1080
accaagcatg gtgtcgctgg caagtacct caacggaggc tgcaagctaa tggctccga     1140
gcagtgactg atacagatgg acccattgtc gtacagtatt tctctgtag ggagagctgg     1200
atccgccact tcagactggc ggaagagcct agcctccctg ggtttgaaga cctcctcaga     1260
ataagggtag agcccaatac gtccgcttgc agtgacaagg gtggaaaaat cttccggttt     1320
ggcagtcaca aatggtacgg tgctggaaag agagcaagga aagcacgctc tggatgacc     1380
accacagtcg ctaccgcgc cttgcccgtc cgtgaaatcc agcaagccaa aaagcacgag     1440

```


-continued

gatgccggcg	ctgataaggc	tgtgcatctc	aggcactatt	ctccgcctgc	cgacgggaac	1500
tgtggttggc	actgcatttc	cgccatcgcc	aaccgaatgg	tgaattccaa	atttгааact	1560
actcttcccg	agagggtgag	accttcagat	gactgggcta	ctgacgagga	ccttgtgaac	1620
accatccaaa	ttctcaagct	ccctgcgggc	ttggacagga	acgggtgctg	tgttggcgcc	1680
aaatacgtgc	ttaagctgga	aggcgagcat	tggactgtct	ctgtgaccct	tgggatgtcc	1740
ccttctttgc	tcccccttga	atgtgttcag	ggctgtttg	agcataagag	cggacttgg	1800
ccccagatg	cggtcgaagt	tttcggattt	gaccctgcct	gccttgaccg	actggctgag	1860
gtaatgcact	tgcctagcag	tgtcatccca	gctgctctgg	ccgaaatgtc	cggcgacccc	1920
aaccgtccgg	cttccccggt	caactactgtg	tggactgttt	cacaattctt	tgcccgccac	1980
agaggaggag	agcacctga	tcaggtgcgc	ttaggaaaaa	tcatcagcct	ttgtcaagtt	2040
gttgaggaat	gctgttgcca	tcagaataaa	accaaccggg	ccaccccgga	agaggttgcg	2100
gcaaggattg	atcagtacct	ccatggtgca	acaagtcttg	aagaatgctt	gattaggctt	2160
gagagggttt	gcccgccgag	cgctgcgggc	accttctttg	attggaatgt	tgtgctccct	2220
ggggttgggg	cttcaactca	gacaaccaa	cagctccatg	tcaaccagtg	ccgcgctctg	2280
gttctctgctg	tgactcaaga	gcctttggac	aaagaccag	tccctctgac	cgcttctctg	2340
ctgtccaatt	gctactatcc	tgcacaaggt	gacgaggttc	gtcaccgtga	gaggctaaac	2400
tccgtactct	ctaagctgga	gggggttgtt	cgtgaggaat	atgggctcac	gccaactgga	2460
cctggcccgc	gacccgcact	accgaacggg	ctcgtcgaac	ttaaagacca	gatggaggag	2520
gatctgctaa	aactagtcaa	cgcccaggca	acttcagaaa	tgatggcctg	ggcagccgag	2580
caggttgatc	tgaagcttg	ggtcaaaaac	taccacgggt	ggacaccgtc	accccctcca	2640
ccaagagttc	agcctcga	aaacaagcct	gtcaagagct	tgccagggaa	caaacctgtc	2700
cccgtccac	gcaggaaggt	cagatctgat	tgtggcagcc	cgatttcgat	gggcgacaat	2760
gttctctgacg	gtcgggaaga	tttgactgtt	ggtggcccc	ttgatcttc	gacaccatcc	2820
gagccgatga	cacctctgag	tgagcctgca	cctatgcccg	cgttgcaata	tatttctagg	2880
ccagtgcac	ctttgagtgt	gctggcccc	gtacctgcac	cgcgtagaac	tgtgtcccga	2940
ccggtgacgc	ccttgagtga	gccaattttt	gtgtctgcac	cgcgacacaa	atttcagcag	3000
gtggaagaag	cgaatctggc	ggcaacaatg	ctgacgcacc	aggacgaacc	tctagatttg	3060
tctgcatcct	cacagactga	atatgaggct	tctcccctaa	caccactgca	gaacatgggt	3120
attctggagg	tgggggggca	agaagctgag	gaagttctga	gtgaaaactc	ggatacactg	3180
aatgacatca	accctgcacc	tgtgtcatca	agcagctccc	tgtcaagtgt	taagatcaca	3240
cgccaaaac	actctgctca	agccatcatt	gactcggggc	ggccctgcag	tgggcatctc	3300
cgaaagggaa	aagaagcatg	cctcagcatc	atgcgtgagg	cttgtgatgc	ggctaagctt	3360
agtgaccctg	ccacgcagga	atggctttct	cgcatgtggg	atagggttga	tatgctgact	3420
tggcgcaaca	cgtctgctta	ccaggcgctt	cgcatcttag	atggtaggtt	tgagtttctc	3480
ccaaagatga	tactcgagac	accgcccgcc	taccctgtg	ggtttgtgat	gctgcctcgc	3540
acgcctgcac	cttccgtggg	tgcagagagt	gacctacca	ttggttcagt	cgccactgaa	3600
gatgttccac	gcatcctcgg	gaaaatagaa	aacgcgggca	agatgcccaa	ccaggggctc	3660
ttgacatcct	tcggggaaga	accggtgtgc	gaccaacctg	tcaaggactc	ctggatgtcg	3720
tcgcggggg	ttgacgagag	cacaacggct	ccgtccgctg	gtacaggtgg	tgctgactta	3780
cccaccgatt	tgccaccttc	agatggtttg	gatgcggacg	agtggggggc	gttacggacg	3840

-continued

gtaagaaaga aagctgaaag gctcttcgac caattgagcc gtcaggtttt taacctcgtc	3900
tcccatctcc ctgttttctt ctcacacctc ttcaaatctg acagtgggta ttctccgggt	3960
gattgggggt ttgcagcttt tactttatth tgctctttt tgtgttacag ctaccattc	4020
tttggttttg tccccctctt ggggtgtttt tctgggtctt ctggcggtgt gcgcatgggg	4080
gtttttggct gttggttggc ttttgctggt ggctgttca agcctgtgtc cgaccagtc	4140
ggcactgctt gtgagtttga ctgcagagag tgtaggaacg tccttcattc ttttgagctt	4200
ctcaaacctt gggaccctgt tcgcagcctt gttgtgggcc ccgtcggctc cggccttgcc	4260
attcttggca gggtactggg cggggcacgc tacatctggc attttttgc taggcttggc	4320
attgttgacg attgtatctt ggctggagct tatgtgcttt ctcaaggtag gtgtaaaaag	4380
tgtcggggat cttgtgtaag aactgctcct aatgaaatcg ccttcaacgt gtccctttt	4440
acgcgtgcga ccaggtcgtc actcatcgac ctgtgcgac ggttttgtgc gccaaaaggc	4500
atggacccca ttttctcgc tactgggtgg cgcgggtgct ggaacggccg aagtccatt	4560
gagcaacct ctgaaaaacc catcgcgttc gccagttgg atgaaaagag gatcacggct	4620
agaactgtgg tcgctcagcc ttatgatcct aaccaagccg taaagtgctt gcgggtgta	4680
caggcgggtg gggcgatagt ggccgaggca gtcccaaaag tggcaaggt ttccgctatt	4740
ccattccgag ctccctttt tcccaccgga gtgaaggttg atcctgagtg caggatcgtg	4800
gtcgaccccg aacttttac tacagctctc cggctctggt actccaccac aaacctcgtc	4860
cttgggtgtag gggactttgc ccaactgaat ggattaaaaa tcaggcaaat ttccaagccc	4920
tcgggaggag gcccgcacct cattgctgcc ctgcatgtt cttgctcgat ggcgttgac	4980
atgcttgctg gagtttatgt aactgcagtg gggctctgct gtaccggcac caacgatccg	5040
tgggtgacta acccattcgc cgtccctggc tacggacctg gctccctctg cacgtccaga	5100
ttgtgcatct cccaacatgg ccttaccctg cccttgacag cacttgtggc aggattcgg	5160
cttcaggaaa ttgcctagt cgttttgatt ttcgtttcca tcggaggcat ggctcatagg	5220
ttgagttgta aggctgatat gctgtgcgtc ttacttgcaa tcgccagcta tgtttgggta	5280
ccccttacct ggttgctctg tgtgtttcct tgctggttgc gctggttctc tttgcacct	5340
ctcaccattc tatggttggg gtttttcttg atgtctgtaa atatgccttc gggaatctta	5400
accgtggtgt tattggttgc tctttggctt ctaggccgtt atactaatgt tgttggctt	5460
gttaccacct atgatattca ccattacacc aatggcccc gcggtgttgc cgccttggct	5520
accgcaccag atgggactta cttggccgct gtccgccgct ctgcgttgac tggccgcacc	5580
gtgctgttta ccccgctca gcttgggtcc cttcttgagg gcgctttcag aactcgaaag	5640
ccctcactga acaccgtaa tgtggctggg tcctccatgg gctctggcgg agtgttact	5700
atcgatggga aaattaagtg cgtgactgcc gcacatgtcc ttacgggtaa ttcagccagg	5760
gtttccgggg tcggctttaa tcaaatgctt gactttgatg taaaagggga cttcgccata	5820
gctgactgcc cgaattggca aggggctgct cctaagacct aattctgca ggatggatgg	5880
actggccgct cctattggct gacatcctct ggcgtcgaac ccggtgtcat tgggaatgga	5940
ttcgcttct gcttaccgc gtgcccgat tccgggtccc cagtgatcac cgaagccggt	6000
gagcttgcg gcgttcacac aggatcaaac aaacaaggag gaggcattgt tacgcgcccc	6060
tctggccagt tttgcaatgt ggcacccatc aagctgagcg aattaagtga gttctttgct	6120
ggacctaaag tcccgcctgg tgatgtgaag gttggcagcc acataattaa agacatatgc	6180
gaggtacctt cagatctttg cgccttgcct gctgccaac ccgaactgga aggaggctc	6240

-continued

tccaccgtcc	aacttctgtg	tgtgtttttc	ctcctgtgga	gaatgatggg	acatgcctgg	6300
acgcccttgg	ttgctgttgg	gttttttata	ttgaatgagg	ttctcccagc	tgtactggtc	6360
cggagtgttt	tctccttgg	aatgtttgtg	ctatcttggc	tcacaccatg	gtctgcgcaa	6420
gttctgatga	tcaggcttct	aacagcagct	cttaacagga	acagattgtc	actcgccttt	6480
tacagccttg	gtgcagcgac	cggttttgtc	gcagatctgg	cggcaactca	agggcacccg	6540
ttgcaggcag	taatgaattt	aagtacctat	gccttctgct	ctcggataat	ggcgtgacc	6600
tcaccagtcc	cagtgattgc	gtgtgggtgt	gtgcacctcc	ttgccataat	tttgtacttg	6660
tttaagtacc	gctgcctgca	caatgtcctt	gttggcgatg	gtgcgttctc	tgcggctttc	6720
ttcttgcat	actttgccga	gggaaattg	aggaagggg	tgtcgcaatc	ctgcgggatg	6780
aatcatgagt	cgctgactgg	tgccctcgct	atgagactta	atgacgagga	cttggatttt	6840
cttacgaaat	ggactgattt	taagtgtttt	gtttctgcat	ccaacatgag	gaatgcggcg	6900
ggccagttca	tcgaggctgc	ctatgctaaa	gcacttagaa	ttgaacttgc	ccagttgggtg	6960
caggttgata	aggttcgagg	tactttggcc	aaacttgaag	cttttgctga	taccgtggca	7020
ccccaactct	cgcccgtgga	cattgttgtt	gctcttggcc	atacgcctgt	tggcggtatc	7080
ttcgacctaa	aggttggtag	caccaagcat	accctccaag	ccattgagac	cagagttctt	7140
gccgggtcca	aatgaccgt	ggcgcgtgtc	gttgatccaa	ccccacacc	cccaccgca	7200
cccgtgccta	tcccccttcc	accgaaagt	ctggagaatg	gtcccaacgc	ctggggggat	7260
gaggatcggt	tgaataagaa	gaagaggcgc	aagatggaag	ccgtcggcat	ctttgttatg	7320
ggtggaaga	aatatcagaa	atthttgggac	aagaactccg	gtgatgtgtt	ttatgaggag	7380
gtccatgata	acacagacgc	gtgggagtgc	ctcagagttg	acaaccctgc	cgactttgac	7440
cctgagaagg	gaactctgtg	cgggcatact	accattgaag	ataagactta	cagtgtctac	7500
gcctccccat	ctggcaagaa	attcctggtc	cccgcctacc	cagagagcaa	aaaaaaccaa	7560
tgggaagctg	cgaagctttc	cgtggaacag	gccttggca	tgatgaatgt	cgacggtgaa	7620
ctgacagcca	aagaagtgga	gaaactgaaa	agaataattg	acaaactcca	gggcctgact	7680
aaggagcagt	gtttaaactg	ctagccgcca	gcggcttgac	ccgctgtggt	cgcgccggct	7740
tggttattac	tgagacagcg	gtaaaaatag	tcaaatttca	caaccggacc	ttcaccttag	7800
gacctgtgaa	tttaaaagtg	gccagtgagg	ttgagctaaa	agacgcggtc	gagcataacc	7860
aacaccgggt	tgcaagaccg	gttgatgggtg	gtgttgtgct	cctgcgctcc	gcagttcctt	7920
cgcttataga	cgtcttaatc	tccggcgctg	atgcatctcc	caagttactc	gcccgccacg	7980
ggccgggaaa	cactgggatc	gatggcacgc	tttgggattt	tgaggccgag	gccactaaag	8040
aggaaattgc	actcagtgcg	caaataatac	aggcttgtga	cattaggcgc	ggcgacgcac	8100
ctgaaattgg	tcttcttat	aagctgtacc	ctgtcagggg	caaccctgag	cgggtaaaag	8160
gagttttaca	gaatacaagg	tttgagata	taccttataa	aacccccagt	gacactggaa	8220
gccagtgca	cgcggtgctc	tgcctcacgc	ccaatgccac	tccggtgact	gatgggcgct	8280
ccgtcttggc	cacgactatg	ccctccgggt	ttgagttgta	tgtaccgacc	attccagcgt	8340
ctgtccttga	ttatcttgat	tctaggcctg	actgccccaa	acagttgaca	gagcacggct	8400
gtgaggacgc	cgcattaaga	gacctctcca	agtatgactt	gtccacccaa	ggctttgttt	8460
tacctggagt	tcttcgctt	gtgcgtaagt	acctgtttgc	tcatgtgggt	aagtgcccg	8520
ccgttcatcg	gccttccact	tacctgcca	agaattctat	ggctggaata	aatgggaaca	8580
ggtttccaac	caaggacatc	cagagcgtcc	ctgaaatcga	cgttctgtgc	gcacaggccg	8640

-continued

ttcgggaaaa	ctggcAAact	gttaccCctt	gtaccCctcaa	gaaacagtat	tgtgggAaga	8700
agaagactag	gacaatactc	ggcaccAata	acttcattgc	gctggctcac	cgggcagcgt	8760
tgagtgggtg	caccCagggc	ttcatgAaaa	aggcgtttaa	ctcgccCatt	gccctcggtA	8820
aaaacaaatt	taaagagctt	cagactCccg	tcttaggcag	gtgccttgaa	gctgatcttg	8880
catcctgcca	tcgctccaca	cctgcaattg	tccgctgggt	tgccgccaat	cttctttatg	8940
aacttgctg	tgctgaagag	caccagccgt	cgtaCgtggt	gaactgctgc	cacgacctac	9000
tggtcacgca	gtccggcgca	gtaactAaga	gaggtggcct	gtcgtctggc	gacccgatca	9060
cttctgtgtc	caacaccatt	tacagcttgg	tgatatatgc	acaacacatg	gtgctcagtt	9120
actttaaaag	tggtcacctt	catggccttc	tgtttctaca	agaccagctg	aagtttgagg	9180
acatgctcaa	ggttcaaccC	ctgatcgtct	attcggaCga	cctcgtactg	tatgccgagt	9240
ctcccaccat	gccaaactac	cactggTggg	ttgaacatct	gaacctgatg	ctgggttttc	9300
agacggaccC	aaagaagaca	gccataacag	actcgccatc	atttctaggc	tgtaggataa	9360
taaatggacg	ccagctcgtc	cctaaccgtg	acaggattct	cgcgccctc	gcctaccata	9420
tgaaggcaag	caatgtctct	gaatactacg	cctcggcggc	tgcgatactc	atggacagct	9480
gtgcttgttt	agagtatgat	cccgaatggT	ttgaagagct	tgtagttggg	atagcgcagt	9540
gtgcccgcaa	ggacggctac	agttttcccg	gcccgcggtt	cttcttgTcc	atgtgggaaa	9600
aactcagatc	caatcatgag	gggaagaagt	ccagaatgtg	cgggtactgc	ggggccccgg	9660
ctccgtacgc	cactgcctgt	ggcctcgacg	tctgtattta	ccacaccac	ttccaccagc	9720
attgtccagt	catcatctgg	tgtggccacc	cggtcggTtc	tggttcttgt	agtgagtgca	9780
aacccccctt	agggaaaggc	acaagccctc	tagatgaggt	gttagaacia	gtcccgtata	9840
agcctccacg	gactgtaatc	atgcatgtgg	agcagggtct	caccctctt	gaccCaggca	9900
gataccagac	tcgccgcgga	ttagtctccg	ttaggcgtgg	cattagagga	aatgaggTtg	9960
atctaccaga	cggtgattat	gctagcaccg	cctactccc	tacttgtaaa	gagattaaca	10020
tggtcgtgtg	cgctctaat	gtgTtgcgca	gcaggttcat	catcgccccc	cctggtgctg	10080
ggaaaacata	ctggctcctt	caacaggTcc	aggatggTga	tgccatttac	acgccaactc	10140
accagaccat	gctcgatatg	attagggctt	tggggacgtg	cgggttcaac	gtcccagcag	10200
gtacgacgct	gcaattccct	gccccctccc	gtaccggccc	ttgggttcgc	atccTagccg	10260
gcggttggtg	tcctggcaag	aattccttcc	tggatgaagc	agcgtattgt	aatcaccttg	10320
atgtcttgag	gcttcttagc	aaaactaccC	tcacctgtct	gggagatttc	aaacaactcc	10380
accCagTggg	ttttgattct	cattgctatg	ttttgacat	catgcctcag	actcaactga	10440
agaccatctg	gagatttgga	cagaatatct	gtgaggccat	tcagccagat	tacagggaca	10500
aacttgTatc	catggtcaac	acaaccCgtg	taacctacgt	ggaaaaacct	gtcaagtatg	10560
ggcaagtcc	cacccttac	cacagggacc	gagaggacgg	cgccatcaca	attgactcca	10620
gtcaaggcgc	cacatttgat	gtggttacac	tgcatTTgcc	cactaaagat	tactcaaca	10680
ggcaaagagc	ccttgTtgct	attaccaggg	caagacatgc	tgtctttgtg	tatgaccCac	10740
acaggcaact	gcagagcatg	tttgatcttc	ctgcgaaagg	cacaccCgtc	aacctcgctg	10800
tgcaaccgtga	cgagcagctg	atcgtgctag	atagaaataa	caaagaatgc	acggttgctc	10860
aggctctagg	caatggggat	aaattcaggg	ccacagacia	gcgcgttgta	gattctctcc	10920
gcgccatttg	tgagatctg	gaagggtcga	gtccccgct	ccccaggtc	gcacacaact	10980
tgggatttta	tttctcgctt	gatttgacac	agtttgctaa	actcccggtA	gaacttgcac	11040

-continued

```

cccactggcc cgtggtgaca acccagaaca atgaaaagtg gccagaccgg ttggttgcta 11100
gccttcgccc cgtccataag tatagccgcg cgtgcatcgg tgccggctac atggtgggcc 11160
cctcagtgtt tctgggcacc cctggggttg tgcatacta tctcacaaaa tttgtcaggg 11220
gcgaggctca aatgcttccg gagacagtct tcagcaccgg ccgaattgag gtagattgcc 11280
gtgagtatct cgatgaccgg gagcgagaaa ttgctgagtc cctcccccat gctttcattg 11340
gcgacgtcaa aggcactacc gttggaggat gtcaccatgt cacctccaaa taccttccgc 11400
gcttccttcc caaggaatca gtcgcggtag tcggggtttc aagccccggg aaagccgcaa 11460
aagcagtttg cacattaaca gatgtgtatc tcccagatct cgaagcttac ctccaccag 11520
agaccagtc caagtgctgg aaaatgatgt tggacttcaa ggaagtcca ctgatggtct 11580
ggaaggacaa gacggcctat tttcaacttg aaggccgcca tttcacctgg taccagcttg 11640
caagctatgc ctctacatc cgagttcctg ttaactctac ggtgtatttg gacccctgca 11700
tgggccctgc cctttgcaac agaagagttg tcgggtccac tcattgggga gctgacctcg 11760
cagtcacccc ttatgattac ggtgccccaa tcatcctgtc tagtgcatc catggtgaaa 11820
tgccccctgg gtacaaaatc ctggcgtgcg cggagttctc gcttgacgat ccagtgaggt 11880
acaaaacacac ctgggggttt gaatcggata cagcgtatct gtacgagttc accggaaacg 11940
gtgaggactg ggaggattac aatgatgcgt ttcgtgcgcg ccagaaaggg aaaatttata 12000
aggccactgc caccagcatg aggtttcatt tcccccggg cctgtcatt gaaccaactt 12060
taggcctgaa ttgaaatgaa atggggtcca tgcaaagcct ctttgacaaa attggccaac 12120
ttttcgtgga tgctttcag gaatttttgg tgtccattgt tgatatcctc atatttttgg 12180
ccattttgtt tggtttacc atcgtgtggt ggctggtggt cttctgcatc cgattggttt 12240
gctccgcggt actccgtgcg cgcctacca ttcacctga gcaattacag aagatcctat 12300
gaggcctttc tttctcagt ccaggtggat attcccact ggggaactag acatcccctg 12360
gggatgcttt ggcaccataa ggtgtcaacc ctgattgatg aaatggtgtc gcgtcggatg 12420
taccgcacca tggaaaaagc aggacaggct gcctggaaac aggtggtgag cgaggccacg 12480
ctgtctogca ttagtggttt ggatgtggtg gctcattttc agcatcttgc cgccattgaa 12540
gccgagacct gtaaataatt ggctctcgg ctgcccactg tacacaatct gcgcatgaca 12600
gggtcaaatg taaccatagt gtataatagt actttgaatc aggtgtttgc tatttttcca 12660
accctggat cccggccaaa gcttcatgat tttcagcaat ggctaatagc tgtgcactcc 12720
tccatatttt cctccgttgc ggcttcttgt actctttttg ttgtgctgtg gttgctgatt 12780
ccaatgctac gtactgtttt tggtttccgc tggttagggg caatttttcc ttogaactca 12840
cggatgaatta cacggtgtgt ccgccttgc tcaccggca agcagccgct gaggtctacg 12900
aaccaggcag gtctctttgg tgcaggatag ggcattgacc atgtagtgag gaagaccatg 12960
acgatctagg gttcatggtt ccgtctggcc tctccagcga aggccacttg accagtgttt 13020
acgcctgggt ggcgttctg tccttcagct acacggccca gttccatccc gagatatttg 13080
ggatagggaa tgtgagtcaa gtttatgttg acatcaagca ccaattcatc tgcgcccgtt 13140
acgacgggga gaacgccacc ttgcctcgtc atgacaatat ttcagccgta tatcagacct 13200
actaccaaca tcaagtcgac ggcggcaatt ggtttcacct agaatggctg cgcccccttct 13260
tttctcttg gttggtttta aatgtttctt ggtttctcag gcgttcgctt gcaagccatg 13320
tttcagttca agtctttcgg acatcaaac caacacaacc gcagcatcag gctttgttgt 13380
cctccaggac atcagctgcc ttaggcatgg cgactcgtcc tctcagacga ttgcgaaaag 13440

```


-continued

```

ctctcagtgc cgcgcggcga tagggacgcc cgtgtacatc actgtcacag ccaatgtcac 13500
agatgagaat tatttacatt cttctgatct ccttatgctt tcttcttgcc ttttctatgc 13560
ttctgagatg agtgaaaagg gattcaaggt gatgtttggc aatgtgtcag gcatcgtggc 13620
tgtgtgtgtc aactttacca gctacgtcca acatgtcaag gagtttacc aacgctcctt 13680
ggtaggtgat catgtgcggc tgetccattt catgacacct gagaccatga ggtgggcaac 13740
cgttttagcc tgttttcttg ccatcttact ggcaatttga atgttcaagt atgttgggga 13800
gatgcttgac cgcgggctgt tgctcgcgat tgctttcttt gtggtgtatc gtgccatttt 13860
gttttgctgc gctcgtcaac gccaacagca acagcagctc tcatcttcag ttaatttaca 13920
acttgacgct atgtgagctg aatggcacag attggctgaa agacaaattt gattgggcat 13980
tggagacttt tgtcatcttt cccgtgttga ctacattgt ctcatatagt gcaactacca 14040
ctagccattt ccttgacaca gtcgggtctgg ttactgtgtc tactgccggg ttctaccacg 14100
ggcggtatgt tctgagtagc atctacggc tctcgcctct ggccgcattg acttgcttcg 14160
tcattaggct tgcaagaac tgcattgctt ggcgctactc ttgtaccaga tatactaact 14220
tccttctgga cactaagggc agactctatc gctggcggtc gcccgttatc atagagaaag 14280
gggtaagggt tgaggtcgaa ggtcacctga tcgacctca aagagttgtg cttgatgggt 14340
ccgtggcaac ccctttatac agagtctcag cggaacaatg gggtcgtctt tagacgactt 14400
ttgctatgat agcacggctc cacaaaagg gcttttggcg ttttccatta cctacacgcc 14460
agtgatgata tatgctctaa aggtaagtcg cggccgactt ttagggcttc tgcacctttt 14520
gatctttctg aattgtactt ttaccttgg gtacatgaca tgcgtgact ttaatagcac 14580
aaataaggtc gcgctcacta tgggagcagt agttgcactt ctttgggggg tgtactcagc 14640
catagaaacc tggaagttca tcacctccag atgtcgtttg tgcttgctag gccgcaagta 14700
cattctggcc cccgcccacc acgtcgaaag tgccgcgggc tttcatccga tcgcgcaaaa 14760
tgataaccac gcatttctcg tccggcgtcc cggctccact acggttaacg gcacattggg 14820
gcccggttg aaaagcctcg tgttgggttg cagaaaagct gttaaacagg gagtggtaaa 14880
ccttgcaaaa tatgccaaat aacaacggca agcagcaaaa gaaaagagg gggaatggcc 14940
agccagtcaa tcagctgtgc cagatgctgg gtaagatcat cgcccagcaa aaccagtcca 15000
gaggcaaggg accggggaag aaaattaaga ataaaaacc ggagaagccc cattttcctc 15060
tagcgactga agatgacgtc aggcactact tcacccttag tgagcggcaa ttgtgtctgt 15120
cgtcgatcca gactgccttt aaccagggcg ctggaacctg taccctatca gattcaggta 15180
ggataagtta cactgtggag tttagtttgc cgacgatca tactgtgctc ctgatccgcg 15240
tcacagcgcc atcatcagcg taatgggctg gcattcctta agcacctcag tgttagaatt 15300
ggaagaatgt gtggtgaatg gcaactgatt gcaactgtgcc tctaagtcac ctattcaatt 15360
agggcgaccg tgtgggggtt aagttaatt ggcgagaacc atgcggccga aattaaaaaa 15420
aaaa 15424

```

<210> SEQ ID NO 2

<211> LENGTH: 15424

<212> TYPE: DNA

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus

<400> SEQUENCE: 2

```

tcgcccgggc aggtgttggc tctatgcctt ggcatthgta ttgtcaggag ctgcgacat 60
tggtacagcc caaaactagc tgcacagaaa acgcccttct gtgacagccc tcttcagggg 120

```


-continued

agcttagggg	tctgtcccta	gcaccttgct	tccggagttg	cactgcttta	cggtctctcc	180
aaccctttaa	ccatgtctgg	gatacttgat	cggtgcacgt	gcacccccaa	tgccaggggtg	240
tttatggcgg	agggccaagt	ctactgcaca	cgatgtctca	gtgcacggtc	tctccttcct	300
ctgaatctcc	aagttcctga	gcttggagtg	ctgggcctat	tttacaggcc	cgaagagcca	360
ctccgggtgga	cgttgccacg	tgcattcccc	actgttgagt	gctcccccg	cggggcctgc	420
tggctttctg	cgatctttcc	aattgcacga	atgaccagtg	gaaacctgaa	ctttcaacaa	480
agaatgggtgc	gggtcgcagc	tgagatttac	agagccggcc	agctcacc	tgcagtcttg	540
aaggctctac	aagtttatga	acggggttgc	cgctggtagc	ctatagtcgg	acctgtccct	600
ggagtggcgcg	tttttgccaa	ctccctacat	gtgagtgata	aacctttccc	gggagcaact	660
catgtgctaa	ccaacctgcc	actcccgag	aggcctaagc	ctgaagactt	ttgccctttt	720
gagtgtgcta	tggctgacgt	ctatgatatt	ggcatggcg	ccgtcatgta	tgtggccaaa	780
gggaaagtct	cctgggcccc	togtggcggg	gatgaggcga	aatttgaac	tgtccctagg	840
gagttgaagt	tgatcgcgaa	ccaactccac	atctccttc	cgccccacca	cgcagtggac	900
atgtctaagt	ttgtgttcac	agccccggg	agtgggtgtc	ctatgcgggt	cgagtgccca	960
cacggctgtc	tccccgctaa	tactgtccct	gaagtaact	gctgggtggcg	cttgtttgac	1020
tcgctcccac	tggacgttca	gaacaaagaa	attcgcctg	ccaaccaatt	cggtatcaa	1080
accaagcatg	gtgtcctgg	caagtaccta	caacggaggc	tgcaagctaa	tggctccga	1140
gcagtgactg	atacagatgg	accattgtc	gtacagtatt	tctctgttag	ggagagctgg	1200
atccgccact	tcagactggc	ggaagagcct	agcctccctg	ggtttgaaga	cctcctcaga	1260
ataagggtag	agcccaatac	gtcgccattg	agtgacaagg	gtggaaaaat	cttccggttt	1320
ggcagtcaca	aatggtacgg	tgtggaaaag	agagcaagga	aagcacgctc	tggatgacc	1380
accacagtgc	ctcaccgagc	cttgcccgt	cgtgaaatcc	agcaagccaa	aaagcacgag	1440
gatgccggcg	ctgataaggc	tgtgcatctc	aggcactatt	ctccgcctgc	cgacgggaac	1500
tgtggttggc	actgcatttc	cgccatcgcc	aaccgaatgg	tgaattccaa	atttgaact	1560
actcttcccg	agagggtag	accttcagat	gactgggcta	ctgacgagga	ccttgtgaac	1620
accatccaaa	ttctcaagct	ccctgcccgc	ttggacagga	acgggtgctt	tgttggcgcc	1680
aaatcgtgc	ttaagctgga	agggcagcat	tggactgtct	ctgtgaccct	tgggatgtcc	1740
ccttctttgc	tccccctga	atgtgttcag	ggctgttgg	agcataagag	cgacttgg	1800
ccccagatg	cggtcgaagt	tttcggattt	gacctgcct	gccttgaccg	actggctgag	1860
gtaatgcact	tgcctagcag	tgcatccca	gctgctctgg	ccgaaatgtc	cggcgacccc	1920
aactgtccgg	cttccccgg	caactactgtg	tggactgttt	cacaattctt	tgcccgccac	1980
agaggaggag	agcacctga	tcaggtgcgc	ttaggaaaaa	tcatcagcct	ttgtcaagtt	2040
gttgaggaat	gctgttgcca	tcagaataaa	accaaccggg	ccaccccgga	agaggttgcg	2100
gcaaggattg	atcagtagct	ccatggtgca	acaagtcttg	agaatgctt	gattaggctt	2160
gagagggttt	gcccgcgag	cgctgcccgc	accttctttg	attggaatgt	tgtgctccct	2220
ggggttgggg	cttcaactca	gacaaccaa	cagctccatg	tcaaccagtg	ccgcgctctg	2280
gttctctg	tgactcaaga	gcctttggac	aaagactcag	tccctctgac	cgcttctctg	2340
ctgtccaatt	gctactatcc	tgcacaaggt	gacgaggttc	gtcaccgtga	gaggctaaac	2400
tccgtactct	ctaagctgga	gggggttgtt	cgtgaggaat	atgggctcac	gccaaactgaa	2460
cctggccccg	gacccgact	accgaacggg	ctcgtcgaac	ttaaagacca	gatggaggag	2520

-continued

gatctgctga	aactagctca	cgcccaggca	acttcagaaa	tgatggcctg	ggcagccgag	2580
caggttgatc	tgaaagcttg	ggtaaaaaac	taccacgggt	ggacaccgcc	acccccctca	2640
ccaagagttc	agcctcgaaa	aacaaagtct	gtcaagagct	tgccagggaa	caaacctgtc	2700
cccgcctcac	gcaggaaggt	cagatctgat	tgtggcagcc	cgattttgat	gggcgacaat	2760
gttctgacg	gtcgggaaga	tttgactggt	ggtggcccc	ttgatctttc	gacaccatcc	2820
gagccgatga	cacctctgag	tgagcctgca	cttatgcccc	cgttgcaata	tattttctagg	2880
ccagtgcacat	ctttgagtgt	gctggcccc	gttctgcac	cgcgtagaac	tgtgtcccga	2940
ccggtgacgc	ccttgagtga	gccaatTTTT	gtgtctgcac	cgcgacacaa	atttcagcag	3000
gtggaagaag	cgaatctggc	ggcaacaacg	ctgacgcacc	aggacgaacc	tctagatttg	3060
tctgcatcct	cacagactga	atatgaggct	tctcccctaa	caccactgca	gaacatgggt	3120
attctggagg	tgggggggca	agaagctgag	gaagttctga	gtgaaatctc	ggatacactg	3180
aatgacatca	accctgcacc	tgtgtcatca	agcagctccc	tgtcaagtgt	taagatcaca	3240
cgcccaaac	actctgctca	agccatcatt	gactcggggc	ggccctgcag	tgggcatctc	3300
cgaagggaaa	aagaagcatg	cctcagcatc	atgctgagg	cttgtgatgc	ggctaagctt	3360
agtgaccctg	ccacgcagga	atggctttct	cgcatgtggg	atagggttga	catgctgact	3420
tggcgcaaca	cgtctgctta	ccaggcgctc	cgcatcttag	atggtaggtt	tgagtttctc	3480
ccaaagatga	tactegagac	accgcccgcc	taccctgtg	ggtttgtgat	gctgcctcac	3540
acgcctgcac	cttccgtggg	tgacagagag	gacctacca	ttggttcagt	cgccactgaa	3600
gatgttccac	gcatcctcgg	gaaaatagaa	aacgcccggc	agatgcccaa	ccaggggctc	3660
ttgacatcct	tgggggaaga	accggtgtgc	gaccaacctg	tcaaggactc	ctggatgtcg	3720
tgcggggggt	ttgacgagag	cacaacggct	ccgtccgctg	gtacaggtgg	tgetgactta	3780
cccaccgatt	tgccaccttc	agatggtttg	gatgcggacg	agtggggggc	gttacggacg	3840
gtaagaaaga	aagctgaaag	gctcttcgac	caattgagcc	gtcaggtttt	taacctcgtc	3900
tcccatctcc	ctgttttctt	ctcacacctc	ttcaaatctg	acagtggtta	ttctccgggt	3960
gattgggggt	ttgcagcttt	tactttatth	tgctctttt	tgtgttacag	ctaccatttc	4020
tttggttttg	ttcccctctt	gggtgttttt	tctgggtctt	ctcggcgtgt	gcgcatgggg	4080
gtttttggct	gttggttggc	ttttgctggt	ggcctgttca	agcctgtgtc	cgaccagtc	4140
ggcactgctt	gtgagtttga	ctcgccagag	tgtaggaacg	tccttcattc	ttttgagctt	4200
ctcaaacctt	gggaccctgt	tcgcagcctt	gttgtggggc	ccgtcggctc	cggccttgcc	4260
attcttggca	ggttactggg	cggggcacgc	tacatctggc	atTTTTgtct	taggcttggc	4320
attgttgacg	attgtatctt	ggctggagct	tatgtgcttt	ctcaaggtag	gtgtaaaaag	4380
tgtcggggat	cttgtgtaag	aactgctcct	aatgaaatcg	ccttcaacgt	gttccctttt	4440
acgcgtgcga	ccaggtcgtc	actcatcgac	ctgtgcgac	ggttttgtgc	gcaaaaaggg	4500
atggacocca	tttccctcgc	tactgggtgg	cgcggtgct	ggaccggccg	aagtccatt	4560
gagcaacctt	ctgaaaaacc	catcgcgttc	gcccagttgg	atgaaaagag	gattacggct	4620
agaactgtgg	gcgctcagcc	ttatgatcct	aaccaagccg	taaagtgctt	gcgggtgtta	4680
caggcgggtg	gggcatagat	ggccgaggca	gtcccaaaag	tggtcaaggt	ttccgctatt	4740
ccattccgag	ctcccttttt	tcccaccgga	gtgaaggttg	atcctgagtg	caggatcgtg	4800
gtcgaccccc	acacttttac	tacagctctc	cggctctggt	actccaccac	aaacctcgtc	4860
cttgggtggt	gggactttgc	ccaactgaat	ggattaaaa	tcaggcaaat	ttccaagccc	4920

-continued

tccggaggag	gccccacact	cattgctgcc	ctgcatgttg	cttgcctgat	ggcgttgac	4980
atgcttgctg	gagtttatgt	aactgcagtg	gggtcttgcg	gtaccggcac	caacgatccg	5040
tggtgacta	accattcgc	cgtccctggc	tacggacctg	gctccctctg	cacgtccaga	5100
ttgtgcatct	cccaacatgg	ccttaccctg	cccttgacag	cacttgtggc	aggattcggg	5160
cttcaggaaa	ttgccctagt	cgttttgatt	ttcgtttcca	tccgaggcat	ggctcatagg	5220
ttgagttgta	aggctgatat	gctgtgcgtc	ttacttgcaa	tcccageta	tgtttgggta	5280
ccccttacct	ggttgctctg	tgtgtttcct	tgctggttgc	gctggttctc	tttgcaccct	5340
ctcaccatcc	tatggttggg	gtttttcttg	atgtctgtaa	atatgccttc	gggaatctta	5400
accgtggtgt	tattggttgc	tctttggctt	ctaggccggt	ataactaatgt	tgttggtctt	5460
gttaccacct	atgatattca	tcattacacc	aatggccccc	gcggtgttgc	cgcttggct	5520
accgcaccag	atgggactta	cttggccgct	gtccgcgcg	ctgcgttgac	tggccgcacc	5580
gtgctgttta	ccccgtctca	gcttgggtcc	cttcttgagg	gcgctttcag	aactcgaaag	5640
ccctcaactga	acaccgtcaa	tgtggtcggg	tcctccatgg	gctctggcgg	agtgttcaact	5700
atcgatggga	aaattaagtg	cgtgactgcc	gcacatgtcc	ttacgggtaa	ttcagccagg	5760
gtttccgggg	tccgcttcaa	tcaaagtctt	gactttgatg	taaaagggga	cttcgccata	5820
gctgattgcc	cgaattggca	aggggctgct	cctaagacct	aattctgcga	ggatggatgg	5880
actggccgcg	cctattggct	gacatcctct	ggcgtcgaa	ccggtgtcat	tgggaatgga	5940
ttcgcttct	gcttcaccgc	gtgcccgat	tccgggtccc	cagtgatcac	cgaagccggt	6000
gagcttgctg	gcggtcacac	aggatcaaac	aaacaaggag	gaggcattgt	tacgcgcccc	6060
tctggccagt	tttgcaatgt	ggcaccatc	aagctgagcg	aattaagtga	gttctttgct	6120
ggacctaaag	tcccgtcgg	tgatgtgaag	gttggcagcc	acataattaa	agacatatgc	6180
gaggtacctt	cagatctttg	cgcttgcctt	gctgccaac	ccgaactgga	aggaggcctc	6240
tccaccgtcc	aacttctgtg	tgtgtttttc	ctcctgtgga	gaatgatggg	acatgcctgg	6300
acgcccttgg	ttgctgttgg	gttttttctc	ttgaatgagg	ttctcccagc	tgtactggtc	6360
cggagtgttt	tctccttgg	aatgtttgtg	ctatcttggc	tcacaccatg	gtctgcgcaa	6420
gttctgatga	tcaggcttct	aacagcagct	cttaacagga	acagattgtc	actcgccttt	6480
tacagccttg	gtgcagcgac	cggttttgtc	gcagatctgg	cggcaactca	agggcaccgc	6540
ttgcaggcag	taatgaattt	aagtacctat	gccttctgct	ctcggataat	ggctgtgacc	6600
tcaccagtcc	cagtgattgc	gtgtggtggt	gtgcacctcc	ttgccataat	tttgtacttg	6660
tttaagtacc	gctgcctgca	caatgtcctt	gttggcgatg	gtgcgttctc	tgcggctttc	6720
ttcttgcat	actttgccga	gggaaattg	agggaggggg	tgtcgcaatc	ctgcgggatg	6780
aatcatgagt	cgctgactgg	tgcctcgcct	atgagactta	atgacgagga	cttggatttt	6840
cttacgaaat	ggactgattt	taagtgtttt	gtttctgcat	ccaacatgag	gaatgcggcg	6900
ggccagtcca	tccaggctgc	ctatgctaaa	gcacttagaa	ttgaacttgc	ccagttgggtg	6960
caggttgata	aggttcgagg	tactttggcc	aaacttgaag	cttttgctga	taccgtggca	7020
ccccaaactct	cgcccggtga	cattgttgtt	gctcttggcc	atacgcctgt	tggcggtatc	7080
ttcgacctaa	aggttggtag	caccaagcat	acctccaag	ccattgagac	cagagttctt	7140
gccgggtcca	aaatgaccgt	ggcgcgtgct	gttgatccaa	ccccacacc	cccaccgcga	7200
cccgtgccta	tcccccttc	accgaaagtt	ctggagaatg	gtcccaacgc	ctggggggat	7260
gaggatcggt	tgaataagaa	gaagaggcgc	aggatggaag	ccgtcggcat	ctttgttatg	7320

-continued

ggtggaaaga aatatcagaa attttgggac aagaactccg gtgatgtgtt ttatgaggag	7380
gtccatgata acacagacgc gtgggagtgc ctacagattg acaaccctgc cgactttgac	7440
cctgagaagg gaactctgtg cgggcatact accattgaag ataagactta cagtgtctac	7500
gcctccccat ctggcaagaa attcctggtc cccgtctacc cagagagcaa aaaaaaccaa	7560
tgggaagctg cgaagctttc cgtggaacag gcccttggca tgatgaatgt cgacggtgaa	7620
ctgacagcca aagaagtgga gaaactgaaa agaataattg acaaactcca gggcctgact	7680
aaggagcagt gtttaaactg ctacccgcca gcgcttgac ccgctgtggt cgcggcggct	7740
tggttggtac tgagacagcg gtaaaaatag tcaaatttca caaccggacc ttcaccctag	7800
gacctgtgaa tttaaaagtg gccagtgagg ttgagctaaa agacgcggtc gagcataacc	7860
aacaccgggt tgcaagaccg gttgatggtg gtgttggtct cctgcgctcc gcagttcctt	7920
cgcttataga cgtcttaatc tccggcgtg atgcatctcc caagttactc gcccgccacg	7980
ggccgggaaa cactgggatc gatggcacgc tttgggattt tgaggccgag gccactaaag	8040
aggaaattgc actcagtgcg caaataatac agccttgtga cattaggcgc ggcgacgcac	8100
ctgaaattgg tcttccttat aagctgtacc ctgtcagggg caaccctgag cgggtaaaag	8160
gagttttaca gaatacaagg tttggagaca taccttataa aacccccagt gacactggaa	8220
gccagtgca cgcggctgcc tgectcacgc ccaatgccac tccggtgact gatgggcgct	8280
ccgtcttggc cactgactatg ccctccgggt ttgagttgta tgtaccgacc attccagcgt	8340
ctgtccttga ttatcttgat tctaggcctg actgccccaa acagttgaca gagcacggct	8400
gtgaggacgc cgcattaaga gacctctcca agtatgactt gtccacccaa ggctttgttt	8460
tacctggagt tcttcgctt gtgcgtaagt acctgtttgc tcatgtgggt aagtgcccg	8520
ccgttcatcg gccttccact taccctgcca agaattctat ggctggaata aatgggaaca	8580
ggtttccaac caaggacatc cagagcgtcc ctgaaatcga cgttctgtgc gcacaggccg	8640
tgccggaaaa ctggcaaaact gttaccctt gtaccctcaa gaaacagtat tgtgggaaga	8700
agaagactag gacaatactc ggcaccaata acttcattgc gctggccac cgggcagcgt	8760
tgagtgggtg caccagggc tcatgaaaa aggcgtttaa ctccgccatt gccctcggt	8820
aaaacaaatt taaagagctt cagactccgg tcttaggcag gtgcctttaa gctgatcttg	8880
catcctgca tgcctccaca cctgcaattg tccgctgggt tgccgccaat cttctttatg	8940
aacttgctg tgctgaagag cacctgccgt cgtacgtgtt gaactgctgc cacgacctac	9000
tggtcacgca gtccggcgca gtaactaaga gagtgggcct gtcgtctggc gaccgatca	9060
cttctgtgtc caacaccatt tacagcttgg tgatatatgc acaacacatg gtgctcagtt	9120
actttaaaag tggtcaccct catggccttc tgtttctaca agaccagctg aagtttgagg	9180
acatgctcaa ggttcaacc ctagatcgtct attcggacga cctcgtactg tatgccgagt	9240
ctcccaccat gccaaactac cactgggtggg ttgaacatct gaacctgatg ctgggttttc	9300
agacggaccc aaagaagaca gccataacag actcgccatc atttctaggc tgtaggataa	9360
taaatggacg ccagctcgtc cctaaccgtg acaggattct cgcggccctc gcctaccata	9420
tgaaggcaag caatgtctct gaatactacg cctcggcggc tgcgatactc atggacagct	9480
gtgcttggtt agagtatgat cccgaatggg ttgaagagct tgtagttggg atagcgcagt	9540
gtgcccgcaa ggacggctac agttttcccg gcccgccgtt cttcttgctc atgtgggaaa	9600
aactcagatc caatcatgag ggggaagaag ccagaatgtg cgggtactgc ggggccccgg	9660
ctccgtacgc cactgcctgt ggctcgcagc tctgtattta ccacaccac ttcaccagc	9720

-continued

attgtccagt	catcatctgg	tgtggccacc	cggtgggttc	tggttcttgt	agtgagtgca	9780
aacccccct	agggaaaggc	acaagccctc	tagatgaggt	gttagaacia	gtcccgtata	9840
agcctccacg	gactgtaatc	atgcatgtgg	agcagggctc	caccctctt	gaccaggca	9900
gataccagac	tcgccgcgga	ttagtctccg	ttaggcgtgg	cattagagga	aatgagggtg	9960
atctaccaga	cggtgattat	gctagcaccg	ccctactccc	tacttgtaaa	gagattaaca	10020
tggtcgctgt	cgctctaat	gtggtgcgca	gcaggttcat	catcgcccgc	cctgggtgctg	10080
ggaaaacata	ctggctcctt	caacaggtcc	aggatgggtga	tgtcatttac	acgccaactc	10140
accagacat	gctcgatatg	attagggctt	tggggacgtg	ccggttcaac	gtcccagcag	10200
gtacgacgct	gcaattccct	gccccctccc	gtaccggccc	ttgggttcgc	atcctagccg	10260
gcggttggtg	tcctggcaag	aattccttcc	tggatgaagc	agcgtattgt	aatcaccttg	10320
atgtcttgag	gcttcttagc	aaaactaccc	tcacctgtct	gggagatttc	aaacaactcc	10380
accagtggtg	tttgattct	cattgctatg	tttttgacat	catgcctcag	actcaactga	10440
agaccatctg	gagatttga	cagaatatct	gtgatgccat	tcagccagat	tacagggaca	10500
aacttgatc	catggtcaac	acaaccctg	taacctacgt	ggaaaaacct	gtcaagtatg	10560
ggcaagtcc	cacccttac	cacagggacc	gagaggacgg	cgccatcaca	attgactcca	10620
gtcaaggcgc	cacattgat	gtggttacac	tgcatctgcc	cactaaagat	tactcaaca	10680
ggcaaagagc	ccttggtgct	attaccaggg	caagacatgc	tatctttgtg	tatgaccac	10740
acaggcaact	gcagagcatg	tttgatcttc	ctgcgaaagg	cacaccctc	aacctcgctg	10800
tgcaccgtga	cgagcagctg	atcgtgctag	atagaaataa	caaagaatgc	acggttgctc	10860
aggctctagg	caatgggat	aaattcaggg	ccacagacia	gcgcgttgta	gattctctcc	10920
gcgccatttg	tgcagatctg	gaagggtcga	gctccccgct	ccccaggctc	gcacacaact	10980
tgggatttta	tttctgcct	gatttgacac	agtttgctaa	actcccggta	gaacttgcac	11040
cccactggcc	cgtggtgaca	accagaaca	atgaaaagtg	gccagaccgg	ttggttgcta	11100
gccttcgccc	cgtccataag	tatagccgcg	cgatcatcgg	tgccggctac	atggtgggccc	11160
cctcagtgtt	tctgggcacc	cctgggggtg	tgatcacta	tctcaciaaa	ttgtcaggg	11220
gcgaggctca	aatgcttccg	gagacagtct	tcagcaccgg	ccgaattgag	gtagattgcc	11280
gtgagtatct	tgatgaccgg	gagcgagaaa	ttgctgagtc	cctcccccat	gctttcattg	11340
gcgacgtcaa	aggcactacc	gttggaggat	gtcaccatgt	cacctcaaa	taccttcgc	11400
gcttccttcc	caaggaatca	gtcgcggtag	tcggggtttc	aagccccggg	aaagccgcaa	11460
aagcagtttg	cacattaaca	gatgtgtatc	tcccagatct	cgaagcttac	ctccaccag	11520
agaccagtc	caagtgctgg	aaaatgatgt	tggacttcaa	ggaagtctga	ctgatggtct	11580
ggaaggacia	gacggcctat	tttcaacttg	aaggccgcca	ttcacctgg	taccagcttg	11640
caagctatgc	ctcgtacatc	cgagttcctg	ttaactctac	ggtgtatttg	gaccctgca	11700
tgggccctgc	cctttgcaac	agaagagttg	tcgggtccac	tcattgggga	gctgacctcg	11760
cagtacccc	ttatgattac	ggtgccaaaa	tcactctgtc	tagtgatac	catggtgaaa	11820
tgccccctgg	gtacaaaatc	ctggcgtgcg	cggagttctc	gcttgacgat	ccagtgaggt	11880
acaaaacac	ctgggggttt	gaatcgata	cagcgtatct	gtacgagttc	accggaaacg	11940
gtgaggactg	ggaggattac	aatgatgcgt	ttcgtgcgcg	ccagaaaggg	aaaatttata	12000
aggccactgc	caccagcatg	aggtttcatt	ttccccggg	cctgtcatt	gaaccaactt	12060
taggcctgaa	ttgaaatgaa	atggggctca	tgcaaagcct	ctttgacaaa	attggccaac	12120

-continued

tttttgtgga	tgctttcacg	gaatTTTTGG	tgtccattgt	tgatatcatc	atatttttgg	12180
ccattttggt	tggetttacc	atcgctggct	ggctgggtgt	cttctgcac	cgattgggtt	12240
gctccgcggt	actccgtgcg	cgccctacca	ttcaccctga	gcaattacag	aagatcctat	12300
gaggcctttc	tttctcagt	ccaggtggat	attcccacct	ggggaactag	acatcccctg	12360
gggatgtttt	ggcaccataa	gggtgcaacc	ctgattgatg	aaatgggtgc	gcgtcggatg	12420
taccgcacca	tggaaaaagc	aggacaggct	gcctggaaac	agggtgtgag	cgaggccacg	12480
ctgtctcgca	ttagtggtt	ggatgtgggt	gctcattttc	agcatcttgc	cgccattgaa	12540
gccgagacct	gtaaataatt	ggcctctcgg	ctgcccacgc	tacacaatct	gcgcatgaca	12600
gggtcaaagt	taaccatagt	gtataatagt	actttgaatc	agggtgttgc	tatttttcca	12660
acccctggat	cccggccaaa	gcttcatgat	ttcagcaat	ggctaatagc	tgtgcactcc	12720
tccatatttt	cctccgttgc	ggcttcttgt	actctttttg	ttgtgctgtg	gttgctggatt	12780
ccaatactac	gtactgtttt	tggtttccgc	tggttagggg	caatTTTTCC	ttogaactca	12840
cggtgaatta	cacggtgtgt	ccgccttgcc	tcaccggca	agcagccgct	gaggtctacg	12900
aaccaggcag	gtctctttgg	tgcaggatag	ggcatgaccg	atgtagtgag	gacgacctg	12960
acgatctagg	gttcatggtt	ccgcctggcc	tctccagcga	aggccacttg	accagtgttt	13020
acgcctggtt	ggcgttctctg	tccttcagct	acacggccca	gttccatccc	gagatatttg	13080
ggatagggaa	tgtgagtcaa	gtttatgttg	acatcaagca	ccaattcatc	tgcgctgctc	13140
acgacgggga	gaacgccacc	ttgcctcgtc	atgacaatat	ttcagccgta	tttcagacct	13200
actaccaaca	tcaagtcgac	ggcggcaatt	ggtttcacct	agaatggctg	cgccccctct	13260
tttctcttg	gttggtttta	aatgtttctt	ggtttctcag	gcgttcgctc	gcaagccatg	13320
tttcagttca	agtctttcgg	acatcaaaac	caacactacc	gcagcatcag	gctttgttgt	13380
cctccaggac	atcagctgcc	ttaggcatgg	cgactcgtcc	tctcagacga	ttcgcaaaag	13440
ctctcagtgc	cgcgcgcgca	tagggacgcc	cgtgtacatc	actgtcacag	ccaatgtcac	13500
agatgagaat	tatttacatt	cttctgatct	ccttatgctt	tcttcttgc	ttttctatgc	13560
ttctgagatg	agtgaaaagg	gattcaaggt	gatatttggc	aatgtgtcag	gcatcgtggc	13620
tgtgtgtgtc	aactttacca	gctacgtcca	acatgtcaag	gagtttacc	aacgctcctt	13680
gggtgctgat	catgtgcggc	tgtctcattt	catgacacct	gagacctga	gggtgggcaac	13740
cgtttttagcc	tgtttttttg	ccatcttact	ggcaatttga	atgttcaagt	atgttgggga	13800
gatgcttgac	cgcgggctgt	tgtctcgcat	tgctttcttt	gtggtgtatc	gtgccatttt	13860
gttttctgct	gctcgtcaac	gccaacagca	acagcagctc	tcatcttcag	ttgatttaca	13920
acttgacgct	atgtgagctg	aatggcacag	attggctgaa	agacaaattt	gattgggcag	13980
tggagacttt	tgtcatcttt	cccgtgttga	ctcacattgt	ctcatatggt	gcactcacca	14040
ctagccattt	ccttgacaca	gtcggctctg	ttactgtgtc	taccgcccgg	ttctaccacg	14100
ggcggtatgt	tctgagtagc	atctacgagg	tctgcgctct	ggccgcattg	atttgcttcg	14160
tcattaggct	tgcgaagaac	tgcattgtct	ggcgtactc	ttgtaccaga	tatactaact	14220
tccttctgga	cactaagggc	agactctatc	gctggcggtc	gcccgttatc	atagagaaag	14280
gggtaagggt	tgaggtcgaa	ggtcacctga	tcgacctcaa	aagagttgtg	cttgatgggt	14340
ccgtggcaac	cccttaacc	agagtctcag	cggaacaatg	gggtcgtctt	tagacgactt	14400
ttgctatgat	agcaaggctc	cacaaaagg	gcttttggcg	ttttcatta	cctacacgcc	14460
agtgatgata	tatgctctaa	aggtaagtcg	cggccgactt	ttaggcttc	tgcacctttt	14520

-continued

```

gatctttctg aattgtactt ttaccttcgg gtacatgaca ttcgtgcact ttaatagcac 14580
aaataaggtc gcgctcacta tgggagcagt agttgcactt ctttgggggg tgtactcagc 14640
catagaaacc tggaagttca tcacctccag atgccgtttg tgcttgctag gccgcaagta 14700
cattctggcc cccgcccacc acgtcgaaag tgccgcgggc tttcatccga tcgcggaaaa 14760
tgataaccac gcatttgcg tccggcgtcc cggctccact acggttaacg gcacattggt 14820
gcccgggttg aaaagcctcg tgttgggtgg cagaaaagct gttaaacagg gagtggtaaa 14880
ccttgtcaaa tatgccaaat aacaacggca agcagcaaaa gaaaaagagg gggaatggcc 14940
agccagtcaa tcagctgtgc cagatgctgg gtaagatcat cgcccagcaa aaccagtcca 15000
gaggcaaggg accggggaag aaaattaaga ataaaaacc ggagaagccc cattttcctc 15060
tagcgactga agatgacgtc aggcactcact tcacccttag tgagcggcaa ttgtgtctgt 15120
cgctgatcca gactgcctt aaccagggcg ctggaacctg taccctatca gattcaggta 15180
ggataagtta cactgtggag tttagtttgc cgacgcatca tactgtgctc ctgatccgcg 15240
tcacagcgcc atcatcagcg taatgggctg gcattcctta agcacctcag tgttagaatt 15300
ggaagaatgt gtgggtaatg gcaactgatt gcaactgtgcc tctaagtcac ctattcaatt 15360
agggcgaccg tgtgggggtt aagtttaatt ggcgagaacc atgcggccga aattaaaaaa 15420
aaaa 15424

```

<210> SEQ ID NO 3

<211> LENGTH: 15413

<212> TYPE: RNA

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus

<400> SEQUENCE: 3

```

augacguaua gguguuggcu cuaugccuug gcauuuguau ugucaggagc ugcgaccauu 60
ggcacagccc aaaacuagcu gcacagaaaa cgccuucug ugacagcccu cuucagggga 120
gcuuaggggu cuguccuag caccuugcuu ccggaguugc acugcuuuac ggucucucca 180
accuuuaac caugucuggg auacuugauc ggugcagug ccccccaau gccagggugu 240
uuauaggcga gggccaaguc uacugcacac gaugucucag ugcacggucu cuccuuccuc 300
ugaauccucca aguuccugag cuuggagugc ugggccuauu uuacagggcc gaagagccac 360
uccgguggac guugccacgu gcauucccca cuguugagug cuccccgcc ggggcccugcu 420
ggcuuucugc gaucuuucca auugcagaa ugaccagugg aaaccugaac uuucaacaaa 480
gaauggugcg ggucgcagcu gagauuuaca gagccggcca gcucaccccu gcagucuuga 540
aggcucuaca aguuaugaa cggggguugc gcugguaccc uauagucgga ccugucccug 600
gaguggccga uuuugccaac ucccuacaug ugagugauaa accuuucccg ggagcaacuc 660
augugcuaac caaccugcca cuccagaga ggccuaagcc ugaagacuuu ugcccuucug 720
agugugcuau ggcugacguc uaugauauug gccaugggcg cgucauguau guggccaaag 780
ggaaagucuc cugggccccu cguggcgggg augaggcgaa auuugaaccu gucccuaggg 840
aguugaaguu gaucgcgaac caacuccaca ucuccuucc gccccaccac gcaguggaca 900
ugucuaaguu uguguucaua gcccugggga guggugucuc uaugcggguc gagugcccac 960
acggcugucu ccccgcuauu acugucccug aagguaacug cugguggcgc uuguuugacu 1020
cgcucccacu ggacguucag aacaaagaaa uucgccgugc caaccaauuc ggcuaucaaa 1080
ccaagcaugg ugucgcugc aaguaccuac aacggaggcu gcaagcuauu ggucuccgag 1140
cagugacuga uacagaugga cccauugucg uacaguauuu cucuguuagg gagagcugga 1200

```


-continued

uccgccacuu	cagacuggcg	gaagagccua	gccucccugg	guuugaagac	cuccucagaa	1260
uaaggguaga	gcccuaucg	ucgccauuga	gugacaaggg	uggaaaaauc	uuccgguuug	1320
gcagucacaa	augguacggu	gcuggaaaga	gagcaaggaa	agcacgcucu	gguaugacca	1380
ccacagucgc	ucaccgcgcc	uugcccgcuc	gugaaaacca	gcaagccaaa	aagcacgagg	1440
augccggcgc	ugauaaggcu	gugcaucuca	ggcacuauuc	uccgccugcc	gacgggaacu	1500
gugguuggca	cugcauuucc	gccaucgcca	accgaauggu	gaaauccaaa	uuugaaacua	1560
cucuucccga	gagggugaga	ccuucagaug	acugggcuac	ugacgaggac	cuugugaaca	1620
ccaucacaa	ucucaagcuc	ccugcggccu	uggacaggaa	cggugcuugu	guuggcgcca	1680
aaucgugcu	uaagcuggaa	ggcgagcauu	ggacugucuc	ugugaccuu	gggauguccc	1740
cuucuuugcu	ccccuugaa	uguguucagg	gcuguuguga	gcauaagagc	ggacuugguc	1800
cccagaugc	ggucgaaguu	uucggauuug	accucgccug	ccuugaccga	cuggcugagg	1860
uaaugcacuu	gccuagcagu	gucaucccag	cugcucuggc	cgaaaugucc	ggcgacccca	1920
accgucggc	uuccccgguc	acuacugugu	ggacuguuuc	acaauucuuu	gcccggcaca	1980
gaggaggaga	gcaccugau	caggugcgcu	uaggaaaaau	caucagccuu	ugucaaguug	2040
uugaggaug	cuguugccau	cagaauaaaa	ccaaccgggc	caccceggaa	gagguugcgg	2100
caaggauuga	ucaguaccuc	cauggugcaa	caagucuuga	agaaugcuug	auuaggcuug	2160
agaggguuug	cccggcgagc	gcugcggaca	ccuucuuuga	uuggaauguu	gugcucccug	2220
ggguuggggc	uucaacucag	acaaccaaac	aguccaugu	caaccagugc	cgcgucucgg	2280
uuccugucgu	gacucaagag	ccuuuggaca	aagaccagc	cccucugacc	gccuucucgc	2340
uguccaaug	cuacuauccu	gcacaaggug	acgagguucg	ucaccgugag	aggcuaaaacu	2400
ccguacucuc	uaagcuggag	gggguuguuc	gugaggaaua	ugggcucacg	ccaacuggac	2460
cuggcccgcg	accgcacua	ccgaacgggc	ucgucgaacu	uaaagaccag	auggaggagg	2520
aucugcuaaa	acuagucaac	gcccaggcaa	cuucagaaau	gauggccugg	gcagccgagc	2580
agguugaucu	gaaagcuugg	gucaaaaacu	accacggug	gacaccguca	ccccuccac	2640
caagaguuca	gccucgaaa	acaagccug	ucaagagcuu	gccagggaac	aaaccugucc	2700
ccgcuccacg	caggaagguc	agaucugauu	guggcagccc	gauuucgaug	ggcgacaauug	2760
uuccugacgg	ucgggaagau	uugacuguug	guggccccc	ugaucuuucg	acaccauccg	2820
agccgaugac	accucugagu	gagccugcac	cuaugccgcg	guugcaauau	auuucuaaggc	2880
cagugacacc	uuugagugug	cuggccccag	uaccugcacc	gcuagaacu	gugucccgac	2940
cggugacgcc	cuugagugag	ccaauuuuug	ugucugcacc	gcgacacaaa	uuucagcagg	3000
uggaagaagc	gaucugggc	gcaacaugc	ugacgcacca	ggacgaaccu	cuagauuugu	3060
cugcauccuc	acagacugaa	uaugaggcuu	cuccccuaac	accacugcag	aaauugggua	3120
uucuggaggu	gggggggcaa	gaagcugagg	aaguucugag	ugaaaacucg	gauacacuga	3180
augacaucaa	cccugcaccu	gugucaucaa	gcagcucccu	gucaaguguu	aagaucacac	3240
gccccaaaaca	cucugcucaa	gccaucauug	acucggggcg	gcccugcagu	gggcaucucc	3300
gaaagggaaa	agaagcaugc	cucagcauca	ugcgugaggc	uugugaugcg	gcuagcuua	3360
gugaccucgc	cacgcaggaa	uggcuuucuc	gcauguggga	uaggguugau	augcugacuu	3420
ggcgcaacac	gucugcuuac	caggcguucc	gcaucuuaga	ugguagguuu	gaguucucc	3480
caaagaugau	acucgagaca	ccgccgcccu	accgugugg	guuugugaug	cugccucgca	3540
cgccugcacc	uuccgugggu	gcagagagug	accuuaccu	ugguucaguc	gccacugaag	3600

-continued

auguuccacg	cauccucggg	aaaauagaaa	acgccggcaa	gaugcccaac	caggggcucu	3660
ugacaucuu	cggggaagaa	cggugugcg	accaaccugu	caaggacucc	uggaugucgu	3720
cgcgggguu	ugacgagagc	acaacggcuc	cguccgcugg	uacagguggu	gcugacuuac	3780
ccaccgauuu	gccaccuuc	gaugguuugg	augcggacga	gugggggccc	uuacggacgg	3840
uaagaaagaa	agcugaaagg	cucuucgacc	aaugagccg	ucagguuuuu	aaccucgucu	3900
cccaucucc	uguuuuuuc	ucacaccucu	ucaaaucuga	cagugguuau	ucuccgggug	3960
auugggguuu	ugcagcuuuu	acuuuuuuu	gccucuuuuu	guguuacagc	uaccuauuc	4020
uugguuuugu	ucuccucuu	gguguuuuu	cugggucuu	ucggcgugug	cgcauggggg	4080
uuuuuggcug	uugguuggcu	uuugcuguug	gccuguucaa	gccugugucc	gaccagucg	4140
gcacugcuug	ugaguugac	ucgccagagu	guaggaaacgu	ccuucuuuc	uuugagcuuc	4200
ucaaaccuug	ggaccucguu	cgcagccuug	uuguggccc	cgucggucuc	ggccuugcca	4260
uucuuaggcag	guuacugggc	ggggcacgcu	acaucuggca	uuuuuugcuu	aggcuuggca	4320
uuguugcaga	uuguaucuu	gcuggagcuu	augugcuuuc	ucaagguagg	uguaaaaagu	4380
gcuggggau	uuguguaaga	acugcuccua	augaaaucgc	cuucaacgug	uuccuuuuu	4440
cgcgugcgac	caggucguca	cucaucgacc	ugugcgaucg	guuuugugcg	ccaaaaggca	4500
uggaccccau	uuuccucgcu	acuggguggc	gcgggugcug	gaacggccga	agucccauug	4560
agcaaccuc	ugaaaaacc	aucgcuucg	cccaguugga	ugaaaagagg	aucacggcua	4620
gaacuguggu	cgucagccu	uaugaucua	accaagccgu	aaagugcuug	cggguguuac	4680
aggcgggugg	ggcgauagug	gccgaggcag	uccaaaagu	ggucaagguu	uccgcuauuc	4740
cauuccgagc	uccuuuuuu	cccaccggag	ugaagguuga	uccugagucg	aggaucgugg	4800
ucgacccga	cacuuuuacu	acagcucucc	ggucugguua	cuccaccaca	aaccucgucc	4860
uugguguagg	ggacuugcc	caacugaaug	gauuaaaaau	caggcaaaau	uccaagcccu	4920
cgggaggagg	cccgcaccuc	auugcugccc	ugcauguugc	uugcucgaur	gcguugcaca	4980
ugcuugcugg	aguuaugua	acugcagugg	ggucuuugcg	uaccggcacc	aacgaucgcu	5040
ggugcacuaa	cccauucgcc	guccucggcu	acggaccugg	cuccucugc	acguccagau	5100
ugugcaucuc	ccaacauggc	cuuaccucg	ccuugacagc	acuuguggca	ggauucgguc	5160
uucaggaaau	ugcccuaguc	guuuugauuu	ucguuuccau	cggaggcaug	gcucauaggu	5220
ugaguuguaa	ggcugauaug	cugugcgucu	uacuugcaau	cgccagcuau	guuuggguac	5280
ccuuaccug	guugcucugu	guguuuuccu	gcugguugcg	cugguucucu	uugcaccuc	5340
ucaccauuc	augguuggug	uuuuucuu	ugucuguaaa	uagccuucg	ggaaucuaa	5400
ccgugguguu	auugguugcu	cuuuggcuuc	uaggccguua	uacuaauguu	guuggucuu	5460
uuaccccu	ugauauucac	cauuacacca	auggccccg	cgguguugcc	gccuuggcua	5520
ccgcaccaga	ugggacuuac	uuggccgucg	uccgccgccc	ugcguugacu	ggccgcaccg	5580
ugcuguuuac	cccgucucag	cuuggguc	uucuuagggg	cgcuuucaga	acucgaaagc	5640
ccucacugaa	caccgucaau	guggucgggu	ccuccauggg	cucuggcgga	guguucacua	5700
ucgaugggaa	aaauaaguc	gugacugccg	cacauguccu	uacggguauu	ucagccaggg	5760
uuuccggggu	cggcuuuau	caauugcuug	acuuugaugu	aaaaggggac	uucgccauag	5820
cugacugccc	gaauuggcaa	ggggcugcuc	cuaagacca	auucugcgag	gauggaugga	5880
cuggccgccc	cuauuggcug	acaucucug	gcgucgaacc	cggugucuu	gggaauggau	5940
ucgccuucug	cuucaccg	ugcggcgauu	ccggguc	agugaucacc	gaagccggug	6000

-continued

agcuugucgg	cguucacaca	ggaucaaaaca	aacaaggagg	aggcauuguu	acgcgccccu	6060
cuggccaguu	uugcaaugug	gcaccccauca	agcugagcga	auuaagugag	uucuuugcug	6120
gaccuaaggu	cccgcucggu	gaugugaagg	uuggcagcca	cauaauuaaa	gacauaugcg	6180
agguaccuuc	agaucuuugc	gccuugcuug	cugccaaacc	cgaacuggaa	ggaggccucu	6240
ccaccgucca	acuucugugu	guguuuuucc	uccuguggag	aaugauggga	caugccugga	6300
cgcccuuggu	ugcuguuggg	uuuuuuaucu	ugaaugaggu	ucucccagcu	guacuggucc	6360
ggaguguuuu	cuccuuugga	auguuugugc	uaucuuggcu	cacaccaugg	ucugcgcaag	6420
uucugaugau	caggcuucua	acagcagcuc	uuaacaggaa	cagauuguca	cucgccuuuu	6480
acagccuugg	ugcagcgacc	gguuuugucg	cagaucuggc	ggcaacucaa	gggcacccgu	6540
ugcaggcagu	aaugaauua	aguaccuaug	ccuuccugcc	ucggauaaug	gucgugaccu	6600
caccaguccc	agugauugcg	ugugguguug	ugcaccuccu	ugccauaaau	uuguacuugu	6660
uuaaguaccg	cugccugcac	aauguccuug	uuggcgaugg	ugcguucucu	gcggcuuucu	6720
ucuugcgaua	cuuugccgag	gggaaauuga	gggaaggggu	gucgcaaucc	ugcgggauga	6780
aucaugaguc	gcugacuggu	gcccucgcua	ugagacuuaa	ugacgaggac	uuggauuuuc	6840
uuacgaaaug	gacugauuuu	aaguguuuug	uuucugcauc	caacaugagg	aaugcggcgg	6900
gccaguucau	cgaggcugcc	uaugcuaaag	cacuuagaau	ugaacuugcc	caguuggugc	6960
agguugauaa	gguucgaggu	acuuuggcca	aacuugaagc	uuuugcugau	accguggcac	7020
cccaacucuc	gcccggugac	auuguuguug	cucuuggcca	uacgccuguu	ggcgguaucu	7080
ucgaccuaaa	gguugguagc	accaagcaua	ccucccaagc	cauugagacc	agaguucuuug	7140
ccggguccaa	aaugaccgug	gcgcgugucg	uugauccaac	ccccacaccc	ccacccgcac	7200
ccgugccuau	cccccuucca	ccgaaaguuc	uggagaauug	ucccaacgcc	uggggggaug	7260
aggaucguuu	gaauaagaag	aagagggcga	agauggaagc	cgucggcauc	uuuguuaugg	7320
guggaaagaa	auaucagaaa	uuuugggaca	agaacuccgg	ugauguguuu	uaugaggagg	7380
uccaugauaa	cacagacgcg	ugggagugcc	ucagaguuga	caaccucugcc	gacuuugacc	7440
cugagaaggg	aacucugucg	gggcauacua	ccauugaaga	uaagacuuc	agugucuacg	7500
ccuccccauc	uggcaagaaa	uuccuggucc	ccgccuaccc	agagagcaaa	aaaaaccaau	7560
gggaagcugc	gaagcuuucc	guggaacagg	ccuuggcau	gaugaauguc	gacggugaac	7620
ugacagccaa	agaaguggag	aaacugaaaa	gaauaauga	caaacuccag	ggccugacua	7680
aggagcagug	uuuaaacugc	uagccgccag	cggcuugacc	cgcugugguc	gcggcggcuu	7740
gguuauuacu	gagacagcgg	uaaaaauagu	caaaaauac	aaccggaccu	ucacccuagg	7800
accugugaau	uuaaaagugg	ccagugaggu	ugagcuaaaa	gacgcggucg	agcauaacca	7860
acacccgguu	gcaagaccgg	uugauggugg	uguugugcuc	cugcgcuccg	caguuccuuc	7920
gcuuauagac	gucuuauacu	ccggcgcuca	ugcaucuccc	aaguuaucug	cccgccacgg	7980
gccgggaaac	acugggaucg	auggcacgcu	uugggauuuu	gaggccgagg	ccacuaaaga	8040
ggaaaugca	cucagugcgc	aaauaaaca	ggcuugugac	auuaggcgcg	gcgacgcacc	8100
ugaaaugggu	cuuccuuua	agcuguaccc	ugucaggggc	aaccucugagc	ggguaaaagg	8160
aguuuuacag	aauacaaggu	uuggagauau	accuuuuuuu	accccagug	acacuggaag	8220
cccagugcac	gcggcugccu	gccucacgcc	caaugccacu	ccggugacug	augggcguc	8280
cgucuuuggcc	acgacuugc	ccuccgguuu	ugaguuguau	guaccgacca	uuccagcguc	8340
uguccuugau	uaucuugauu	cuaggccuga	cugcccaaaa	caguugacag	agcacggcug	8400

-continued

ugaggacgcc	gcauuuagag	accucuccaa	guaugacuug	uccaccecaag	gcuuuguuuu	8460
accuggaguu	cuucgccuug	ugcguaagua	ccuguuugcu	caugugggua	agugcccgcc	8520
cguucaucgg	ccuuccacuu	accugccaa	gaauucuaug	gcuggaauaa	augggaacag	8580
guuuccaacc	aaggacaucc	agagcguccc	ugaaaucgac	guucugugcg	cacaggccgu	8640
ucgggaaaac	uggcaaacug	uuaccccuug	uacccucaag	aaacaguauu	gugggaagaa	8700
gaagacuagg	acaauacucg	gcaccaauaa	cuucauugcg	cuggcucacc	gggcagcguu	8760
gagugguguc	accagggcu	ucaugaaaaa	ggcguuuuac	ucgcccduug	cccucgguaa	8820
aaacaaauuu	aaagagcuuc	agacuccggu	cuuaggcagg	ugccuugaag	cugaucuugc	8880
auccugcgau	cguccacac	cugcaauugu	ccgcugguuu	gccgccauuc	uucuuuuga	8940
acuugccugu	gcugaagagc	accagccguc	guacguguug	aacugcugcc	acgaccuacu	9000
ggucacgcag	uccggcgcag	uaacuaagag	agguggccug	ucgucuggcg	accggaucac	9060
uucugugucc	aacaccuuu	acagcuuggu	gauauaugca	caacacaugg	ugcucaguua	9120
cuuuuuuagu	ggucaccuc	auggccuuuc	guuuuacaa	gaccagcuga	aguuuaggga	9180
caugcucaag	guucaacccc	ugaucgucua	uucggacgac	cucguacugu	augccgaguc	9240
ucccaccaug	ccaaacuacc	acuggugggu	ugaacaucug	aaccugaugc	uggguuuuca	9300
gacggacca	aagaagacag	ccaauacaga	cucgccauca	uuucuaggcu	guaggauauu	9360
aauggacgc	cagcucguc	cuaaccguga	caggauucuc	gcgcccucg	ccuaccuau	9420
gaaggcaagc	aaugucucug	aaucacuacg	cucggcggcu	gcgauacuca	uggacagcug	9480
ugcuuuguua	gaguaugauc	ccgaaugguu	ugaagagcuu	guaguuggga	uagcgcagug	9540
ugcccgaag	gacggcuaca	guuuucccgg	cccgcgcuuc	uucuuugucca	ugugggaaaa	9600
acucagauc	aaucaugagg	ggaagaaguc	cagaauuguc	ggguacugcg	gggccccggc	9660
uccguaagcc	acugccugug	gccucgacgu	cuguauuuac	cacaccacu	uccaccagca	9720
uuguccaguc	aucaucuggu	guggccaccc	ggcugguuc	gguucuuuga	gugagugcaa	9780
accccccuua	gggaaaggca	caagcccucu	agaugaggug	uuagaacaag	ucccguaaua	9840
gccuccacgg	acuguaauca	ugcaugugga	gcagggucuc	accccucuug	accagggcag	9900
auaccagacu	cgccgcggau	uagucuccgu	uaggcguggc	auuagaggaa	augagguuga	9960
ucuaccagac	ggugauuau	cuagcaccgc	ccuacucccu	acuuguaaag	agauuaacau	10020
ggucgcuguc	gccucuaau	uguugcgcag	cagguucauc	aucggcccgc	cuggugcugg	10080
gaaaacauac	uggcuccuuc	aacaggucca	ggauuggugau	gccauuuaca	cgccaacuca	10140
ccagaccaug	cucgauauga	uuagggcuuu	ggggacgugc	cgguucaacg	ucccagcagg	10200
uacgacgcug	caauucccug	ccccucccg	uaccggcccu	uggguucgca	uccuagccgg	10260
cgguuggugu	ccuggcaaga	auuccuuccu	ggauagaagca	gcuuuuuga	aucaccuuga	10320
ugucuugagg	cuucuuagca	aaacuaccu	caccugucug	ggagauuuca	aaacuucca	10380
cccagugggu	uuugauucuc	auugcuaugu	uuuugacauc	augccucaga	cucaacugaa	10440
gaccaucugg	agauuuggac	agaauaucug	ugaggccauu	cagccagauu	acagggacaa	10500
acuuguauc	auggucaaca	caacccgugu	aaccuacgug	gaaaaaccug	ucaaguaugg	10560
gcaaguccuc	accccuuacc	acagggaccg	agaggacggc	gccaucacaa	uugacuccag	10620
ucaaggcgcc	acauuugaug	ugguuacacu	gcauuugccc	acuaaagauu	cacucaacag	10680
gcaaagagcc	cuuguugcua	uuaccagggc	aagacaugcu	gucuuugugu	augaccaca	10740
caggcaacug	cagagcaugu	uugaucucc	ugcgaaaggc	acaccguc	accucgcugu	10800

-continued

gcaccgugac	gagcagcuga	ucgugcuaga	uagaaauaac	aaagaaugca	cgguugcuca	10860
ggcucuaggg	aauggggaua	aaucaggggc	cacagacaag	cgcguguuag	auucucuccg	10920
cgccauuugu	gcagaucugg	aagggucgag	cucuccgcuc	ccaaggucg	cacacaacuu	10980
gggauuuuau	uucucgccug	auuugacaca	guuugcuaaa	cucccgguag	aacuugcacc	11040
ccacuggccc	guggugacaa	cccagaacia	ugaaaagugg	ccagaccggu	ugguugcuag	11100
ccuucgcccc	guccauaagu	auagccgcgc	gugcaucggu	gccggcuaca	ugguggggccc	11160
cucaguguuu	cugggcaccc	cuggggguugu	gucauacuau	cucacaaaau	uugucagggg	11220
cgaggcucaa	augcuuccgg	agacagucuu	cagcaccggc	cgaaugagg	uagauugccg	11280
ugaguaucuc	gaugaccggg	agcgagaaa	ugcugagucc	cuccccaug	cuuucauugg	11340
cgacgucaaa	ggcacuaccg	uuggaggaug	ucaccauguc	accuccaaa	accuuccgcg	11400
cuuccuuccc	aaggaucag	ucgcgguagu	cgggguuua	agccccggga	aagccgcaaa	11460
agcaguuuug	acauaacag	auguguaucu	cccagaucuc	gaagcuuacc	uccaccaga	11520
gaccagucc	aagugcugga	aaaugaugu	ggacuucag	gaaguucgac	ugauggucug	11580
gaaggacaag	acggccuau	uucaacuuga	aggccgccau	uuccaccggu	accagcuugc	11640
aagcuauucc	ucguacauc	gaguuccugu	uaacucucg	guguauuugg	acccugcau	11700
gggcccugcc	cuuugcaaca	gaagaguugu	cgguuccacu	cauuggggag	cugaccucgc	11760
agucaccccu	uauuuuacg	gugccaaaau	cauccugucu	agugcauacc	auggugaaa	11820
gccccuggg	uacaaaaucc	uggcgugcgc	ggaguucucg	cuugacgauc	cagugaggua	11880
caaacacacc	uggggguuug	aaucggauac	agcguaucug	uacgaguuca	ccggaaacgg	11940
ugaggacugg	gaggauuaca	augaugcguu	ucgugcgcgc	cagaaaggga	aaauuuauaa	12000
ggccacugcc	accagcauga	gguuucuuu	ucccccgggc	ccugucauug	aaccaacuuu	12060
aggccugaau	ugaaaugaaa	ugggguccau	gcaaagccuc	uuugacaaaa	ugggccaacu	12120
uuucguggau	gcuuucacgg	aauuuuuggu	guccauuguu	gauaucauca	uauuuuuggc	12180
cauuuuguuu	ggcuuuacca	ucgucggcug	gcuggguguc	uucugcaucc	gauugguuug	12240
cuccgcggua	cuccgugcgc	gccuaccuau	ucaccugag	cauuacaga	agaucuaug	12300
aggccuuucu	uucucagugc	cagguggaua	uucccaccug	gggaacuaga	cauccccugg	12360
ggaugcuuug	gcaccuaaag	gugucaaccc	ugauugauga	aauggugucg	cgucgggaug	12420
accgcaccau	ggaaaaagca	ggacaggcug	ccuggaaaca	gguggugagc	gaggccacgc	12480
ugucucgcau	uagugguuug	gauguggugg	cucuuuuuca	gcaucuugcc	gccauugaag	12540
ccgagaccug	uaaaauuuug	gccucucggc	ugccaugcu	acacaucug	cgcaugacag	12600
ggucaaaugu	aaccuagug	uaauauagua	cuuugaauca	gguguuugcu	auuuuuccaa	12660
ccccuggauc	ccggccaaag	cuucaugauu	uucagcaaug	gcuaauagcu	gugcacuccu	12720
ccaauuuuuc	cuccguugcg	gcuucuuua	cucuuuuugu	ugugcugugg	uugcggauuc	12780
caaugcuacg	uacuguuuuu	gguuuccgcu	gguuaggggc	aauuuuuccu	ucgaacucac	12840
ggugaauuac	acgguguguc	cgccuugccu	caccggcga	gcagccgcug	aggucucgca	12900
accaggcagg	ucucuuuugg	gcaggauagg	gcaugaccga	uguagugagg	aagaccauga	12960
cgaucuaggg	uucaugguuc	cgucuggccu	cuccagcgaa	ggccacuuga	ccaguguuua	13020
cgccuggguug	gcuuuccugu	ccuucagcua	cacggcccag	uuccaucccg	agauuuuugg	13080
gauagggauu	gugagucaag	uuuauuguu	caucaagcac	cauucaucu	gcgcccguca	13140
cgacggggag	aacgccaccu	ugccucguca	ugacaauuu	ucagccguau	aucagaccua	13200

-continued

```

cuaccaacau caagucgacg gcggaauug guuacacua gaauggcugc gccccuucu 13260
uuccucuugg uugguuuaa auguuucuug guuucucagg cguucgccug caagccaugu 13320
uucaguucua gucuuucgga caucaaaacc aacacaaccg cagcaucagg cuuuguuguc 13380
cuccaggaca ucagcugccu uaggcauggc gacucguccu cucagacgau ucgcaaaagc 13440
ucucagugcc gcgcggcgau agggacgcc guguacauca cugucacagc caaugucaca 13500
gaugagaauu auuuacauuc uucugaucuc cuuauugcuu cuucugccu uuucuaugcu 13560
ucugagauga gugaaaagg auucaaggug auguuuggca augugucagg caucguggcu 13620
guguguguca acuuuaccag cuacguccaa caugucaagg aguuuaccca acgcuccuug 13680
guggucgauc augugcggcu gcuccauuuc augacaccug agaccaugag gugggcaacc 13740
guuuuagccu guuuucugc caucuucug gcauuugaa uguucaagua uguuggggag 13800
augcuugacc gcgggcuguu gcucgcgauu guuuuuuug ugguguaucg ugccauuuug 13860
uuuugcugcg cucgucaacg ccaacagcaa cagcagcucu caucuucagu uauuuuaca 13920
cuugacgcuu ugugagcuga auggcacaga uggcugaaa gacaaauuug auugggcauu 13980
ggagacuuuu gucaucuuc cgguguugac ucacauuguc ucauauagug cacucaccac 14040
uagccauuuc cuugacacag uggucuggu uacugugucu acugccgggu ucuaccacgg 14100
gcgguauguu cugaguagca ucuacgcggu cugcgcucug gccgcauga cuugcuucgu 14160
cauuaggcuu gcgaagaacu gcauguccug gcgcuaucuu uguaccagau auacuaacuu 14220
ccuucuggac acuaaggga gacucuaucg cuggcggucg cccguuauca uagagaaagg 14280
ggguaagguu gaggucgaag gucaccugau cgaccucaa agaguugugc uugaugguuc 14340
cguggcaacc ccuuuaacca gaguuucagc ggaacaauug ggucgucuuu agacgacuuu 14400
ugcuaugaua gcacggcucc acaaaaggug cuuuuggcgu uuuccauuac cuacacgcca 14460
gugaugauau augcucuaaa gguaagucgc ggccgacuuu uagggcuucu gcaccuuuug 14520
aucuuucuga auuguacuuu uaccuucggg uacaugacau gcgugcacuu uauuagcaca 14580
aauaaggucg cgcucacua uggagcagua guugcacuuc uuuggggggu guacucagcc 14640
auagaaaccu ggaagucau caccuccaga ugucguuugu gcuugcuagg ccgcaaguac 14700
auucuggccc cgcgccacca cgucgaaagu gccgcgggcu uucauccgau cgcggcaau 14760
gauaaccacg cauuugucgu cggcgucucc gguccacua cgguaaacgg cacauuggug 14820
cccggguuga aaagccucgu guuggguggc agaaaagcug uuaaacaggg agugguaaac 14880
cuugucuuuu augccaaaua acaacggcaa gcagcaaaag aaaaagaggg ggaugggcca 14940
gccagucaau cagcugugcc agaugcuggg uaagaucauc gccagcaaa accaguccag 15000
aggcaaggga cggggaaga aaauaagaa uaaaaccgg gagaagccc auuuuccucu 15060
agcgacugaa gaugacguca ggcaucacuu caccuccuagu gagcggcaau ugugucuguc 15120
gucgauccag acugccuuu accagggcgc uggaaccugu acccuacag auucagguag 15180
gauaaguua acuguggagu uuaguugcc gacgcaucau acugugcgc ugaucgcgu 15240
cacagcga ucaucagcgu aaugggcug cauuccuuu gcaccucagu guuagaauug 15300
gaagaugug uggugaauug cacugaauug cacugugccu cuaagucacc uauucaauu 15360
ggcgaccgu guggggguu aguuuuuug gcgagaacca ugcggccga auu 15413

```

<210> SEQ ID NO 4

<211> LENGTH: 15413

<212> TYPE: RNA

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus

-continued

<400> SEQUENCE: 4

augacguaua	gguguuggcu	cuaugccuug	gcauuuguau	ugucaggagc	ugcgaccauu	60
gguacagccc	aaaacuagcu	gcacagaaaa	cgcccuucug	ugacagcccu	cuucagggga	120
gcuuaggggu	cugucccuag	caccuugcuu	ccggaguugc	acugcuuuac	ggucucucca	180
acccuuuac	caugucuggg	auacuugauc	ggugcacgug	cacccccaa	gccagggugu	240
uuauaggcga	gggccaaguc	uacugcacac	gaugucucag	ugcacggucu	cuccuuccuc	300
ugaaucucca	aguuccugag	cuuggagugc	ugggccuauu	uuacaggccc	gaagagccac	360
uccgguggac	guugccacgu	gcauucccca	cuguugagug	cucccccgcc	ggggccugcu	420
ggcuuucugc	gaucuuucca	auugcacgaa	ugaccagugg	aaaccugaac	uuucaacaaa	480
gaauggugcg	ggucgcagcu	gagauuuaca	gagccggcca	gcucaccccu	gcagucuuga	540
aggcucuaca	aguuuauгаа	cggguugcc	gcugguaccc	uauagucgga	ccugucccug	600
gaguggccgu	uuuugccaac	ucccuacaug	ugagugauaa	accuuucccg	ggagcaacuc	660
augugcuaac	caaccugcca	cucccgagca	ggccuaagcc	ugaagacuuu	ugccuuuuug	720
agugugcuau	ggcugacguc	uauauuuug	gucaugggcg	cgucauguau	guggccaaag	780
ggaaagucuc	cuggggcccu	cguggcgggg	augaggcgaa	auuugaaacu	gucccuaggg	840
aguugaaguu	gaucgcgaac	caacuccaca	ucuccuuccc	gccccaccac	gcaguggaca	900
ugucuaaguu	uguguucaua	gccccuggga	guggugucuc	uauagggguc	gagugcccac	960
acggcugucu	ccccgcuaau	acugucccug	aagguaacug	cugguggcg	uuguuugacu	1020
cgucuccacu	ggacguucag	aacaaagaaa	uucgccgugc	caaccaauuc	ggcuaucaaa	1080
ccaagcaugg	ugucgcuggc	aaguaccuac	aacggaggcu	gcaagcuauu	ggucuccgag	1140
cagugacuga	uacagaugga	cccuaugucg	uacaguauuu	cucuguuagg	gagagcugga	1200
uccgccacuu	cagacuggcg	gaagagccua	gccucccugg	guuugaagac	cuccucagaa	1260
uaaggguaga	gcccuaucg	ucgccauuga	gugacaaggg	uggaaaaauc	uuccgguuug	1320
gcagucacaa	augguacggu	gcuggaaaga	gagcaaggaa	agcacgcucu	gguaugacca	1380
ccacagucgc	ucaccgcgcc	uugcccgcuc	gugaaaucca	gcaagccaaa	aagcacgagg	1440
augccggcg	ugauaaggcu	gugcaucuca	ggcacuauuc	uccgccugcc	gacgggaacu	1500
gugguuggca	cugcauuucc	gccaucgcca	accgaauggu	gaauuccaaa	uuugaaacua	1560
cucuucccga	gagggugaga	ccuucagaug	acugggcuc	ugacgaggac	cuugugaaca	1620
ccauccaaau	ucucaagcuc	ccugcgcccu	uggacaggaa	cggugcuugu	guuggcgcca	1680
aaucgugcu	uaagcuggaa	ggcgagcauu	ggacugucuc	ugugacccuu	gggauguccc	1740
cuucuuugcu	ccccuugaa	uguguucagg	gcuguuguga	gcauaagagc	ggacuugguc	1800
ccccagaugc	ggucgaaguu	uucggauuug	accucgccug	ccuugaccga	cuggcugagg	1860
uaaugcacuu	gccuagcagu	gucaucccag	cugcucuggc	cgaaaugucc	ggcgacccca	1920
acuguccggc	uuccccgguc	acuacugugu	ggacuguuuc	acaauucuuu	gcccggccaca	1980
gaggaggaga	gcaccucgau	caggugcgcu	uaggaaaaau	caucagccuu	ugucaaguug	2040
uugaggaaug	cuguugccau	cagaauaaaa	ccaaccgggc	caccccgaa	gagguugcgg	2100
caaggauuga	ucaguaccuc	cauggugcaa	caagucuuga	agaauugcuu	auuaggcuug	2160
agaggguuug	cccggcgagc	gcugcggaca	ccuucuuuga	uuggaauguu	gugcucccug	2220
ggguuggggc	uucacucag	acaaccaaac	agcuccaugu	caaccagugc	cgcgucucgg	2280
uuccugucgu	gacucaagag	ccuuuggaca	aagacucagu	cccucugacc	gccuucucgc	2340

-continued

uguccaaauug	cuacuauc	gcacaaggug	acgagguucg	ucaccgugag	aggcuaaacu	2400
ccguacucuc	uaagcuggag	ggguuguuuc	gugaggaaua	ugggcucacg	ccaacugaac	2460
cuggcccgcg	acccgcacua	ccgaacgggc	ucgucgaacu	uaaagaccag	auggaggagg	2520
aucugcugaa	acuagucaac	gcccaggcaa	cuucagaaau	gauggccugg	gcagccgagc	2580
agguugaucu	gaaagcuugg	gucaaaaacu	accacggug	gacaccgcca	ccccuccac	2640
caagaguuca	gccucgaaaa	acaaagucug	ucaagagcuu	gccagggaac	aaaccugucc	2700
ccgucuccacg	caggaagguc	agaucugauu	guggcagccc	gauuuugaug	ggcgacaau	2760
uuccugacgg	ucgggaagau	uugacuguug	guggccccc	ugaucuuucg	acaccauccg	2820
agccgaugac	accucugagu	gagccugcac	uuaugcccgc	guugcaauau	auuucagggc	2880
cagugacauc	uuugagugug	cuggccccag	uuccugcacc	gcuagaacu	gugucccgac	2940
cgguagcgc	cuugagugag	ccaauuuuug	ugucugcacc	gcgacacaaa	uuucagcagg	3000
uggaagaagc	gaaucuggcg	gcaacaacgc	ugacgcacca	ggacgaaccu	cuagauuugu	3060
cugcauccuc	acagacugaa	uaugaggcuu	cuccccuaac	accacugcag	aacaugggua	3120
uucuggaggu	gggggggcaa	gaagcugagg	aaguucugag	ugaaaucucg	gauacacuga	3180
augacaucua	cccugcaccu	gugucaucua	gcagcucccu	gucaaguguu	aagaucacac	3240
gccccaaaaca	cucugcucua	gccaucauug	acucggggcg	gccucgagc	gggcauccc	3300
gaagggaaaa	agaagcaugc	cucagcauca	ugcgugaggc	uugugaugcg	gcuagcuua	3360
gugaccucgc	cacgcaggaa	uggcuuucuc	gcauguggga	uagguugac	augcugacuu	3420
ggcgcaaac	gucugcuuac	caggcguucc	gcaucuuaga	ugguagguuu	gaguuuucc	3480
caaagaugau	acucgagaca	ccgccgccc	accgugugg	guuugugaug	cugccucaca	3540
cgccugcacc	uuccgugggu	gcagagagug	accuuaccu	ugguucaguc	gccacugaag	3600
auguuccacg	cauccucggg	aaaauagaaa	acgccggcga	gaugcccaac	caggggcucu	3660
ugacaucuu	cggggaagaa	ccggugugcg	accaaccugu	caaggacucc	uggaugucgu	3720
cgcggggguu	ugacgagagc	acaacggcuc	cguccgcugg	uacagguggu	gcugacuuac	3780
ccaccgauuu	gccaccuuc	gaugguuugg	augcggacga	guggggggccg	uuacggacgg	3840
uaagaaagaa	agcugaaagg	cucuucgacc	aaugagccg	ucagguuuuu	aaccucgucu	3900
cccuaucucc	uguuuuuuc	ucacaccucu	ucaaaucuga	cagugguuau	ucuccgggug	3960
auugggguuu	ugcagcuuuu	acuuuuuuu	gccuuuuuu	guguuacagc	uaccuauuc	4020
uugguuuuug	uccccucuu	gguguuuuu	cugggucuu	ucggcgugug	cgcauggggg	4080
uuuuuggcug	uugguuggcu	uuugcuguug	gccuguucua	gccugugucc	gaccagucg	4140
gcacugcuug	ugaguuuagc	ucgccagagu	guaggaacgu	ccuucuuuc	uuugagcuuc	4200
ucaaacuuug	ggaccucguu	cgcagccuug	uuguggggcc	cgucggucuc	ggccuugcca	4260
uucuuuggcag	guuacugggc	ggggcacgcu	acaucuggca	uuuuuugcuu	aggcuuggca	4320
uuguugcaga	uuguaucuug	gcuggagcuu	augugcuuc	ucaagguagg	uguaaaaagu	4380
gcuggggau	uuguguaaga	acugcuccua	augaaaucgc	cuucaacgug	uuccuuuuu	4440
cgcgugcgac	caggucguca	cucaucgacc	ugugcgaucg	guuuugugcg	ccaaaaggca	4500
uggaccccau	uuuccucgcu	acuggguggc	gcgggugcug	gaccggccga	agucccauug	4560
agcaaccuc	ugaaaaacc	aucgcguucg	cccaguugga	ugaaaagagg	auuacggcua	4620
gaacuguggg	cgucagccu	uaugauccua	accaagccgu	aaagugcuug	cggguguuac	4680
aggcgggug	ggcgauagug	gccgaggcag	ucccaaaagu	ggucaagguu	uccgcuauc	4740

-continued

cauuccgagc	uccuuuuuu	cccaccggag	ugaagguuga	uccugagugc	aggauccgugg	4800
ucgacccccga	cacuuuuacu	acagcucucc	ggucugguua	cuccaccaca	aaccucgucc	4860
uugguguggg	ggacuuugcc	caacugaaug	gauuaaaaau	caggcaaaau	uccaagcccu	4920
cgggaggagg	cccgcaccuc	auugcugccc	ugcauguugc	uugcucgaug	gcguugcaca	4980
ugcuugcugg	aguuuaugua	acugcagugg	ggucuugcgg	uaccggcacc	aacgauccgu	5040
ggugcacuaa	cccuuugcgc	guccucuggcu	acggaccugg	cucccucugc	acguccagau	5100
ugugcaucuc	ccaacauggc	cuuaccucgc	ccuugacagc	acuuguggca	ggauucgguc	5160
uucaggaaau	ugcccuaguc	guuuugauuu	ucguuuccau	cggaggcaug	gcucauaggu	5220
ugaguuguaa	ggcugauaug	cugugcgucu	uacuugcaau	cgccagcuau	guuuggguac	5280
ccuuuaccug	guugcucugu	guguuuuccu	gcugguugcg	cugguucucu	uugcaccuc	5340
ucaccauucu	augguuggug	uuuuucuga	ugucuguaaa	uauccuucg	ggauucuaa	5400
ccgugguguu	auugguugcu	cuuuggcuuc	uaggccguua	uacuaauguu	guuggucuu	5460
uuacccccua	ugauauucau	cauuacacca	auggcccccg	cgguguugcc	gccuuggcua	5520
ccgcaccaga	ugggacuuac	uuggccgcug	uccgcccgcg	ugcguugacu	ggccgcaccg	5580
ugcuguuuac	cccgucucag	cuuggguccc	uucuugaggg	cgcuuucaga	acucgaaagc	5640
ccucacugaa	caccgucaau	guggucgggu	ccuccauggg	cucuggcgga	guguucacua	5700
ucgaugggaa	aaauaagugc	gugacugccg	cacauguccu	uacggguauu	ucagccaggg	5760
uuuccggggg	cggcuucaau	caaauugcu	acuuugaugu	aaaaggggac	uucgccauag	5820
cugauugccc	gaauuggcaa	ggggcugcuc	cuaagacca	auucugcgag	gauggaugga	5880
cuggccgcgc	cuauuggcug	acaucucug	gcgucgaacc	cggugucauu	gggaauggau	5940
ucgccuucug	cuucaccgcg	ugcggcgauu	ccgggucccc	agugaucacc	gaagccggug	6000
agcuugcgg	cguucacaca	ggaucaaca	aacaaggagg	aggcauuguu	acgcgccccu	6060
cuggccaguu	uugcaaugug	gcacccauca	agcugagcga	auuaagugag	uucuuugcug	6120
gaccuaaggu	cccgcucggu	gaugugaagg	uuggcagcca	cauaauuaaa	gacauaugcg	6180
agguaccuuc	agaucuuugc	gccuugcuug	cugccaaacc	cgaacuggaa	ggaggccucu	6240
ccaccgucca	acuucugugu	guguuuuucc	uccuguggag	aaugauggga	caugccugga	6300
cgcccuuggu	ugcuguuggg	uuuuuuaucu	ugaauagaggu	ucucccagcu	guacuggucc	6360
ggaguguuuu	cuccuuugga	auguuugugc	uaucuuggcu	cacaccaugg	ucugcgcaag	6420
uucugaugau	caggcuucua	acagcagcuc	uuaacaggaa	cagauuguca	cucgccuuuu	6480
acagccuugg	ugcagcgacc	gguuuugucg	cagaucuggc	ggcaacucua	gggcaccgcu	6540
ugcaggcagu	aaugaauua	aguaccuau	ccuuccugcc	ucggauaau	gucgugaccu	6600
caccaguccc	agugauugcg	ugugguguug	ugcaccuccu	ugccauaau	uuguacuugu	6660
uuuaguccg	cugccugcac	aauguccuug	uuggcgauug	ugcguucucu	gcggcuuucu	6720
ucuuugcga	cuuugccgag	gggaaauuga	gggaaggggu	gucgcauuc	ugcgggauga	6780
aucaugaguc	gcugacuggu	gccucgcua	ugagacuua	ugacgaggac	uuggauuuuc	6840
uuacgaaaug	gacugauuuu	aaguguuuug	uuucugcauc	caacaugagg	aaugcggcgg	6900
gccaguucau	cgaggcugcc	uauucuaaag	cacuuagaau	ugaacuugcc	caguuggugc	6960
agguugauaa	gguucgaggu	acuuuggcca	aacuugaagc	uuuugcugau	accguggcac	7020
cccaacucuc	gcccggugac	auuguuguug	cucuuuggcca	uacgccuguu	ggcgguaucu	7080
ucgaccuaaa	gguugguagc	accaagcaua	cccuccaagc	cauugagacc	agaguucuu	7140

-continued

ccggguccaa	aaugaccgug	gcgcgugucg	uugaaccaac	ccccacacc	ccaccgcac	7200
ccgugccuau	ccccuucca	ccgaaaguuc	uggagaauug	ucccaacgcc	uggggggaug	7260
aggaucguuu	gaauaagaag	aagagggcga	ggauugaagc	cgucggcauc	uuuguuauug	7320
guggaaagaa	auaucagaaa	uuuugggaca	agaacuccgg	ugauguguuu	uaugaggagg	7380
uccaugauaa	cacagacgcg	ugggagugcc	ucagaguuga	caaccugcc	gacuuugacc	7440
cugagaagg	aacucuguc	gggcauacua	ccauugaaga	uaagacuac	agugucuacg	7500
ccucccauc	uggcaagaaa	uuccuggucc	ccgucuacc	agagagcaa	aaaaaccau	7560
gggaagcugc	gaagcuuucc	guggaacagg	ccuuggcau	gaugauguc	gacggugaac	7620
ugacagccaa	agaaguggag	aaacugaaaa	gaauaauga	caaacuccag	ggccugacua	7680
aggagcagug	uuuaaacugc	uagccgccag	cgguugacc	cgucugguc	gcggggcuu	7740
gguuuuacu	gagacagcg	uaaaaaugu	caaaauucac	aaccggaccu	ucaccuagg	7800
accugugaau	uuaaaagugg	ccagugaggu	ugagcuaaaa	gacgcgucg	agcauaacca	7860
acaccgguu	gcaagaccgg	uugauggugg	uguuguguc	cugcgucgg	caguuccuuc	7920
gcuuauagac	gucuuaaucu	ccggcgcuca	ugcaucucc	aaguucucg	cccggccagg	7980
gccgggaaac	acugggaucg	auggcacgcu	uugggauuuu	gaggccgagg	ccacuaaaga	8040
ggaaaugca	cucagugcgc	aaauauaca	ggcuugugac	auuaggcgcg	gcgacgcacc	8100
ugaaauggu	cuuccuuua	agcuguacc	ugucaggggc	aaccugagc	ggguaaaagg	8160
aguuuuacag	aaacaaggu	uuggagacau	accuuauaaa	accccagug	acacuggaag	8220
cccagugcac	gcgcgugccu	gccucacgcc	caaugccacu	ccggugacug	augggcguc	8280
cgucuuuggcc	acgacuaugc	ccuccgguuu	ugaguuguau	guaccgacca	uuccagcguc	8340
uguccuugau	uaucuugauu	cuaggccuga	cugcccaaaa	caguugacag	agcacggcug	8400
ugaggacgcc	gcauuagag	accucuccaa	guaugacuug	uccaccaag	gcuuuguuuu	8460
accuggaguu	cuucgcuug	ugcguaagua	ccuguuugcu	caugugggua	agugcccgcc	8520
cguucaucgg	ccuuccacuu	accugccaa	gaauucuaug	gcuggaauaa	augggaacag	8580
guuuccaacc	aaggacaucc	agagcgucc	ugaaaucgac	guucugugcg	cacaggccgu	8640
gcgggaaaac	uggcaaacug	uuaccccuug	uacccucaag	aaacaguauu	gugggaagaa	8700
gaagacuagg	acaauacucg	gcaccaauaa	cuucauugcg	cuggcccacc	gggcagcguu	8760
gagugguguc	accagggcu	ucaugaaaaa	ggcguuuaac	ucgcccuuug	cccucgguaa	8820
aaacaaauuu	aaagagcuuc	agacuccggu	cuuaggcagg	ugccuugaag	cugaucuugc	8880
auccugcgau	cguccacac	cugcaauugu	ccgucgguuu	gccgccauuc	uucuuuauga	8940
acuugccugu	gcugaagagc	accugccguc	guacguguug	aacugcugcc	acgaccuacu	9000
ggucacgcag	uccggcgag	uaacuaagag	agguggccug	ucgucuggcg	accgcaucac	9060
uucugugucc	aacaccauuu	acagcuuggu	gauauaugca	caacacaugg	ugcucaguuu	9120
cuuuuuuagu	ggucaccuc	auggccuucu	guuucuaaca	gaccagcuga	aguuuaggga	9180
caugcucaag	guucaacccc	ugaucgucua	uucggacgac	cucguacugu	augccgaguc	9240
uccaccaug	ccaaacuacc	acuggugggu	ugaacaucug	aaccugaugc	uggguuuuca	9300
gacggacca	aagaagacag	ccauaacaga	cucgccauca	uuucuaaggcu	guaggauuuu	9360
aaauggacgc	cagcucguc	cuaaccguga	caggauucuc	gcgcccucg	ccuaccuau	9420
gaaggcaagc	aaugucucug	aaucacuacg	cucggcggu	gcgauacuca	uggacagcug	9480
ugcuuguuuu	gaguaugauc	ccgaaugguu	ugaagagcuu	guaguuggga	uagcgagug	9540

- continued

ugcccgaag	gacggcuaca	guuuucccg	cccgccguuc	uucuugucca	ugugggaaaa	9600
acucagaucc	aaucaugagg	ggaagaaguc	cagaauuguc	ggguacugcg	gggccccggc	9660
uccguacgcc	acugccugug	gccucgacgu	cuguauuuac	cacaccacu	uccaccagca	9720
uuguccaguc	aucaucuggu	guggccaccc	ggcugguucu	gguucuugua	gugagugcaa	9780
acccccua	gggaaaggca	caagcccucu	agaugaggug	uuagaacaag	ucccguaaa	9840
gccuccacgg	acuguaauca	ugcaugugga	gcagggucuc	acccucuuug	accaggcag	9900
auaccagacu	cgccgaggau	uagucuccgu	uaggcguggc	auagaggaa	augagguuga	9960
ucuaccagac	ggugauuau	cuagcaccgc	ccuacucccu	acuuguaaag	agauuaacau	10020
ggucgcuguc	gccucuaaug	uguugcgag	caggucauc	aucggccccg	cuggugcugg	10080
gaaaacauac	uggcuccuuc	aacaggucca	ggauggugau	gucauuuaca	cgccaacuca	10140
ccagaccaug	cucgauauga	uuagggcuuu	ggggacgugc	cgguucaacg	ucccagcagg	10200
uacgacgcug	caauucccug	ccccucccg	uaccggcccu	uggguucgca	uccuagccgg	10260
cgguuggugu	ccuggcaaga	auuccuuccu	ggaugaagca	gcuauugua	aucaccuuga	10320
ugucuugagg	cuucuagca	aaacuaccu	caccugucug	ggaguuuca	aacaacucca	10380
cccagugggu	uuugauucuc	auugcuaugu	uuuugacauc	augccucaga	cucaacugaa	10440
gaccaucugg	agauuuggac	agaauaucug	ugaugccauu	cagccagauu	acagggacaa	10500
acuuguauc	auggucaaca	caaccggugu	aaccuacgug	gaaaaaccug	ucaaguaugg	10560
gcaaguccuc	accccuuacc	acagggaccg	agaggacggc	gccaucacaa	uugacuccag	10620
ucaaggcgcc	acauuugaug	ugguuacacu	gcauuugccc	acuaaagauu	cacucaacag	10680
gcaaagagcc	cuuguugcua	uuaccagggc	aagacaugcu	aucuuugugu	augaccacaa	10740
caggcaacug	cagagcaugu	uugaucucc	ugcgaaaggc	acaccguc	accucgcugu	10800
gcaccgugac	gagcagcuga	ucgugcuaga	uagaaauaac	aaagaaugca	cgguugcuca	10860
ggcucuaggg	aauggggaua	aaucagggc	cacagacaag	cgcuuguuag	auucucuccg	10920
cgccauuugu	gcagaucugg	aagggucgag	cuccccguc	cccaggucg	cacacaacuu	10980
gggauuuuau	uucucgccug	auuugacaca	guuugcuaaa	cucccgguag	aacuugcacc	11040
ccacuggccc	guggugacaa	cccagaacaa	ugaaaagugg	ccagaccggu	ugguugcuag	11100
ccuucgcccc	guccauaagu	auagccgagc	gugcaucggu	gccggcuaca	ugguggggccc	11160
cucaguguuu	cugggcaccc	cugggguguu	gucauacuau	cucacaaaau	uugucagggg	11220
cgaggcucua	augcuuccgg	agacagucuu	cagcaccggc	cgaauugagg	uagauugccg	11280
ugaguaucuu	gaugaccggg	agcgagaaau	ugcugagucc	cucccccag	cuuucuuugg	11340
cgacgucaaa	ggcacuaccg	uuggaggaug	ucaccauguc	accuccaaa	accuuccgcg	11400
cuuccuucc	aaggaucag	ucgcgguagu	cgggguuca	agccccggga	aagccgcaaa	11460
agcaguuuug	acauuaacag	auguguauc	cccagaucuc	gaagcuuacc	uccaccagaa	11520
gaccagucc	aagugcugga	aaaugauguu	ggacuucacg	gaaguucgac	ugauggucug	11580
gaaggacaag	acggccuauu	uucacuuga	agcccgccau	uucaccuggu	accagcuugc	11640
aagcuaugcc	ucguacaucc	gaguuccugu	uacucucag	guguuuuugg	acccugcau	11700
gggcccugcc	cuuugcaaca	gaagaguugu	cggguccacu	cauuggggag	cugaccucgc	11760
agucaccccu	uagauuacg	gugccaaaau	cauccugucu	agugcauacc	auggugaaa	11820
gccccuggg	uacaaaacc	uggcgugcgc	ggaguucucg	cuugacgac	cagugaggua	11880
caaacacacc	uggggguuug	aaucggauac	agcguaucug	uacgaguuca	ccggaaacgg	11940

-continued

ugaggacugg	gaggauuaca	augaugcguu	ucgugcgcgc	cagaaaggga	aaauuuauaa	12000
ggccacugcc	accagcauga	gguuucauuu	ucggccgggc	ccugucauug	aaccaacuuu	12060
aggccugaau	ugaaaugaaa	ugggguccau	gcaaagccuc	uuugacaaaa	uuggccaacu	12120
uuuuguggau	gcuuucacgg	aauuuuuggu	guccauuguu	gauaucauca	uauuuuuggc	12180
cauuuuguuu	ggcuuuacca	ucgcuggcug	gcuggugguc	uucugcaucc	gauugguuug	12240
cuccgcggua	cuccgugcgc	gcccuaaccau	ucaccugag	cauuacaga	agauccuug	12300
aggccuuucu	uucucagugc	cagguggaua	uuccaccug	gggaacuaga	cauccccugg	12360
ggauuuuuug	gcaccauaag	gugucaaccc	ugauugauga	aauggugucg	cgucggauug	12420
accgcaccau	ggaaaaagca	ggacaggcug	ccuggaaaca	gguggugagc	gaggccacgc	12480
ugucucgcau	uagugguuug	gauguggugg	cucauuuua	gcaucuugcc	gccauugaag	12540
ccgagaccug	uaaaauuuug	gccucucggc	ugcccaugcu	acacaaucug	cgcaugacag	12600
ggucaaaugu	aaccuauagug	uaauauagua	cuuugaauca	gguguuugcu	auuuuuccaa	12660
ccccuggauc	ccggccaaaag	cuucaugauu	uucagcaaug	gcuaauagcu	gugcacuccu	12720
ccauuuuuuc	cuccguugcg	gcuucuugua	cucuuuuugu	ugugcugugg	uugcggauuc	12780
cauacuacg	uacuguuuuu	gguuuccgcu	gguuaggggc	aauuuuuccu	ucgaacucac	12840
ggugaauuac	acgguguguc	cgccuugccu	caccggcaa	gcagccgucg	aggucuacga	12900
accaggcagg	ucucuuuugu	gcaggauagg	gcaugaccga	uguagugagg	acgaccauga	12960
cgaucuaggg	uucaugguuc	cgccuggccu	cuccagcgaa	ggccacuuga	ccaguguuuu	13020
cgccugguug	gcuuuccugu	ccuucagcua	cacggcccag	uuccaucccg	agauuuuugg	13080
gauagggauu	gugagucaag	uuuanguuga	caucaagcac	cauucaucu	gcgccguuca	13140
cgacggggag	aacgccaccu	ugccucguca	ugacaauuu	ucagccguau	uucagaccua	13200
cuaccaacau	caagucgacg	gcggaauug	guuucaccua	gaauggcugc	gccccuucuu	13260
uuccucuuug	uugguuuuua	auguuucuug	guuucucagg	cguucgcccg	caagccaugu	13320
uucaguucua	gucuucgga	caucaaaacc	aacacuaccg	cagcaucagg	cuuuguuguc	13380
cuccaggaca	ucagcugccu	uaggcauggc	gacucguccu	cucagacgau	ucgcaaaagc	13440
ucucagugcc	gcgcgccgau	agggacgccc	guguacauca	cugucacagc	caaugucaca	13500
gaugagaauu	auuuacauuc	uucugaucuc	cuuaugcuuu	cuucugccu	uuucuaugcu	13560
ucugagauga	gugaaaaggg	auucaaggug	auuuuuggca	augugucagg	caucguggcu	13620
guguguguca	acuuuaccag	cuacguccaa	caugucaagg	aguuuacca	acgcuccuug	13680
guggucgauc	augugcggcu	gcuccauuuc	augacaccug	agaccaugag	gugggcaacc	13740
guuuuagccu	guuuuuuugc	caucuucacug	gcauuuugaa	uguucaagua	uguuggggag	13800
augcuugacc	gcgggcuguu	gcucgcgauu	gcuuucuuug	ugguguaucg	ugccauuuug	13860
uuuugcugcg	cucgucaacg	ccaacagcaa	cagcagcucu	caucuucagu	ugauuuucaa	13920
cuugacgcua	ugugagcuga	auggcacaga	uuggcugaaa	gacaaauuug	auugggcagu	13980
ggagacuuiu	gucaucuuc	ccguguugac	ucacauuguc	ucauauuggu	cacucaccac	14040
uagccauuuc	cuugacacag	ucggucuggu	uacugugucu	accgccgggu	ucuaccacgg	14100
gcgguauguu	cugaguagca	ucuacgccc	cugcgcucug	gccgcauuga	uuugcuucgu	14160
cauuaggcuu	gcgaagaacu	gcauguccug	gcgcuacucu	uguaccagau	auacuaacuu	14220
ccuucuggac	acuaagggca	gacucuucg	cuggcggucg	cccguuauca	uagagaaagg	14280
ggguaagguu	gaggucgaag	gucaccugau	cgaccucaa	agaguugucg	uugaugguuc	14340

-continued

```

cguggcaacc ccuuuaacca gaguuucagc ggaacaaugg ggucgucuuu agacgacuuu 14400
ugcuaugaua gcacggcucc acaaaaggug cuuuuggcgu uuuccauuac cuacacgccca 14460
gugaugauau augcucuaaa gguaagucgc ggccgacuuu uagggcuucu gcaccuuuug 14520
aucuuucuga auuguacuuu uaccuucggg uacaugacau ucgugcacuu uauuagcaca 14580
aauaaggucg cgcucacuau gggagcagua guugcacuuc uuuggggggu guacucagcc 14640
auagaaaccu ggaaguucan caccuccaga ugccguuugu gcuugcuagg ccgcaaguac 14700
auucuggccc ccgccacca cgucgaaagu gccgcgggcu uucauccgau cgccggcaau 14760
gauaaccacg cauugucgu ccggcguccc gguccacua cgguaaacgg cacauuggug 14820
cccggguuga aaagccucgu guuggguggc agaaaagcug uaaacaggg agugguaaac 14880
cuugucuuu augccaaaua acaacggcaa gcagcaaaag aaaaagagg ggaauggcca 14940
gccagucuu cagcugugcc agaugcuggg uaagaucauc gccagcaaa accaguccag 15000
aggcaagggg ccggggaaga aaauaagaa uaaaaaccg gagaagccc auuuuccucu 15060
agcgacugaa gaugacguca ggcaucacu caccuccuagu gagcggcaau ugugucuguc 15120
gucgauccag acugccuuu accagggcgc uggaaccugu acccuacag auucagguag 15180
gauaaguua acuguggagu uuaguuugc gagcaucau acugugcgc ugauccgcu 15240
cacagcgcca ucaucagcu aaugggcugg cauuccuuu gcaccucagu guuagaaug 15300
gaagaugug uggugaaug cacugauugg cacugugccu cuaagucac uauucauuu 15360
ggcgaccgu guggggguu aguuuuuug gcgagaacca ugcggccga auu 15413

```

```

<210> SEQ ID NO 5
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Artificial Primer

```

```

<400> SEQUENCE: 5

```

```

cgccctaatt gaataggtga c 21

```

```

<210> SEQ ID NO 6
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Artificial Primer

```

```

<400> SEQUENCE: 6

```

```

ccttcggcag gcggggagta gtgtttgagg tgctcagc 38

```

We claim:

1. A method of vaccinating swine against reproductive or respiratory failure comprising administering a vaccine comprising a PRRS RNA virus encoded by the cDNA sequence of SEQ ID NO:1 or a JA142 virus that initially was encoded by a cDNA sequence of SEQ ID NO:2 that has subsequently been attenuated by serial passage in culture at least 200 times to said swine in an amount effective to vaccinate said swine against reproductive or respiratory failure resulting from infection by PRRSV.

2. The method of claim 1, said administering step occurring at least two times.

3. The method of claim 2, said times being separated by about 30 days.

4. The method of claim 1, said reproductive failure including increased incidence of abortion, increased incidence of stillborn pigs and decreased viability of liveborn pigs.

5. The method of claim 1, said administering step occurring prior to conception.

6. An isolated cDNA sequence encoding an RNA molecule encoding a PRRS virus, wherein said cDNA sequence comprises the sequence of selected from the group consisting of SEQ ID No. 1 or SEQ ID No. 2.

7. The cDNA sequence of claim 6, wherein administration of an RNA virus corresponding to said cDNA sequence to a host swine confers effective immunity against PRRS virus infection.

8. An isolated cDNA sequence that encodes an infectious RNA molecule, wherein said sequence comprises the sequence is of SEQ ID No. 2.

89

9. A PRRS virus encoded by the cDNA sequence of SEQ ID NO:1 or is generated by serial passaging of an infectious PRRS virus encoded by the cDNA sequence of SEQ ID NO:2 until said PRRS virus is attenuated.

10. The virus of claim **9**, said virus is generated by serial passaging of an infectious PRRS virus encoded by the cDNA sequence of SEQ ID NO:2, for a minimum of 200 times in cell culture.

11. The virus of claim **9**, said virus has been attenuated by serial passaging of an infectious PRRS virus encoded by the cDNA sequence of SEQ ID NO:2.

12. The virus of claim **10** or claim **11**, said virus being substantially avirulent.

13. The virus of claim **9**, wherein said virus elicits an antibody response in swine when administered as part of a vaccine.

14. The virus of claim **13**, said antibody response being specific for porcine reproductive and respiratory syndrome virus strains.

90

15. A vaccine comprising a PRRS virus encoded by the cDNA sequence of SEQ ID NO:1 or a JA-142 virus strain that initially was encoded by a cDNA sequence of SEQ ID NO:2 and has subsequently been attenuated by serial passaging in cell culture for at least 200 times.

16. The vaccine of claim **15**, said vaccine elicits an antibody response in swine when administered in a therapeutically effective amount.

17. The vaccine of claim **16**, said antibody response being specific to porcine reproductive and respiratory syndrome virus strains.

18. The vaccine of claim **17**, said strains including atypical porcine reproductive and respiratory syndrome strains.

19. A PRRS virus strain deposited under ATCC Accession No. VR-2638.

* * * * *